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1 INTRODUCTION 
1.1 Anatomy and histology of the large intestine 
1.1.1 Anatomy of the colon and rectum 
The large intestine (intestinum crassum; colorectum) is a 100-150 cm long abdominal 
organ and the final part of the gastrointestinal (GI) tract (Ponz de Leon and Di Gregorio, 
2001). As such, it contributes to the digestive process by absorbing water and nutrients 
(e.g., salts) from the remnants of the predigested digested foods of the upper GI tract. 
In the colorectal passage, unabsorbed material is fermented by the aid of bacteria prior 
to the expelling of stool. These tasks are primarily performed from cecum to sigmoid 
colon (Figure 1), whereas the rectum instead stores fecal matter (Ponz de Leon and 
Di Gregorio, 2001; Väyrynen, 2016). 
 
The large intestine, apart from the rectum, is covered by the serous membrane of 
the peritoneum anchoring the colon to the abdominal wall. Two artery branches, i.e., 
superior mesenteric and inferior mesenteric, maintain the blood supply to the colon. 
This subdivides the organ into two vascular regions: (i) from the cecum to the splenic 
flexure and (ii) from the descending colon to the upper rectum (Väyrynen, 2016). How-
ever, blood for the lower rectum is derived from the middle and inferior rectal arteries 
(Ponz de Leon and Di Gregorio, 2001). Thus, the vascularization of the colorectum 
supports the concept of differentiation between right- and left-sided colon and the 
Figure 1. Anatomy of the colorectum. Schematic representation of the anatomical terminology and 
structure of the large intestine which is subdivided by sections (regular) and sides (bold). Image rec-
reated according to Ponz de Leon and Di Gregorio (2001). 
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rectum, respectively. Venous blood leaves the colon through the portal vein system 
into the liver which is the principal organ of hematogenous metastases from colorectal 
cancers (Ponz de Leon and Di Gregorio, 2001). The unique position occupied by the 
rectum is underlined by venous blood which leaves this section through the hemorrhoi-
dal plexus anastomosing into the caval vein system, leading to lung metastasis for 
rectal cancer. It is assumed that three different types of colorectal malignancies may 
occur varying by localization within the large intestine (Weisburger and Wynder, 1987), 
namely, cancer of the right colon, cancer of the left colon and cancer of the rectum. 
 
1.1.2 Histology of the colon and rectum 
The walls of the colon and rectum are composed of distinct histological layers (Ponz 
de Leon and Di Gregorio, 2001) (Figure 2). The mucosa constitutes the inner-most 
(luminal) layer of the colon. It accommodates the colonic crypts and the lamina propria, 
which lies beneath the crypts (Väyrynen, 2016). Moreover, columnar cells shape the 
surface epithelium which functions as the protective barrier between the host and the 
gut lumen. Mucosa and subjacent submucosa are separated by the smooth muscle 
layer of the muscularis mucosae. The submucosa contains fibroblasts, vasculature, 
nerves and a variety of white blood cells which are located beneath strands of collagen 
tissue (Ponz de Leon and Di Gregorio, 2001). This layer houses a neuronal plexus, 
i.e., the Meissner plexus, which innervates the muscularis mucosae. The inner colon 
layers are surrounded by a thick muscular layer (muscularis externa) which consists of 
circular and longitudinal muscle tissue (Ponz de Leon and Di Gregorio, 2001).  These 
are innervated by the Auerbach plexus (located in the tunica muscularis). The outer-
most histological components of the colon are formed by the subserosa and the serosa 
(intraperitoneal). However, the rectum is surrounded by the adventitia (retroperitoneal). 
Figure 2. Histopathology of the colorectum. Microscopic image of an H&E stained section from the 
rectum showing the characteristic histology in the large intestine. Image modified from Gulwani (2016) 
with courtesy of PathologyOutlines.com. 
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1.1.3 Microanatomy of the colon: epithelial crypts 
The anatomy of the colon consists of crypts which are formed by monolayered epithe-
lial cells (Figure 3). The crypts increase the surface of the colorectum by the invagi-
nated architecture. Moreover, the crypts have a polarized topographical organization 
where the location of a specific cell is closely related to its function (Radtke and Clev-
ers, 2005). At the bottom of the crypt, stem cells give rise to cell types which shape the 
crypt. Enteroendocrine cells are located at the lower third of the crypt, whereas the 
well-differentiated goblet cells (mucus-secretion) and absorptive cells (colonocytes) 
are found in the upper two-thirds of the crypt (Fodde et al., 2001). The cells migrate 
from the crypt’s bottom towards the surface to replenish the colonocyte amassment. 
Essential to maintain the homeostasis of an efficiently and correctly functioning colon 
(Barrasa et al., 2013), the senescent colonocytes are exfoliated into the lumen by un-
dergoing a unique form of apoptosis, i.e., anoikis (Aust and Barretton, 2010; Potten et 
al., 1997). Cell renewal is believed to take three to six days (Cotran et al., 1999). Ac-
cordingly, the frequency of mitotic cells equals the rate of apoptotic cells. However, 
neoplastic lesions of the colorectum are the result of an imbalance of these frequencies 
towards an accumulation of proliferative cells (Fodde et al., 2001). 
 
Figure 3. Structure of the colonic crypt. (A) Schematic structural architecture of a colonic crypt, which 
is the basic functional unit of the colon. It consists of different cells varying in proliferation activity and 
localization. There is an inverse correlation between proliferation and differentiation. Senescent colon-
ocytes undergo apoptosis and are secreted into the lumen of the colon. Image modified from Barrasa 
et al. (2013). (B) Histopathology of a regular colonic crypt within normal colon mucosa stained by he-
matoxylin and eosin. Scale bar, 100 µm. 
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1.2 Colorectal cancer: epidemiology and etiology 
The colorectum is a common cancer site reflected by a lifetime probability of cancer 
diagnosis of 5.0% in men and 4.3% in women (Hornick and Odze, 2015; Jemal et al., 
2008). In Germany, colorectal cancer (CRC) is the third most common cancer in men 
and the second most common cancer in women with 34,050 and 28,360, respectively, 
new cases in 2013. Consequently, men have a higher CRC age-standardized inci-
dence rate compared to women (56.6 vs 36.3 cases per 100,000 inhabitants) (Zentrum 
für Krebsregisterdaten, 2016). Epidemiologic data have shown that CRC incidence is 
not equally distributed around the world (Figure 4). The (historically) highest incidence 
rates were reported in long-standing economically developed countries (Center et al., 
2009). Albeit, incidence rates in these countries have stabilized and started to de-
crease due to screening practices, colonoscopic polypectomy and improved treat-
ments (Center et al., 2009; Welch and Robertson, 2016). In contrast, economically 
transitioning countries still report an incline of CRC incidences, most likely due to the 
‘westernization’ of lifestyles, e.g., obesity, physical inactivity and high-calorie food 
(Center et al., 2009; Giovannucci, 2002; Popkin, 2015). 
Figure 4. CRC incidences worldwide. Estimated age-standardized incidence rates per 100,000 inhab-
itants of colorectal cancers distributed by regions of the world and sex. Extracted and modified from 
Zentrum für Krebsregisterdaten (2016). Data was collected by GLOBOCAN 2012 (International Agency 
for Research on Cancer). 
Mortality rates of CRC decreased in the past decades, arguably due to declining 
incidence rates in developed countries (American Cancer Society, 2017). Disease-re-
lated deaths affected 13,609 men and 12,085 women in Germany in 2013. The relative 
survival rate for CRC is 63% at 5-years following diagnosis, likewise in men and women 
(Zentrum für Krebsregisterdaten, 2016). Nevertheless, the prognosis of patients 
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suffering from CRC strongly depends on the tumor stage at the time of diagnosis. This 
circumstance is emphasized by a 5-year relative survival rate of CRC declining from 
over 90% in early stages towards 60% in advanced stages and under 10% in meta-
static CRC (O’Connell et al., 2004). 
Moreover, CRC risk increases with age, with a median age at diagnosis of 70.3 
years in men and 72.9 years in women in Germany (Zentrum für Krebsregisterdaten, 
2016). Studies have reported that a racial disparity for CRC risk exists, i.e., some eth-
nicities (e.g., Afroamericans and American natives) are confronted with higher CRC 
incidence and mortality rates than average (American Cancer Society, 2017; Irby et 
al., 2006). Aside from age and ethnicity, several risk factors influence CRC formation: 
(i) hereditary and family history, (ii) personal medical history and (iii) behavioral risk 
factors (American Cancer Society, 2017).  
While approximately 70% of CRC arise sporadically, estimations state that up to 
30% of CRC patients have a family history of the disease, approximately 5% of which 
are caused by known hereditary genetic alterations (Patel and Ahnen, 2012). People 
with a family history (first-degree relative) have a two-to-four time increased risk for 
developing the disease compared to people without a family history (Butterworth et al., 
2006). Although familial CRC has no apparent association with an identifiable heredi-
tary syndrome so far increasingly more susceptibility genes were and will be identified 
(Jasperson et al., 2010). Conversely, hereditary CRCs are composed of well-defined 
inherited syndromes (Figure 5): (i) the nonpolyposis phenotype Lynch syndrome (LS); 
(ii) the adenomatous polyposis phenotype including the familial adenomatous polypo-
sis (FAP), the attenuated familial adenomatous polyposis (AFAP) and MUTYH-asso-
ciated polyposis (MAP); (iii) and the hamartomatous polyposis phenotype comprising 
Cowden syndrome (CS), juvenile adenomatous syndrome (JAS), oligopolyposis (OP) 
and Peutz-Jeghers syndrome (PJS) (Burt, 2000; Jasperson et al., 2010). 
Figure 5. Distribution of CRC types. Fractions and frequencies of CRC arising in various family risk 
settings. HNPCC, hereditary nonpolyposis colorectal cancer. Image recreated according to Burt (2000). 
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Another important risk factor is the personal medical history: the individual risk for 
CRC increases in patients which had a history of CRC and/or adenomatous polyps 
(Mysliwiec et al., 2006; Ren et al., 2016). Moreover, patients suffering from chronic 
inflammatory bowel disease, e.g., ulcerative colitis and Crohn’s disease, have a dou-
bled risk of developing CRC compared to the people of the general population (Lutgens 
et al., 2013). A meta-analysis revealed a strong association between CRC and type-2 
diabetes patients, suggesting this disease is a risk factor for CRC (Tsilidis et al., 2015). 
Behavioral risk factors for CRC include (modifiable) parameters traditionally associ-
ated with a sedentary lifestyle and Western diet (American Cancer Society, 2017). 
Consequently, physical inactivity (Schmid and Leitzmann, 2014), overweight and obe-
sity (Ma et al., 2013), consumption of red and/or processed meat (Chan et al., 2011), 
moderate and heavy alcohol intake (Cho et al., 2004) and smoking (Secretan et al., 
2009) negatively affect the individual risk of CRC (Boyle et al., 2012). Nevertheless, 
several behavioral factors beneficial to CRC prevention have been identified. Dietary 
consumption of calcium from dairy, fiber, fruits and vegetables may all help to decrease 
CRC risk (Song et al., 2015; Kushi et al., 2012). Additionally, physical activity and the 
intake of vitamin D or aspirin were shown to reduce CRC risk (Boyle et al., 2012; Roth-
well et al., 2010; Song et al., 2015). Most importantly, endoscopic polypectomy during 
colonoscopy is believed to reduce CRC risk most efficiently (Elmunzer et al., 2015). 
 
1.3 Precursor lesions of sporadic colorectal cancer 
1.3.1 Adenoma-carcinoma sequence: a pathway to cancer 
CRC develops slowly in a multi-step tumorigenesis of 10-20 years (Fearon and Vo-
gelstein, 1990). First described by Morson et al. (1975), the carcinogenesis of the large 
bowel follows the gradual model of the adenoma-carcinoma sequence. This model has 
developed into a textbook paradigm according to which normal colonic epithelium is 
genetically transformed and progresses via premalignant lesions, i.e., small and large 
adenomas, into a malignant adenocarcinoma (Figure 6). Fearon and Vogelstein (1990) 
have provided the molecular basis for the adenoma-carcinoma-sequence. They iden-
tified specific genetic alterations which not only initiated the carcinogenesis but also 
progressively accumulated during the transformation from adenoma into a solid carci-
noma. The advanced model of the adenoma-carcinoma sequence has gained out-
standing reward and is often referred to as “Vogelgram” (Haan et al., 2014; Krimpenfort 
et al., 2012). Despite this reputation, the “model has started to live a life of its own” 
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(Sillars-Hardebol et al., 2012). Thus, people stopped looking for alternatives. Intensi-
fied research on the colorectal carcinogenesis has accumulated striking evidence of 
multiple gene pathways frequently affected by alterations. Notwithstanding, the model 
reflects an oversimplification of a slightly more complex and diverse process. Jass 
(2007) describes the dogmatic linking of CRC to the mono-directional model as detri-
mental for the research in the field. Hence, Issa (2008) postulates the concept of ade-
noma-carcinoma sequence needs revision. This fact is underpinned by improved mo-
lecular analyzes of the colorectal carcinogenesis which unveiled several overlapping 
ways of CRC development (Snover, 2011) (see 1.4.1 Molecular pathogenesis). 
 
1.3.2 Aberrant crypt foci (ACF) 
ACF have emerged as earliest morphological precursors to both adenoma and CRC 
(Gupta et al., 2009; Hamilton et al., 2000). ACF revealed a prevalence of 50% in pa-
tients of 40-49 years, sharply increasing with age and occurrence of adenomas or CRC 
(73% and 100%, respectively) (Takayama et al., 1998). Defined as microscopical pre-
neoplastic clusters of aberrant crypts, ACF vary in size ranging from single altered 
glands to plaques greater than 30 crypts (Pretlow et al., 1991). Several genomic and 
epigenomic alterations, among which mutations of KRAS were most consistently de-
scribed (13-82% of cases), were identified as shared by ACF, adenomas, and CRC 
(Gupta et al., 2007; Jen et al., 1994; Pretlow et al., 1993). Despite intensive research, 
the clinical relevance of ACF remains controversial regarding frequencies and impact.  
A 
B 
Figure 6. Adenoma-carcinoma sequence. (A) Histopathology of the evolution in colorectal cancer. 
From left to right, normal colorectal mucosa develops stepwise to adenoma and carcinoma by accu-
mulating genomic events (top row). Image extracted from Vogelstein et al. (2013). (B) Endoscopic 
images taken at a colonoscopy. From left to right: normal epithelium, small adenoma, large adenoma 
and adenocarcinoma of the colon. Image extracted from Cardoso et al. (2007). 
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1.3.3 Epithelial polyps 
The largest group of precursor lesions of sporadic CRC is composed of epithelial 
polyps (Figure 7). Historically, these polyps were distinguished by two major types, i.e., 
the hyperplastic polyp and the adenomatous polyp. Characterized by neoplastic cyto-
logical and histological atypia adenomas have been exclusively recognized as precur-
sor lesions of carcinomas, while hyperplastic polyps seemed not capable to malig-
nantly progress into CRC (Morson, 1962). Albeit, evidence has accumulated that the 
group of polyps with hyperplastic changes is, in fact, rather complicated and heteroge-
neous concerning both pathological and molecular features (East et al., 2008; Lon-
gacre and Fenoglio-Preiser, 1990; Snover et al., 2005; Torlakovic et al., 2003). In gen-
eral, it was found that the group of hyperplastic polyps (in the sense of “serrated 
polyps”) can be subdivided into four groups: (i) classical hyperplastic polyps (HP); (ii) 
sessile serrated adenomas (SSA); (iii) traditionally serrated adenomas (TSA) and (iv) 
mixed polyps (Aust and Baretton, 2010; Bettington et al., 2013; Rüschoff et al., 2007). 
All serrated polyps share the same pattern of characteristic saw-tooth, luminal serra-
tions with branching and distortion in both crypts and epithelium (Strum, 2016). How-
ever, the molecular landscape of these lesions is more diverse with mutations predom-
inantly affecting KRAS or BRAF, and methylation of CpG islands (Bettington et al., 
2013; Snover, 2011). Although the classical HP is not associated with a risk for cancer 
progression, all other serrated polyps are perceived, meanwhile, as precursors of the 
serrated pathway carcinoma (Iion et al., 1999; Jass et al., 1999; Snover, 2011).  
Figure 7. Terminology and systematic scheme of sporadic epithelial polyps of the colorectum. 
The Scheme displayes the hyperplastic and adenomatous subgroups of polyps. Polyps displaying diag-
nostic criteria which match both adenomatous and hyperplastic cytological dysplasia are termed mixed 
polyps (MP). Although HPs are the most common hyperplatic polyps they seem not to harbor malignant 
potential for progression into CRC. Image recreated according to Rüschoff et al. (2007). 
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1.3.4 Adenomas 
Adenomatous polyps are the most common premalignant neoplasia of the large intes-
tine with an incidence of about 30-40% in individuals over 60 years of age (Eide, 1991; 
Levine and Ahnen, 2006; Paspatis et al., 2001; Vatn and Stalsberg, 1982). The inci-
dence has been shown to increase dramatically with age emphasized by half the West-
ern population who will have developed an adenoma by the age of 70 years (Fodde et 
al., 2001). Histologically, adenomas are defined by their grade of intraepithelial neo-
plasia (IEN) which is estimated by consideration of histological and cytological findings, 
i.e., dysplasia of low-grade (LGD) or high-grade (HGD) character (Fodde et al., 2001; 
Hamilton et al., 2000). Hence, epithelial cells grow in multiple layers while the align-
ment to the basal membrane is lost (Fodde et al., 2001). The cells display characteristic 
hypercellularity with enlarged and hyperchromatic nuclei which may appear spindle-
shaped (Hamilton et al., 2000). Histopathology of adenomas differentiates between 
tubular (less than 25% villous structures), tubulo-villous (25-75% villous structures) or 
villous (>75% villous structures) gland architecture, respectively (Hamilton et al., 2000; 
Strum, 2016). Adenomas may macroscopically emerge polypoid (pedunculated or ses-
sile) or non-polypoid (flat, superficially elevated or depressed) (Hornick and Odze, 
2015; Soetniko et al., 2008). 
Adenomatous polyps are perceived as benign but potential precancerous lesions in 
the colorectal carcinogenesis representing an essential link from normal epithelium to-
wards cancer. Molecularly, there is broad consensus that the first, i.e., “gatekeeping,” 
mutation often affects APC conferring a selective growth advantage to the cells to out-
grow adjacent normal cells (Kinzler and Vogelstein, 1997; Vogelstein et al., 2013). Ad-
enomas grow slowly, however, the clonal expansion may be promoted by another mu-
tation, e.g., KRAS, accelerating the exponential increase of mutated cells (Fearon and 
Vogelstein, 1990). Despite the paradigm of linear progression, it is estimated that only 
3-5% of detected adenomas progress to malignancy which takes many years (Eide, 
1991; Shinya and Wolff, 1979; Sillars-Hardebol et al., 2012). Several histological risk 
factors are believed to be associated with progression of adenomas: e.g., size, villous 
features and HGD (DiSario et al., 1991; Hornick and Odze, 2015; Muto et al., 1975). 
Polyps with malignancies (early adenocarcinomas with adenomas) may comprise 
two percent of all endoscopically resected polyps (Morson et al., 1984). In addition to 
adenomatous tissue, these lesions also expose carcinoma cells which invaded the 
submucosa throughout the muscularis mucosa (Cooper, 1983).  
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1.3.5 Resection of adenomas and surveillance intervals 
CRC arises from adenomatous polyps according to the adenoma-carcinoma se-
quence. Detection and removal of these lesions are routinely performed by endoscopic 
colonoscopy. This technique provides the opportunity to most accurately detect cancer 
(at early and curable stages) and adenomas, whose removals reduce the risk of cancer 
by 76-90% (Winawer et al., 1993; Zauber et al., 2012). However, colonoscopy is also 
an invasive and cost-intensive procedure which is associated with morbidity and com-
plications (Bond, 2000). As CRC risk increases in an age-dependent manner, colon-
oscopy is recommended for cancer prevention in patients aged ≥55 years (Stock et al., 
2011). Colorectal adenomas are usually detected asymptomatically in colonoscopies 
and are subsequently endoscopically resected via electrocautery excision techniques 
(Bond, 2000). The endoscopist removes polyps preferentially by en-bloc excision (in 
toto) or, if not possible, by piecemeal snare excision. However, both techniques aim to 
retrieve tissue for pathological evaluation of malignancy, and if en-bloc resected to 
confirm complete resection (in sano) (Bond, 2000). 
Patients who have undergone colonoscopy (with adenoma excision) are at an in-
creased risk of two-to-four time of developing cancer compared to the average popu-
lation (Levine and Ahnen, 2006). Accordingly, current guidelines recommend re-colon-
oscopy in defined time intervals based on clinical and pathological factors (Table 1). 
Firstly, post-polypectomy surveillance includes to determine the frequency of colonos-
copies for re-examination and to clarify complete resection. Secondly, patients need to 
be defined who benefit from an intensified follow-up which does not invariably apply to 
all patients (Bond, 2000; Leitlinienprogramm Onkologie, 2014). Today, histology, size, 
and multiplicity of polyps are the significant factors to define screening intervals (Avi-
dan et al., 2002; Neugut et al., 1995; Noshirwani et al., 2000; van Heijningen et al., 
2013). However, none of these factors was prospectively evaluated, and retrospective 
studies often have methodical limitations. Noteworthy, the utilization of individual 
pathological characteristics as criteria for surveillance intervals and recurrence predic-
tion will come under scrutiny (Avidan et al., 2002; Bond, 2000). 
Since 20-40% of adenomas recur after endoscopic polypectomy (Avidan et al., 
2002; Bonithon-Kopp et al., 2004; Neugut et al., 1995; Winawer et al., 1993), studies 
on adenoma recurrence may represent a unique way of examining the phenomenon 
of adenoma development. Given that the removal of polyps provides the opportunity 
for cancer prevention, a failure to detect and remove adenomas during colonoscopy 
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conversely increases the patient’s risk for both adenoma recurrence and cancer (Cor-
ley et al., 2014). Adenoma recurrence seems likely due to lesions missed by colonos-
copy, incomplete resection and, arguably, the phenomenon of field cancerization (De 
Maio et al., 2017; Levine and Ahnen, 2006). Hotta and colleagues (2008) also showed 
that local recurrence of adenomas occurred more frequently after piecemeal resection 
compared to en-bloc excision. Nevertheless, both procedures were named an ade-
quate treatment achieving cure in most patients (Hotta et al., 2008; Walsh et al., 1992). 
In summary, the lack of favorable pathological characteristics for the assessment of 
an individual risk of adenoma recurrence emphasizes the need for molecular markers 
which could predict recurrence more accurately in both sensitivity and specificity. 
 
Table 1. Guidelines for post-polypectomy surveillance. Excerpt of guidelines for colonoscopic sur-
veillance after polypectomy defined by the European Society of Gastrointestinal Endoscopy (ESGE) 
(Hassan et al., 2013). The recommendations apply for patients only who underwent high quality colon-
oscopy with complete removal (in toto) of all neoplastic lesions. Inadequately removed adenomas are 
not subject to the hereby suggested surveillance intervals. 
 
Colonoscopic findings Recommended interval 
between colonoscopies 
Low-risk 
group 
• 1-2 tubular adenomas with low-grade 
dysplasia and size <10mm 
• Serrated polyps without dysplasia, size 
<10mm 
10-year surveillance interval 
High-risk 
group 
• ≥3 adenomas 
• Adenomas with villous histology 
• Adenomas with high-grade dysplasia 
• Adenomas with size ≥10mm 
• Serrated polyps with dysplasia and/or 
size ≥10mm 
3-year surveillance interval 
(If no high-risk adenoma was de-
tected at the first surveillance ex-
amination a 5-year surveillance 
interval is recommended.) 
• >10 adenomas Genetic counseling 
 
1.4 Molecular pathogenesis in colorectal lesions 
1.4.1 Molecular carcinogenesis pathways 
The model of the adenoma-carcinoma sequence contributed fundamentally to the 
understanding of the colorectal carcinogenesis. To explain the clinical progression of 
colorectal tumors, understanding the molecular basis became an important objective 
in the last decades. Evidence accumulated that three major molecular pathways may 
drive colorectal carcinogenesis (Issa, 2008): 
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(i) The first pathway to be identified is the chromosomal instability (CIN) pathway, 
also referred to as the suppressor pathway. It accounts for approximately 60% of spo-
radic CRC including the conventional adenoma-carcinoma sequence (Fearon and Vo-
gelstein, 1990; Jass, 2007). CIN denotes the characteristic aberrations of gains and 
losses of whole or substantial portions of chromosomes with high frequencies 
(Lengauer et al., 1998), and is accepted to increase as the tumor progresses (Fearon 
and Vogelstein, 1990). Consequently, CIN leads to an imbalance in chromosome num-
ber (termed aneuploidy) and structure, genetic mutations in oncogenes and tumor sup-
pressor genes (i.a., APC), sub-chromosomal genomic amplifications and high frequen-
cies of loss of heterozygosity (LOH) (Pino and Chung, 2010). 
(ii) The second pathway is termed microsatellite instability (MSI) pathway, also re-
ferred to as the mutator pathway. It affects up to 18% of sporadic CRC (Ionov et al., 
1993; Popat et al., 2005), most of which were following the serrated-precursor pathway 
(Issa, 2008; Snover, 2011). The basis for this pathway is DNA tandem repeats (mi-
crosatellites) of one to six base pairs which are distributed throughout the genome. 
These repetitive sequences are prone to errors occurring during the process of DNA 
replication (Ionov et al., 1993). However, coding errors are normally repaired by mis-
match repair (MMR) proteins (namely MLH1, MSH2, MSH6, and PMS2) which interact 
together to recognize and excise mismatches (Vilar and Gruber, 2010). A loss of func-
tion in one of the MMR system proteins induces the accumulation of frameshift muta-
tions by inactivation of mismatch-repair (Buecher et al., 2013). This accumulation af-
fects not only microsatellite sequences but also gene coding regions of key genes in-
volved in several cellular processes (Duval and Hamelin, 2002). Consequential, MSI 
leads to genetic hypermutability. While sporadic CRC with MSI+ is caused by somatic 
hypermethylation of the MLH1 promoter, hereditary CRC with MSI+ (LS) is induced by 
germline mutations of MMR protein genes (Buecher et al., 2013). MSI+ cancers are 
subdivided into MSI-high or MSI-low, whereas non-affected tumors are termed mi-
crosatellite stable (MSS) (Buecher et al., 2013). 
(iii) The third pathway towards CRC is the CpG island methylator phenotype (CIMP) 
(Toyota et al., 1999), also termed the epigenetic instability pathway. It was demon-
strated that this pathway accounts for 20-30% of sporadic CRC (Jass, 2007; van 
Rijnsoever et al., 2002), which are predominately associated with serrated neoplasia 
precursor lesions (Snover, 2011). The name is derived from the characteristic epige-
netic changes on the DNA, i.a., methylation of CpG sites (Jones and Baylin, 2007). 
Based on the degree of hypermethylation, CIMP can be either of low-level (CIMP-L) or 
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high-level (CIMP-H) (Bettington et al., 2013). Tumors affected by CIMP+ exhibit hyper-
methylation of CpG islands in gene promoter regions of tumor suppressor genes 
(TSGs) whose expression becomes silenced (Tycko, 2000). Accordingly, the progres-
sion of the tumor may be promoted accompanied by an increased tumoral growth. 
The concept of linear pathways responsible for the progression towards CRC is yet 
an oversimplification (Issa, 2008). The multiplicity of pathways increases in complexity 
due to an overlap of the underlying features (Snover, 2011). That implies that the path-
ways are not mutually exclusive; however, their relevance is not yet fully defined and 
somewhat inconclusive (Pino and Chung, 2010). Hence, the inferred model of colorec-
tal carcinogenesis pathways takes the shape of a complex disease reigned by multiple 
genotypes and phenotypes (Figure 8). The inconsistency of the current classifications 
emphasizes the need for a more stratified classification system. Recently, the CRC 
Subtyping Consortium assessed the distinct subtypes by sharing large-scale data and 
analytics among experts to proclaim new taxonomic patterns: the consensus molecular 
subtypes (CMS) of CRC (Guinney et al., 2015).  
Figure 8. Venn-diagram depicting the overlap of molecular pathways in CRC development. 
Shown are pathways which are either based on putative initiation factors (i.a., suppressor versus mu-
tator pathway; red circles), based on the precursor lesion towards CRC (conventional adenoma-carci-
noma sequence versus serrated pathway; blue circles) or which are hitherto poorly understood (yellow 
circles). Annotations in boxes reflect the intersections in the respective pathways. CIMP+/-, CIMP pos-
itive/negative; MSI-H/-L, degree of MSI high/low. Image extracted from Snover (2011). 
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1.4.2 Key genes in the colorectal carcinogenesis 
It is reported that >70% of solid neoplasms show aneuploidy (Bakhoum and Compton, 
2012). These genomic alterations affect specific sets of proto-oncogenes and tumor 
suppressor genes (Pino and Chung, 2010). Aberrations may lead to activation of on-
cogenic pathways or inactivation of tumor suppressive pathways. Aneuploidy-induced 
loss of heterozygosity (LOH) contributes to tumor progression (Weaver and Cleveland, 
2006). Frequently targeted genes in the colorectal tumorigenesis are presented below. 
 
Adenomatous polyposis coli (APC) and β-catenin (CTNNB1) 
Mutations of APC on 5q22 are widely accepted as the earliest genetic event in the 
tumorigenesis of the colorectum, activating the WNT signaling pathway (Groden et al., 
1991; Powell et al., 1992). While germline inactivating mutations in this gene show 
responsibility for hereditary CRC associated with FAP (Kinzler and Vogelstein, 1996), 
somatic mutations in APC are present in a small number of dysplastic aberrant crypt 
foci and strongly increase to 30-70% in sporadic adenomas and carcinomas, respec-
tively (De Filippo et al., 2002; Miyaki et al., 1994; Otori et al., 1998). The disruption of 
APC is a “gatekeeping” (i.e., tumor-initiating) event providing a selective growth ad-
vantage for the affected cells (Kinzler and Vogelstein, 1997). Mutations truncating the 
encoded protein within its N-terminal 1,600 amino acids are considered as driver gene 
mutations, whereas missense mutations in APC and protein-truncating mutations of 
the C-terminal 1,200 amino acids are likely passenger gene mutations (Vogelstein et 
al., 2013). Hypermethylation of the APC promoter was found in 18% of CRCs and 
adenomas suggesting an alternative process of APC inactivation (Esteller et al., 2000). 
Expression of APC is involved in cellular differentiation, adhesion, polarity, migra-
tion, development, apoptosis and chromosomal segregation (Pino and Chung, 2010). 
Molecularly, intact APC interacts in the WNT signaling pathway in the absence of WNT 
by forming a “destruction complex” with β-catenin, glycogen synthase kinase-3β (GSK-
3β) and casein kinase 1α/ε (CK1) on an axin-conductin scaffold. Accordingly, the phos-
phorylation of β-catenin by GSK-3β initiates the ubiquitin-driven proteasome-depend-
ent degradation (Rubinfeld et al., 1996). Aberrant APC blocks the formation of the “de-
struction complex” leading to cytoplasmic accumulation of β-catenin. The protein is 
translocated into the nucleus to trigger the transcription of downstream genes which 
promote tumor growth and invasion (Mann et al., 1999). The APC pathway, hence, 
indirectly targets colorectal oncogenes, i.a., MYC and CCND1 (He et al., 1998). The 
downstream-target gene β-catenin (CTNNB1), per se, is renowned as commonly 
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affected by gain-of-function mutations in colonic tumors with MSI-H (Jass et al., 2003; 
Sparks et al., 1998). Nevertheless, mutations in CTNNB1 are mainly limited to LS 
(Johnson et al., 2005; Miyaki et al., 1999). However, neither of these genes plays a 
role in clinical practice due to hitherto insufficient validation (Walther et al., 2009). 
 
Proto-oncogene K-Ras (KRAS) and proto-oncogene B-Raf (BRAF) 
The alteration of KRAS (located on 12q12.1) is an early event in the colorectal tumor-
igenesis underlined by a prevalence of 30-50% in sporadic CRC (Andreyev et al., 1998; 
Santini et al., 2008). KRAS encodes the GTPase-enzyme RAS which is involved in 
multiple signal transduction pathways (Figure 9). As such, RAS is an effector of cellular 
growth, differentiation, apoptosis, survival, motility, transformation, vesicle trafficking 
and proliferation (Pino and Chung, 2010). RAS affects the major cellular proliferation 
MAPK/ERK pathway by triggering the cascade of MEK and ERK. ERK is translocated 
and phosphorylates cytosolic and nuclear substrates regulating the transcription of 
downstream targets, e.g., CCND1, p21 and p27 (Pruitt and Der, 2001). Aberrant KRAS 
leads to constitutive activation of the MAPK/ERK cascade (Armaghany et al., 2012). 
Fearon and Vogelstein (1990) proclaim in the adenoma-carcinoma sequence that 
KRAS mutations occur after APC alterations, marking the tumor’s transition from the 
breakthrough phase into the expansion phase (Vogelstein and Kinzler, 2015). 
An important downstream target of RAS in the MAPK/ERK pathway is the enzyme 
RAF (encoded by BRAF located on 7q34) (Figure 9). Importantly, BRAF mutations are 
not only observed within serrated neoplasia and CIMP+ CRC but also in MSI+ CRC 
(Iacopetta et al., 2006; Torlakovic et al., 2003). Lesions presenting a mutation of BRAF 
show an inhibition of apoptosis in colonic epithelial cells (Snover, 2011).  
Figure 9. Schematic representation of 
the RAS signaling pathway. Growth fac-
tors (red), e.g., EGF and TGF-α, bind to the 
respective growth factor receptor (green). 
This activates a cascade including the 
growth-factor-receptor bound protein 2 
(GBR2) and son of sevenless (SOS) which 
stimulate the exchange of guanosine di-
phosphate (GDP) for guanosine triphos-
phate (GTP) in RAS GTPase by guanosine 
exchange factors (GEFs). Activated RAS-
GTP activates several downstream target 
proteins (e.g., PI3K and RAF) which are in-
volved in the regulation of a multiplicity of 
cellular processes. Image extracted from 
Pino and Chung (2010). 
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Epidermal growth factor receptor (EGFR)  
The proto-oncogene EGFR (located on 7p11.2) encodes a transmembrane receptor 
tyrosine kinase of the ERBB family of receptors which binds protein ligands of the EGF 
family. If a ligand binds to the extracellular domain, a dimerization of EGFR is induced 
which leads to autophosphorylation of the intracellular domain (Herbst, 2004). Subse-
quently, signal transduction pathways, e.g., MAPK/ERK pathway and the PI3K/AKT 
pathway, are activated in a downstream cascade starting with RAS activation (Fig-
ure 9). EGFR is involved in cellular differentiation, proliferation, and survival (Herbst, 
2004). Hence, EGFR activity was linked to the expansion of intestinal tumors (Roberts 
et al., 2002). Phenotypically in line with mutations of KRAS and BRAF, EGFR altera-
tions lead to constitutive activation of the downstream signaling cascades empowering 
cells to growth aggressively (Ethier, 2002). Interestingly, chromosomal aberrations af-
fecting chromosome 7 are believed to be an early and frequent event in the colorectal 
carcinogenesis (Meijer et al., 1998). Therefore, EGFR is a prominent target of copy 
number gain influencing tumor propagation by gene overexpression. The presence of 
EGFR copy number gains in 30-36% of colorectal adenomas emphasizes the pivotal 
role of EGFR in colorectal tumorigenesis (Habermann et al., 2011; Ried et al., 1996). 
 
Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic SU alpha (PIK3CA) 
PIK3CA (located on 3q26.32) encodes the catalytic subunit of class I phosphatidylino-
sitol 3-kinase (PI3K), a downstream regulator of the EGFR pathway targeted by acti-
vated RAS, i.e., RAS-GTP (Figure 9). PI3K is a lipid kinase regulating signaling cas-
cades which influence cellular growth, proliferation, motility, and survival (Samuels and 
Velculescu, 2004). When activated by RAS, PI3K translocates to the plasma mem-
brane and converts phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinosi-
tol-3,4,5-triphosphate (PIP3) by phosphorylation. PIP3 binds to either 3-phosphoinosi-
tide-dependent protein kinase-1 (PDPK1) or AKT serine/threonine kinase (protein ki-
nase B, PKB) (Samuels and Velculescu, 2004). Mutations in hotspots of PIK3CA lead 
to constitutive activation of the PI3K-AKT pathway in >30% of CRCs (Samuels et al., 
2004). DNA alterations of PIK3CA lead to overexpression and were revealed to be 
frequent in CRC patients with both amplifications (38%) and gains (19%), while 25% 
of colorectal adenomas exhibited amplification of PIK3CA (Jehan et al., 2009). Of note, 
PTEN (located on 10q23.1) is another prominent dysregulated target gene in the PI3K-
AKT pathway exhibiting predictive value for metastatic CRC (Frattini et al., 2007; 
Jhawer et al., 2008).  
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Caudal type homeobox protein 2 (CDX2) 
CDX2 (located on 13q12.2) encodes a transcription factor of the caudal-related home-
obox family. Typically expressed in nuclei of intestinal epithelial cells (German et al., 
1994), CDX2 is involved in gastrointestinal lineage development and differentiation 
which is emphasized by the utilization as a biomarker in diagnostic pathology (Liu et 
al., 2007). While multiple studies demonstrated tumor suppressive abilities for CDX2 
expression (Bai et al., 2003; Choi et al., 2006; Hinoi et al., 2001), oncogenic amplifica-
tion of CDX2 was, contrarily, shown to promote cellular proliferation and provide sur-
vival advantages for colorectal cancer cells compared to normal mucosa cells (Dang 
et al., 2006; Salari et al., 2012). Recently, a loss of CDX2 was named a negative bi-
omarker in stage II/III cancer (Dalerba et al., 2016). Anyhow, recurrent copy number 
gain of chr13 in colorectal tumorigenesis were revealed in numerous cytogenetic stud-
ies (Bomme et al., 1994; Grade et al., 2006; Meijer et al., 1998; Ried et al., 1996). 
 
Tumor protein P53 (TP53) 
TP53 (located on 17p13.1) represents a frequently altered tumor suppressor gene 
which lost activity in a variety of cancers (Lane, 1992). The prevalence of mutated 
TP53 in CRC is denoted with 35-55% (Markowitz and Bertagnolli, 2009). Despite this, 
TP53 alterations are a late event in the adenoma-carcinoma sequence with rare oc-
currence in adenomatous lesions compared to carcinomas (Fearon and Vogelstein, 
1990; Leslie et al., 2002). TP53 encodes a transcription factor which coordinates the 
cellular responses to different types of cellular stress, e.g., nutrient deprivation, hypoxia 
and ribosomal stress (Vogelstein et al., 2000). The protein triggers DNA repair as a 
response to DNA damage and arrests the cell cycle in G1 phase (Vousden and Lane, 
2007). TP53 is capable of inducing senescence and apoptosis of the cell when DNA 
repair failed (Vousden and Lane, 2007). TP53 dysfunctions deregulate cellular prolif-
eration and apoptotic machinery, resulting in tumor progression and genomic instability 
(Leslie et al., 2002). Thus, TP53 is recognized as “the guardian of the genome” (Lane, 
1992), and frequently affected by allelic losses in aneuploid CRCs (Meling et al., 1993). 
 
Mothers against decapentaplegic homolog-4 (SMAD4) and -7 (SMAD7) 
Fearon and Vogelstein (1990) identified the allelic loss of chromosome-arm 18q as a 
widespread event affecting >70% of CRCs. While chr18 houses several TSGs the most 
important are DCC, SMAD2, and SMAD4. Last mentioned genes encode intracellular 
proteins which transduce the extracellular signal of ligands binding to the TGFβ-
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receptor. SMAD2 belongs to the receptor-regulated class of R-SMADs. After activation 
by TGFβ-receptor, R-SMADs form a heteromeric complex with SMAD4 (class of co-
SMAD). The complexes translocate into the nucleus to regulate gene expression (Roe-
len et al., 2003). Therefore, SMAD4 regulates cellular growth, cellular differentiation 
and apoptotic processes (Heldin et al., 1997). Aneuploidy-associated heterozygotic 
loss of SMAD4 leads to cellular deregulation and has been observed in 16% of CRCs 
(Takagi et al., 1996). In contrast, SMAD7 is a member of the class of inhibitory SMADs 
(i-SMAD), which are capable to antagonistically block proteins of other classes of 
SMADs (Itoh et al., 2001). Hence, SMAD7 regulates TGFβ signaling and provides neg-
ative feedback of the pathways of activin and BMP, respectively (Heldin et al., 1997; 
Ishisaki et al., 1999). Alterations of SMAD7 have been observed in ~10% of both col-
orectal adenomas and carcinomas (Habermann et al., 2011). 
 
1.5 Epigenetics 
1.5.1 Epigenetic modifications 
The definition of epigenetics comprises heritable and acquired abnormalities in gene 
expression which are not due to changes in the DNA sequence (Holliday, 1987). Alt-
hough multiple epigenetic processes have been identified in transcription regulation, 
the covalent modifications of DNA, histone proteins or chromatin remodeling factors 
are hitherto most intensively studied (Esteller, 2011). Post-translational modifications 
on N-terminal amino acids (“tails”) of histones form a “histone code” which involves 
different chemical groups (i.a., methylation, acetylation, phosphorylation, ubiquityla-
tion) (Esteller, 2008). The effects vary depending on the degree (e.g., mono-, di-, and 
trimethylation), histone protein (e.g., H3 or H4), histone residue (e.g., lysine, arginine, 
serine) and their position (H3K4 and H3K9). However, the most-researched epigenetic 
modification occurs on the DNA. Methylation of DNA is exclusively observed on cyto-
sines which are followed by guanines in 5’→3’ direction, namely CpG dinucleotides. A 
methyl group is covalently added onto a cytosine which converts the pyrimidine deriv-
ative into 5-methylcytosine. Estimations state that about three out of four CpG sites 
are methylated in mammals (Jabbari and Bernardi, 2004). Moreover, CpG sites are 
not randomly distributed within the genome but cluster with high density in regions 
known as CpG islands (CGIs; length 0.5-2 kb). 70% of gene promoters located near 
the transcription start sites comprise CGIs (Saxonov et al., 2006). Analogous to CGIs, 
CpG sites in “shore” (up to 2 kb) and “shelf” regions (2-4 kb away from CGI) may also 
Introduction 
19 
be considered as regulatory regions for gene expression (Irizarry et al., 2009; Schnei-
der et al., 2016). Methylation of CGIs in development or disease progression was 
shown to be associated with post-translational modifications of histones. This methyl-
ation leads to an inactivating condensation of chromatin structures and, consequently, 
to gene silencing (Jaenisch and Bird, 2003; Weber et al., 2007). Conversely, unmethyl-
ated CGIs and CpG methylation within the gene body is associated with gene tran-
scription and silencing of transposable elements (e.g., LINE and SINE) (Esteller, 2008; 
Jones, 2012; Yoder et al., 1997). The methylome, which comprises the sum of the 
methylated CpG sites, is maintained by DNA methyltransferase 1 (DNMT1). This en-
zyme adds methyl-groups to replicated DNA strands. However, DNMT3A and 
DNMT3B are capable of catalyzing the addition of methyl-group to CpG sites de novo, 
and are, thus, associated with aberrant CpG methylation in CRC (Ibrahim et al., 2011). 
Most procedures which determine the methylation status of CpGs within the DNA 
utilize bisulfite conversion. In this procedure, sodium bisulfite converts unmethylated 
cytosine residues to uracil. However, 5-methylcytosines are protected from hydrolytic 
deamination by the catalyst. Although methylation analysis can be conducted by re-
striction enzyme sites, e.g., combined bisulfite restriction analysis (Fraga and Esteller, 
2002), most methods use PCR-amplification of converted DNA to characterize differ-
entially methylated positions (DMPs): qualitatively, e.g., by methylation-specific PCR 
(Herman et al., 1996), or quantitatively by methylation-sensitive qPCR MethyLight 
(Eads et al., 2000), DNA pyrosequencing (Tost et al., 2003) or DNA methylation mi-
croarray (Bibikova et al., 2011). The HumanMethylation450K BeadChip array permits 
the profiling of CGIs within a genome-wide scale with a single-nucleotide resolution. 
The array covers more than 485,000 CpG sites and, therefore, is a powerful tool as 
the analysis allows the detection of many thousands of DMPs (De Meyer et al., 2015). 
 
1.5.2 DNA methylation in colorectal tumorigenesis 
One of the first epigenetic alterations discovered was the low level of DNA methylation 
in tumors compared to corresponding normal tissues (Feinberg and Vogelstein, 1983). 
The state of hypomethylation contributes to CIN by promoting chromosomal recombi-
nation and rearrangement, reactivating transposable elements and causing the loss of 
imprinting (Bestor, 2005; Eden et al., 2003; Esteller, 2008). In the development of ne-
oplasms DNA methylation of 5-methylcytosines globally decreases as the lesion pro-
gresses, i.e., global hypomethylation (Fraga et al., 2004). Conversely, both the 
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frequency of hypermethylated CGIs and the imbalance of histone modifications in-
crease as a tumor progresses (Esteller, 2008). Hypermethylation of CpG-dense pro-
moters plays a central role in the initiation and the progression of neoplasms since it 
causes silencing of TSGs which are involved in cellular processes (Esteller, 2007; We-
ber et al., 2007). Interestingly, patterns of hypermethylated CGIs in promoters of TSGs 
appear to be specific to the cancer type (Costello et al., 2000; Esteller et al., 2001). 
The profile of frequently hypermethylated TSGs in colorectal tumorigenesis may com-
prise (Esteller, 2008): (i) transcription factors, e.g., RARβ2, GATA-4 and GATA-5; (ii) 
cell-cycle modulators, e.g., RASSF1A and p16INK4a; (iii) DNA repair proteins, e.g., 
MLH1 and MGMT; (iv) WNT-signaling modulators, e.g., APC, WIF1 and SFRP1. 
Colorectal tumors, which are affected in no small degree by CGI hypermethylation, 
are classified as CIMP+ tumors (Tycko, 2000). The high frequency is evaluated by as-
sessing the methylation status of marker loci, e.g., CDKN2A, MINT1, MINT2, MINT31, 
and MLH1 (Weisenberger et al., 2006). Nevertheless, CIMP+ tumors are predominantly 
associated with serrated neoplasia precursor lesions (Snover, 2011). This is under-
pinned by the presence of DMPs in serrated compared to conventional CRC (Conesa-
Zamora et al., 2015) and by hyper-methylated loci in sessile polyps and serrated can-
cers (Andrew et al., 2017). Genome-wide studies on aberrant DNA methylation re-
vealed the presence of four methylation clusters associated with CRC (Hinoue et al., 
2012; The Cancer Genome Atlas Network, 2012). Interestingly, the methylation status 
of CDKN2A, MLH1, and MGMT in CRC was previously linked to cancer recurrence 
(Chang et al., 2016). Multiple authors also claim that aberrant DNA methylation ap-
peared already in sporadic colorectal adenomas which are CIMP-/low (Galamb et al., 
2016; Patai et al., 2015; Silva et al., 2014; Voorham et al., 2013). Most of these studies 
focused solely on promoter methylation whereas the methylation of gene bodies is also 
believed to be crucial for the regulation of gene expression (Jones, 2012; Yang et al., 
2014). Galamb et al. (2016) showed that DMPs in colorectal tumors compared to nor-
mal tissue were most commonly found in gene body regions of WNT pathway genes, 
i.a., APC, AXIN2, CTNNB1 or SFRP1. DNA methylome analysis mapped aberrant CGI 
methylation to genes involved in the TGF-β pathway (including BMP3) (Ashktorab et 
al., 2014). Luo et al. (2014) found evidence for differences in methylation patterns 
across the progression from normal mucosa to adenoma and CRC. 
Despite these advances in profiling the methylome of colorectal adenomas and can-
cers, the putative role of CpG methylation in sporadic colorectal adenoma recurrence 
and tumor evolution is yet elusive and requires intense research.  
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1.6 Aneuploidy and chromosomal instability 
1.6.1 Abnormal karyotypes 
Tumor formation was firstly associated with the alteration of chromosomal material al-
most 130 years ago (von Hansemann, 1890). Boveri (1914) suggested that cancer 
originates from “imbalances in the chromosomes,” and hence, should be recognized 
as a disease of the chromosomes (Ried, 2009). Nowadays, the presence of an abnor-
mal number of chromosomes in a cell is termed “aneuploidy.” The gain and loss of 
chromosomes due to missegregation at high rates are defined as chromosomal insta-
bility (CIN) (Lengauer et al., 1997; Lengauer et al., 1998). Although aneuploidy is a 
common feature in tumor cells, aneuploidy and CIN are not synonymous (McGranahan 
et al., 2012). An aneuploid cell may originate from a single event of chromosome mis-
segregation accompanied by clonal expansion. Ultimately, aneuploid cells irrespective 
of CIN may present rather “homogeneous” clonal patterns of chromosomal aberra-
tions, while CIN causes “heterogeneous” patterns of chromosomal aberrations (Bak-
houm and Compton, 2012). However, CIN contributes as a form of genomic instability 
to the widely accepted “hallmarks of cancer” (Hanahan and Weinberg, 2011). CIN is 
classified by the gain or loss of whole chromosomes (i.e., numerical CIN) or chromo-
some fragments and rearrangements (i.e., structural CIN) (Lengauer et al., 1998; 
McGranahan et al., 2012). Structurally abnormal chromosomes and rearrangements 
are the results of chromosomal deletions, duplications, translocations, inversions, in-
sertions, rings and isochromosome formation (Huret et al., 2013). CIN cancer genomes 
often exhibit alterations of the whole- and the sub-chromosomal level (McGranahan et 
al., 2012). 
There is a controversy whether aneuploidy is the origin, or vice versa, principle con-
sequence of CIN. While many authors name aneuploidy as the direct consequence of 
CIN (Duesberg et al., 1998; Reish et al., 2006; Yuen, 2010), more recent studies claim 
that, in fact, aneuploidy leads to CIN (Lengauer et al., 1997; Nicholson et al., 2015; 
Passerini et al., 2016; Thompson and Compton, 2008; Sheltzer et al., 2011). 
 
1.6.2 Mechanisms leading to chromosomal instability 
CIN is a direct result of defects in the dynamic signaling cascade which conducts the 
mechanism of segregation of the chromosomes during mitosis. Briefly, the process of 
chromosome separation begins in prometaphase of mitosis. The nuclear envelope is 
broken down, and chromosomes attach to the spindle by binding of microtubules at 
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kinetochores (Compton, 2000), i.e., protein structures located at the chromosomal cen-
tromeres (Maiato et al., 2004). Kinetochore microtubules emerge from the spindle 
poles and reach for the kinetochores. During metaphase, chromosomes are aligned at 
the metaphase plate in the center of the cell. Nevertheless, a single chromosome un-
attached or falsely oriented to the spindle is capable of delaying the onset to anaphase 
by emitting a “wait anaphase” signal (Rieder et al., 1994; Rieder et al., 1995; Thompson 
et al., 2010). This “signal” is transduced by spindle-checkpoint proteins inducing the 
inhibition of the anaphase-promoting complex/cyclosome (APC/C; ubiquitin-protein lig-
ase) via formation of the spindle assembly checkpoint (SAC) (Herzog et al., 2009). 
Both SAC and cyclin-dependent kinases preserve the cohesion of sister chromatids 
(Thompson et al., 2010). When no errors occur in the transition towards anaphase, 
APC/C will not be inhibited and ubiquitinylates securin. The protease separase is acti-
vated and cleaves the multiprotein complexes of cohesins (Herzog et al., 2009). 
Due to the multiplicity of genes involved in the process of accurate chromosome 
segregation, there are multiple error-prone targets whose alteration eventually leads 
to cancer formation and CIN (Thompson et al., 2010). Yuen (2010) summarized the 
mitotic errors possibly affecting chromosome segregation: (i) sister chromatid cohesion 
defects (Zhang et al., 2008), (ii) defective centrosome duplications (i.e., supernumerary 
centrosomes) (Ganem et al., 2009), (iii) weakened (i.e., nondisjunction errors) or hy-
peractivated spindle assembly checkpoint (Cahill et al., 1998; Weaver and Cleveland, 
2006), and (iv) extremely stable kinetochore-microtubule attachments to chromosomes 
(Bakhoum et al., 2009). Structural CIN is also linked to being driven by telomere dys-
function caused by chromosomal ends which enter breakage-fusion-bridge-cycles 
(O’Hagan et al., 2002; Pino and Chung, 2010). Alterations in genes encoding cell cycle 
proteins are perceived to allow cells with DNA double-strand breaks to divide and ac-
cumulate structural CIN (Lengauer et al., 1998). Thus, alterations of DNA repair genes 
of the DNA damage response machinery (i.a., fixing DNA double-strand breaks) are 
involved in carcinogenesis (Gorgoulis et al., 2005; Khanna and Jackson, 2001). 
The tumorigenesis of epithelial cancers is commonly (incidences exceeding 50% 
[Carter et al., 2012]) affected by genome duplication, i.e., polyploidization. This cata-
lyzes CIN (Holland and Cleveland, 2009). Polyploidy depicts the condition of a cell 
which possesses more than two haploid chromosome sets (i.e., diploid; 2N), with near-
triploid (3N) and near-tetraploid (4N) being the most common forms observed (Weaver 
and Cleveland, 2006). Tetraploidy can be caused by cell-cell fusion, cytokinesis failure, 
mitotic slippage or endoreduplication (Holland and Cleveland, 2009; Quintanilla, 2017).  
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1.6.3 Consequences of aneuploidy and chromosomal instability 
Aneuploidy has been recognized for decades as severely detrimental for the patients. 
Thus, chromosome abnormalities induce miscarriages of unborn, lead to congenital 
mental retardation and are associated with cancer (Nagaoka et al., 2012). However, 
cellular effects caused by aneuploidy remained elusive in the past. Recently, a direct 
correlation between mRNA expression and chromosome copy number was demon-
strated: mRNAs of corresponding genes, located on aneuploid chromosomes, were 
present in more considerable extent compared to euploid controls (Ried et al., 2012; 
Rutledge and Cimini, 2016; Stingele et al., 2012). Interestingly, observations in yeast 
and human cells suggest that aneuploidy not only affects the corresponding genes but 
also has genome-wide effects on gene expression (Dephoure et al., 2014; Sheltzer et 
al., 2017). Speculatively, genes located on aneuploid chromosomes may encode tran-
scriptional regulators of genes on other chromosomes (Rutledge and Cimini, 2016). 
CNAs were also associated with changes in the abundance of proteins, e.g., protein 
complexes and kinases (Stingele et al., 2012; Torres et al., 2007). Imbalances in pro-
tein levels interfere with the stoichiometry of specific protein complexes and lead to an 
excess of uncomplexed proteins generating proteotoxic stress (Gordon et al., 2012).  
Consequently, aneuploid cells may exhibit an overwhelmed protein degradation 
pathway resulting in protein misfolding and aggregation (Gordon et al., 2012). That in 
turn negatively affects the cellular fitness and proliferation, although aneuploidy ap-
pears to be beneficial for cancer cells under certain circumstances (Rutledge and Ci-
mini, 2016). Storchová (2012) conjectured that aneuploidy protects the cells from other 
stress factors and that increased CIN accelerates the evolution of clones with advan-
tageous karyotypes. Hence, aneuploidy may be an effective mechanism to confer a 
selective advantage to the cells by providing tolerance to stress (Gordon et al., 2012). 
 
1.6.4 Aneuploidy in colorectal tumorigenesis 
Beroukhim and colleagues (2010) revealed that 25% of a typical cancer sample’s ge-
nome is affected by arm-level somatic CNAs. This fact corroborates the relevance of 
aneuploidy for tumor initiation and progression. Hence, chromosomal imbalances were 
also investigated among colorectal tumors. Proposed by the adenoma-carcinoma se-
quence, chromosomal abnormalities occur early and increase in the evolution from 
normal mucosa to adenoma and adenocarcinoma (Fearon and Vogelstein, 1990). Cy-
togenetic analysis of colorectal adenomas displayed chromosomal gains of 3, 7, 13 
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and 20 and the loss of 18 (Bomme et al., 1994). Other researchers identified a similar 
pattern with chromosomal gains of 9, 12, 13 and 20, and losses of 18q (Muleris et al., 
1994). The first investigation by comparative genomic hybridization (CGH) showed no 
chromosomal alterations in MSI+ CRC, whereas sporadically occurring CIN+ CRC re-
vealed characteristic CNAs, namely: gains of the chromosome (arms) 7, 13 and 20q 
and losses of 9p, 17 and 18 (Schlegel et al., 1995). However, Ried and collaborators 
(1996) were the first to analyze the progression from adenoma to carcinoma by CGH 
which unveiled a stepwise accumulation of chromosomal aberrations including gains 
of 1, 7, 8q, 13 and 20 and losses of 4, 8p and 18q. A rash of similar studies utilized 
CGH to confirm these earlier results in colorectal adenomas and CRC (Camps et al., 
2006; De Angelis et al., 1999; Douglas et al., 2004; Hermsen et al., 2002; Ried et al., 
1999). Noteworthy, these characteristic CNAs were not only presented in Western pa-
tients but also consistently found in Asians (He et al., 2003; Poeaim et al., 2005). 
Accordingly, this led to the updated view (Figure 10) that the accumulation of char-
acteristic chromosomal aberrations drives the colorectal tumorigenesis of sporadically 
occurring lesions. These include gains of 7 and 20q in low-grade adenomas and is 
accompanied by gains of 8q and 13 and losses of 4q, 8p, 17p and 18 in the progression 
from high-grade adenomas towards CRC (Grade et al., 2006; Ried et al., 2012). A few 
aneuploid adenomas were identified to be affected by CIN (Jones et al., 2007), while 
studies on CNA profiles of polypoid and nonpolypoid adenomas revealed controversial 
results (Postma et al., 2005; Richter et al., 2003). Many studies focused on colorectal 
tumor development, patient survival and metastasis (Grade et al., 2006), hitherto none 
investigated the relevance of CNAs on local adenoma recurrence.  
Figure 10. Summary plot of chromosomal aberrations in CRC detected by aCGH. Chromo-
somal gains (red) are predominantly seen on chromosomes 7, 8q, 13 and 20q, while chromosomal 
losses (green) show the highest frequencies on 8p and 18. Y-axis depicts the average values 
expressed as log2 ratio. Image extracted from Camps et al. (2008). 
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1.7 Tumor heterogeneity 
1.7.1 The concept of tumor heterogeneity 
The theory of the evolutionary development of cancer subclones dates back four dec-
ades ago. Peter Nowell (1976) proposed in his groundbreaking article that a progenitor 
cell may give rise to mutant clonal subpopulations within cancer and that the progres-
sion of neoplasms is based on the acquisition of genetic alterations which lead to the 
Darwinian development of clones. Since then, intensified research on cancer develop-
ment utilized a broad spectrum of genomic approaches which substantiated the widely 
accepted view of tumors bearing inter- and intratumor heterogeneity (Figure 11). Inter-
tumor heterogeneity describes the genetic and phenotypical divergence among tumors 
from individual patients. That is further substantiated by variations between tumors of 
different tissues and cell types, which vary in genomic landscapes and, consequently, 
in prognosis and treatment response (Burrell et al., 2013). 
However, intratumor heterogeneity (ITH) denominates the observation that even an 
individual tumor may be reigned by multiple subclonal populations which acquired dif-
ferent genetic alterations (Burrell et al., 2013). An ongoing generation of (genetically 
anomalous) subclones leads to an increase of the intratumor heterogeneity and influ-
ences the degree of genomic instability (i.e., CIN) which confers the basis for multiple 
features defining the tumor (Camps et al., 2013). 
  
Figure 11. Inter- and intratumor heterogeneity. Among individual cancer patients there is a genetic 
and phenotypical variation between cancers of different tissue and cell type. Additionally, variation 
among patients with the same cancer type is frequently observed. A phenomenon called intertumor 
heterogeneity (left image). Moreover, the fraction of cancer cells might display a set of genetically 
divergent subclones which contribute to intratumor heterogeneity (middle image). Subclonal popula-
tions can be revealed by fluorescence in situ hybridization (FISH; square). Image extracted from Bur-
rell et al. (2013). 
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The underlying causations for inter- and intratumor heterogeneity are a constant 
matter of debate. Visvader (2011) proposed two models causing intertumoral hetero-
geneity: (i) the “(epi-)genetic mutation model” and (ii) the “cell-of-origin model.” Con-
trary, ITH is generated in the model of clonal evolution by tumor cells emerging from a 
single or multiple subclones (Nowell, 1976; Russnes et al., 2011). However, according 
to the model of cancer stem cells, a single progenitor stem cell expands and generates 
a monogenomic clone population while multiple rare stem cell progenitors give rise to 
polygenomic populations. Nevertheless, evidence also suggests a mutator phenotype 
model gradually accumulating genetic alterations which result in a highly genetically 
diverse subclonal tumor (Russnes et al., 2011). Burrell and Swanton (2014) proposed 
that ITH is generated by the clonal evolution of the cancer genome which occurs in a 
linear or branched fashion (Figure 12A). Linear evolution of the tumor is characterized 
by the acquisition of beneficial genetic alterations which allow both clonal expansion 
and clonal succession in competing with other clones. The elimination of competing 
subclones via outgrowing by a novel dominant clone is described as clonal sweep 
(Burrell et al., 2013). Branched evolution, in contrast, could be the result of a failed 
clonal sweep which is accompanied by the appearance of sister clones which grow in 
parallel and compete in Darwinian evolution (Burrell and Swanton, 2014). Given that 
tumors are subject to constant evolutionary variation, the composition of the subclonal 
pattern within a particular lesion is rather temporal than static which is expressed in 
temporal heterogeneity (Burrell and Swanton, 2016). Cross et al. (2016) suggested 
that the model of gradualism in the clonal evolution of cancers demands adjustment 
and is better described by a punctuated equilibrium of variable evolutionary tempos. 
The clonal composition of a tumor may vary between surgical excision and clinical 
recurrence as minor and major clones take part in clonal selection (Figure 12B). Un-
derstanding the relevance of clones with different frequencies (i.e., major and minor 
clones) “over space and time” attracts notice (Burrell and Swanton, 2016). 
Utilization of single-cell next-generation sequencing (NGS) approaches and the sin-
gle-cell variant of multiplex-interphase fluorescence in situ hybridization (miFISH) (see 
1.7.2 FISH) confirmed the presence of branched intratumor heterogeneity in both he-
matological and solid tumors, e.g., the pancreas and the breast (Anderson et al., 2011; 
Campbell et al., 2010; Heselmeyer-Haddad et al., 2012). As early as in the 1990s, 
colonic adenomas were shown to be of polyclonal origin contrary to the scientific per-
spective at that time which favored monoclonal development (Novelli et al., 1996). 
Thirlwell and coworkers (2010) accumulated evidence for polyclonality present in 
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colorectal neoplasms by analyzing the loss of heterozygosity in APC, KRAS, and TP53 
via Sanger sequencing of multiple crypts within a single tumor. Although the role of 
ITH was elucidated within colorectal lesions, the putative variation of subclonal pat-
terns between primary and recurrent colorectal adenomas is yet elusive. 
 
1.7.2 Fluorescence in situ hybridization (FISH)  
The approach of molecular cytogenetics offers the opportunity to utilize chromosomes 
and their respective architecture as prognostic, predictive and diagnostic biomarkers 
(Wippold and Perry, 2007). Additionally, the cytogenetic detection of chromosomal 
structures may support the identification of subclonal populations which contribute to 
tumor heterogeneity. Therefore, molecular cytogenetics provides several powerful 
techniques among which FISH is of outstanding importance in research and routine 
diagnostics. While the first in situ hybridization for chromosome analysis was 
performed by radioactively labeled DNA probes (Pardue and Gall, 1969), utilization of 
fluorescent dye-labeled probes demonstrated superiority since their discovery (Rudkin 
and Stollar, 1977). Although nuclei in metaphase preparations were exclusively 
accessible by FISH back in the days, improvements of the technique then provided 
hybridization procedures of nuclei in interphase which paved the way for analyses of 
both fresh and archived clinical samples (Cremer et al., 1986). Moreover, advances in 
the technique contributed to the widespread and everyday use. FISH is based on the 
Figure 12. Trajectories reflect the evolution of cancers. (A) The evolution of cancer follows either 
the linear (left box) or the branched (right box) trajectory. Linear evolution is characterized by clonal 
sweeps which eliminate antecedent clones by outgrowing the population. In contrast, branched evo-
lution is distinguished by genetically different clones arising independently and expanding in parallel. 
Image extracted from Burrell and Swanton (2014). (B) While a tumor may be dominated by several 
clones at the time of (surgical) excision, early divergence of clones might, in fact, account for clinical 
recurrence. Image extracted from Burrell and Swanton (2016). 
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complementary binding of labeled DNA probe strand fragments onto a target DNA 
locus (Figure 13A). The probe has to be of a certain length to precisely bind the target 
DNA and to emit a sufficient signal intensity allowing the detection by fluorescence 
DNA microscopy (Wippold and Perry, 2007). Combining multiple FISH probes with 
multi-colored fluorochromes makes the simultaneous hybridization of interphase nuclei 
assessable (Figure 13B). Nuclei are specifically counter-stained with DAPI. In this 
study, the whole technique is termed miFISH in the abbreviated notation. Location, 
presence, and size of the probe signals are of particular relevance for the evaluation 
of the probe and the targeted DNA. FISH probes can be targeted against (i) specific 
genes and small chromosomal regions, (ii) repetitive sequences within the centromeric 
region of chromosomes, (iii) repetitive sequences at the telomeric regions of 
chromosomes and (iv) sequences painting whole-chromosomes for karyotyping 
(Kontogeorgos, 2004). Specific gene probes were designed using bacterial artificial 
chromosomes (BAC) which cover the entire human genome. Hence, gene-specific and 
centromere probes, respectively, proved useful to study chromosomal alterations 
within tumors. Consequently, numerous studies demonstrated that FISH and single-
cell miFISH are powerful cytogenetic techniques to investigate tumorigenesis, disease 
progression and tumor heterogeneity within a variety of cancers (Habermann et al., 
2013; Heselmeyer-Haddad et al., 2012; Heselmeyer-Haddad et al., 2014; Oltmann et 
al., 2018; Wangsa et al., 2009; Wangsa et al., 2016).  
Figure 13. Schematic representation of FISH and miFISH on adenoma nuclei. (A) Schematic repre-
sentation of fluorescence in situ hybridization. The fluorescent dye-labeled DNA probe is denatured to-
gether with the target DNA. DNAs hybridize with each other according to the complementary bases. The 
fluorescence tag is detected with a fluorescence microscope allowing to assess the copy number status 
of genes. Image extracted from Wippold and Perry (2007). (B) Representative merged fluorescence image 
of single-cell miFISH performed on adenoma nuclei fixed on cytospin-slides. Nuclei were counter-stained 
with DAPI and digitally marked by a white frame. FISH revealed neutral copy numbers ( i.e., two signal 
counts) for all probes hybridized except for the blue probe (three signals, i.e., copy number gain). 
 
A B 
Introduction 
29 
1.8 Objectives 
Knowledge of the epigenetic and genetic signatures underlying local recurrences of 
colorectal adenomas are hitherto limited, which confers a health burden for patients. 
Overall, this study aimed to improve the understanding of the development of recur-
rence of sporadic colorectal adenomas. The thesis does not only provide an integrative 
analysis of the epigenetic and genetic landscapes of primary colorectal adenomas 
without and with recurrence but also an examination of primary adenomas with the 
corresponding recurrent adenomas, so-called matched pairs. 
The first objective was to determine whether epigenetic and genetic markers could 
augment the prediction of adenoma recurrence based on the signature of the primary 
tumor. With our epigenetic approach, we sought to highlight signatures of putative dif-
ferentially methylated CpG positions (DMPs). DMPs were evaluated to uncover spe-
cific associations with emphasis on the genomic distribution and pathway enrichment. 
Our genetic approaches assessed copy number alterations (CNA) in the tumor bulk 
and at the level of single cells. CNAs were utilized to quantify clonal diversity within the 
samples and to identify predictive biomarkers for local recurrence of adenomas. This 
should elucidate whether adenoma recurrence occurs as a consequence of an acqui-
sition of distinct genetic alterations. 
Second, this study was focused on the clonal evolution from the primary adenoma 
to the corresponding recurrent adenoma. Particularly, patterns of genomic imbalances 
within the adenoma samples could aid to clarify whether genomic instability and intra-
tumor heterogeneity change throughout the process of adenoma recurrence. Quanti-
tative diversity measures were applied to assess inter- and intratumor heterogeneity 
across the adenomas. Moreover, CNAs of single cells were used to infer patterns of 
clonal evolution in adenoma recurrence. 
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2 MATERIALS AND METHODS 
2.1 Materials 
Table 2. List of kits. 
Kit Supplier 
DNA Clean & Concentrator™-25 (# D4033) 
EnVision Detection System, Peroxidase/DAB, Rab-
bit/Mouse, Dako (# K5007) 
EpiTect® Plus DNA Bisulfite Kit (# 59124) 
Genomic ULS Labeling Kit 
Genomic ULS Purification Module, KREApure 
Gentra Puregene Tissue Kit (# 158667) 
Infinium FFPE QC Kit (#WG-321-1001) 
Infinium HD FFPE DNA Restore Kit (#WG-321-1002) 
Infinium HumanMethylation 450K BeadChip Array 
Oligo aCGH/ChiP-on-chip Hybridization Kit 
Oligo aCGH/ChiP-on-chip Wash Buffer Kit 
Plasmid Maxi Kit 25 (# 12163) 
PyroGold SQA Reagent Kit 
SurePrint G3 Human CGH Microarray Kit 8x60K 
Zymo Research, Irvine, CA, USA 
Agilent, Santa Clara, CA, USA 
 
Qiagen, Hilden, Germany 
Agilent, Santa Clara, CA, USA 
Agilent, Santa Clara, CA, USA 
Qiagen, Hilden, Germany 
Illumina, San Diego, CA, USA 
Illumina, San Diego, CA, USA 
Illumina, San Diego, CA, USA 
Agilent, Santa Clara, CA, USA 
Agilent, Santa Clara, CA, USA 
Qiagen, Hilden, Germany 
Qiagen, Hilden, Germany 
Agilent, Santa Clara, CA, USA 
 
Table 3. List of consumables. 
Consumable Supplier 
Abgene™ 96-well 0.8ml, Deep-well plate MSA5 
Aluminum foil, Reynolds Wrap® 
Corning™ 30 ml Glass Tube 
Corning™ Mini Bioreactor 50 ml 
Coverslips, 22x22 mm2, Glass 
Cytology Funnel, Fisherbrand™, Single (# 10-335) 
Fixogum Rubber Cement 
Lens cleaning tissue, Whatman® 
Microscope Adhesion Slides, SuperFrost™ Plus 
Microscope Slides, Duran® frosted 
Magnetic stir bar, Spinbar® 
Nalgene™ Oak Ridge Glass Centrifuge Tube 30 ml 
Nalgene™ Oak Ridge PPCO Centrifuge Tube 50 ml 
PCR tube, 0.5 ml, multiply® strip 
Parafilm® M  
Pasteur pipettes, Brand®, plastic 
Pasteur pipettes, glass 
Pipette Tips, epT.I.P.S.® (red, grey, yellow, blue) 
Thermo Fisher Sc., Waltham, MA, USA 
Reynolds Cons. Pro., Lake Forest, IL, USA 
Corning, Corning, NY, USA 
Corning, Corning, NY, USA 
VWR International, West Chester, PA, USA 
Thermo Fisher Sc., Waltham, MA, USA 
Marabu, Tamm, Germany 
GE Healthcare, Chicago, IL, USA 
Langenbrinck, Emmendingen, Germany 
DWK Life Sciences, Wertheim, Germany 
VWR International, West Chester, PA, USA 
Thermo Fisher Sc., Waltham, MA, USA 
Thermo Fisher Sc., Waltham, MA, USA 
Sarstedt, Nümbrecht, Germany 
Bemis Company, Neenah, WI, USA 
Sigma-Aldrich, St.Louis, MO, USA 
Carl Roth, Karlsruhe, Germany 
Eppendorf, Hamburg, Germany 
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Consumable Supplier 
Polypropylene Centrifuge Tube 15 ml 
Precision wipes, KIMTECH 
Q-PCR plate MicroAMP Fast 96-well 
Reaction tube, 1.5 ml 
Reaction tube, 2.0 ml 
Serological pipettes (2 ml, 5 ml, 10 ml, 25 ml) 
Surgical Scalpel FEATHER® 
Syringe and Hypodermic Needle “Sterican” 
Corning, Corning, NY, USA 
Kimberly-Clark Corp., Neenah, WI, USA 
Applied Biosystems, Foster City, USA 
Eppendorf, Hamburg, Germany 
Eppendorf, Hamburg, Germany 
Sarstedt, Nümbrecht, Germany 
Sigma-Aldrich, St. Louis, MO, USA 
B. Braun AG, Melsungen, Germany 
 
Table 4. List of reagents and chemicals. 
Reagent Supplier 
Acetone  
Agarose, UltraPure™, 100 g (# 16500-100) 
Antibody, CDX2, clone DAK-CDX2, Dako (# M3636) 
Antibody, MLH1, clone ES05, Dako (# M3640) 
Antibody, MSH2, clone FE11, Dako (# IR085) 
Antibody, MSH6, clone EP49, Dako (# IR086) 
Antibody, PMS2, clone EP51, Dako (# M3647) 
Antibody diluent (# ZUC025) 
Aqua Ad Injectabilia (ddH2O) 10 ml (# 3113087) 
β-Mercaptoethanol (2-Mercaptoethanol) (# M6250) 
BAC clones, stab agar cultures 
Bovine Serum Albumin (BSA), lyophilized (# A2153) 
CCP10 FISH Probe (# CT-CCP010)  
Chloramphenicol, 20 mg/ml (# C0378) 
DAPI (4′,6-diamidino-2-phenylindole) (# D9542) 
Dextran Sulfate, 50% Solution, 100 ml (# S4030) 
DNA Gel Loading Solution (# 351-028-661) 
DNA Molecular Weight Marker II (# 10236250001) 
DNA Polymerase I, Kornberg, 5 units/µl (# 104 485) 
DNase I, from bovine pancreas, 100 mg (# 104 159) 
dNTPs: dATP (# 105 1440), dCTP (# 105 1482), 
dGTP (# 105 1466), dTTP (# 105 1458) 
EDTA, 0.5M, pH 8.0, 100 ml (# 351-027-721) 
Ethidium Bromide, UltraPure™, 10 ml (# 15585011) 
Ethyl Alcohol, Pure, Proof 200 
Fluorophore DY-415-dUTP, 100 nmol (# 415-34) 
Fluorophore DY-505-dUTP, 100 nmol (# 505-34) 
Fluorophore DY-547P1-dUTP, 100 nmol (# 547-34) 
Fluorophore DY-590-dUTP, 100 nmol (# 590-34) 
Carl Roth, Karlsruhe, Germany 
Invitrogen, Carlsbad, CA, USA 
Agilent, Santa Clara, CA, USA 
Agilent, Santa Clara, CA, USA 
Agilent, Santa Clara, CA, USA 
Agilent, Santa Clara, CA, USA 
Agilent, Santa Clara, CA, USA 
Zytomed Systems, Berlin, Germany 
B. Braun AG, Melsungen, Germany 
Sigma-Aldrich, St. Louis, MO, USA 
BACPAC Resources Center, CA, USA 
Sigma-Aldrich, St. Louis, MO, USA 
CytoTest, Rockville, MD, USA 
Sigma-Aldrich, St. Louis, MO, USA 
Sigma-Aldrich, St. Louis, MO, USA 
Sigma-Aldrich, St. Louis, MO, USA 
Quality Biological, Gaithersburg, MD, USA 
Roche-Boehringer, Mannheim, Germany 
Roche-Boehringer, Mannheim, Germany 
Roche-Boehringer, Mannheim, Germany 
Roche-Boehringer, Mannheim, Germany 
 
Quality Biological, Gaithersburg, MD, USA 
Invitrogen, Carlsbad, CA, USA 
Warner Graham, Cockeysville, MD, USA 
Dyomics, Jena, Germany 
Dyomics, Jena, Germany 
Dyomics, Jena, Germany 
Dyomics, Jena, Germany 
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Reagent Supplier 
Fluorophore DY-651-dUTP, 100 nmol (# 651-34) 
Formamide, deionized, 500 g (# AM9342) 
GelRed™ Nucleic Acid Gel Stain (# 41001-41003-T) 
GeneRuler 100 bp DNA ladder (# SM0243) 
Glycerol, 100 ml (# G5516) 
Isopropanol (2-Propanol), 500 ml (# I9516) 
Hematoxylin, Mayer’s (# 1092490500) 
Human Cot-1 DNA™, 1 mg/ml (# 15279011) 
Human Genomic DNA, female (# G1521) 
Human Genomic DNA, male (# G1471) 
Lysogeny broth, Miller (# L3152-1KG) 
Magnesium Chloride, 2 M, 100 ml (# 340-034-721) 
Magnesium Chloride Solution, 25 mM (# M8787) 
NP-40 Lysis Buffer (# A611-J619-10) 
PBS Buffer, 1x, pH 7.2, 1 L (# RGE-3190) 
Pepsin from porcine gastric mucosa (# P6887) 
Peroxidase Blocking Solution, Dako (# S202386) 
Pertex Mounting Medium (# 41-4011-00) 
Primer, desalted, variable DNA sequences 
Proteinase, Bacterial Type XXIV (# P8038) 
Proteinase K, Puregene (# 158918) 
REDTaq® ReadyMix™ PCR Reaction Mix 
ROTISOLV® HPLC Gradient, ddH2O (# A5112) 
Salmon Testes Sonicated DNA (# GE27-4565-01) 
Sodium Acetate, 3M, pH 5.2, 100 ml (# 351-035-721) 
Sodium Chloride, 5M, 100 ml (# 351-036-721) 
SSC Buffer, 20x premixed  
Stabilization and Drying Solution for aCGH 
Sulforhodamine 101 (# S7635) 
SYBR® Green Premix Ex Taq™ II (# RR820A) 
 
Target Retrieval Solution, pH 9.0, Dako (# S2367) 
TBS buffer (# WL587C2500) 
Tris-HCl, 1M, pH 8.0, 100 ml (# 351-007-101) 
Tween 20, 50% Solution, 20 ml (# 003005) 
Vectashield Antifade Mounting Medium w/o DAPI 
Xylene 
Dyomics, Jena, Germany 
Invitrogen, Carlsbad, CA, USA 
Biotium, Fremont, CA, USA 
Thermo Fisher Sc., Waltham, MA, USA 
Sigma-Aldrich, St. Louis, MO, USA 
Sigma-Aldrich, St. Louis, MO, USA 
Merck, Darmstadt, Germany 
Invitrogen, Carlsbad, CA, USA 
Promega, Fitchburg, WI, USA 
Promega, Fitchburg, WI, USA 
Sigma-Aldrich, St. Louis, MO, USA 
Quality Biological, Gaithersburg, MD, USA 
Sigma-Aldrich, St. Louis, MO, USA 
Quality Biological, Gaithersburg, MD, USA 
KD Medical, Columbia, MD, USA 
Sigma-Aldrich, St. Louis, MO, USA 
Agilent, Santa Clara, CA, USA 
Medite, Nussloch, Germany 
Sigma-Aldrich, St. Louis, MO, USA 
Sigma-Aldrich, St. Louis, MO, USA 
Qiagen, Hilden, Germany 
Sigma-Aldrich, St. Louis, MO, USA 
Carl Roth, Karlsruhe, Germany 
GE Healthcare, Chicago, IL, USA 
Quality Biological, Gaithersburg, MD, USA 
Quality Biological, Gaithersburg, MD, USA 
Roche, Basel, Switzerland 
Agilent, Santa Clara, CA, USA 
Sigma-Aldrich, St. Louis, MO, USA 
Takara Bio Europe, Saint-Germain-en-
Laye, France 
Agilent, Santa Clara, CA, USA 
DCS Diagnostics, Hamburg, Germany 
Quality Biological, Gaithersburg, MD, USA 
Thermo Fisher Sc., Waltham, MA, USA 
Vector Laboratories, Burlingame, CA, USA 
Carl Roth, Karlsruhe, Germany 
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Table 5. List of technical equipment. 
Equipment Supplier 
Agilent Microarray Scanner Bundle 8x60K 
Autostainer Plus Staining System, Dako 
Centrifuge, BeckmanCoulter© AvantiJ25 
Centrifuge, Eppendorf 5417 R 
Centrifuge, Minifuge GL 
Centrifuge, Shandon Cytospin® 3 
Dri-Block® heater, Techne 
DUET scanning imaging workstation 
Electrophoresis Chamber, Bio-Rad 200 
Fluorescence microscope BX63 with 8 slide-stage 
Glass pen with tungsten tip (# 2-5030) 
Glassware 
Hybridization chamber (SureHyb) and gasket slides 
Hybridization chamber and gasket slides (HM450K) 
Hybridization oven, temperature set at 65°C 
Hybridization oven rotisserie 
Incubator (20% O2; 5% CO2; 37°C) 
Incubator and Shaker, Series 25 
iScan Microarray Scanner 
Laboratory scale 
Magnetic hot plate stirrer, Brinkmann® Heidolph® 
Microscope and Scanner M8 
Microtome HM560 
Ozone-barrier slide cover 
Ozone-controlled enclosure 
Qubit 4 Fluorometer 
Real-time Analyzer, ABI StepOne Plus PCR System 
pH-Meter, digital, WTW pH320 
Phase contrast microscope, Axiovert 25 
Pipetboy acu 2 
Pipetus® 
Pipettes, Eppendorf Research® plus (0.1-2.5 µl, 0.5-
10 µl, 2-20 µl, 10-100 µl, 20-200 µl, 100-1000 µl) 
PyroMark Q24 cartridge 
PyroMark Q24 device 
PyroMark Vacuum Prep Station 
Scale, BP3015 
Shaker MTS4 
Slide-staining dish with rack, 250 ml and 1.5 l 
Agilent, Santa Clara, CA, USA 
Agilent, Santa Clara, CA, USA 
BeckmanCoulter, Fullerton, CA, USA 
Eppendorf, Hamburg, Germany 
Heraeus, Hanau, Germany 
Thermo Fisher Sc., Waltham, MA, USA 
Cole-Parmer, Staffordshire, UK 
BioView, Rehovot, Israel 
Bio-Rad Laboratories, Hercules, CA, USA 
Olympus, Tokyo, Japan 
neoLab Migge, Heidelberg, Germany 
Schott, Mainz, Germany 
Agilent, Santa Clara, CA, USA 
Illumina, San Diego, CA, USA 
SciGene, Sunnyvale, CA, USA 
SciGene, Sunnyvale, CA, USA 
Heraeus / Kendro, Düsseldorf, Germany 
New Brunswick Scientific, Edison, NJ, USA 
Illumina, San Diego, CA, USA 
Sartorius, Göttingen, Germany 
Heidolph, Schwabach, Germany 
PreciPoint, Freising, Germany 
Microm International, Walldorf, Germany 
Agilent, Santa Clara, CA, USA 
Agilent, Santa Clara, CA, USA 
Thermo Fisher Sc., Waltham, MA, USA 
Applied Biosystems, Foster City, USA 
Xylem Analytics, Weilheim, Germany 
Zeiss, Jena, Germany 
INTEGRA Biosciences, Biebertal, Germany 
Hirschmann, Eberstadt, Germany 
Eppendorf, Hamburg, Germany 
 
Qiagen, Hilden, Germany 
Qiagen, Hilden, Germany 
Qiagen, Hilden, Germany 
Sartorius, Göttingen, Germany 
IKA-Werke, Staufen, Germany 
DWK Life Sciences, Wertheim, Germany 
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Equipment Supplier 
SOLO satellite workstation 
Spectrophotometer, NanoDrop™ ND-1000 
Speed Vacuum Concentrator, SpeedVac 
SureScan mircoarray scanner (# G2565BA) 
Thermal Cycler with heated lid, peqSTAR® 
Thermomixer, Eppendorf 5436 
ThermoBrite StatSpin System 
UV-transilluminator 
Vortex MS2 Minishaker 
Vortex-Genie 2 
Water bath (37°C, 45°C, 60°C), VWR 1245 
BioView, Rehovot, Israel 
Thermo Fisher Sc., Waltham, MA, USA 
Savant, Ramney, MN, USA 
Agilent, Santa Clara, CA, USA 
PEQLAB, Erlangen, Germany 
Eppendorf AG, Hamburg, Germany 
Abbott Molecular, Des Plaines, IL, USA 
Intas Science Imaging, Göttingen, German 
IKA-Werke, Staufen, Germany 
Scientific Industries, Woburn, USA 
VWR International, West Chester, PA, USA 
 
Table 6. List of software and databases. 
Software Supplier 
Bioconductor software package minfi (R-based) 
BioView, Version 3.6.0.16 
CpG Island Finder database 
DotEditor, Version 0.3.1 
ENSEMBL database 
Excel Spreadsheet 2016 
Feature Extraction Software, Version 10.7.1.1 
FISHtrees 
GeneCards database 
Gene Cluster, Version 3.0 
 
Gene Expression Omnibus (GEO) database 
Gene Set Enrichment Analysis (GSEA)/MSigDB v6.1 
 
GenomeStudio® Methylation Module, Version 1.8 
GraphPad Prism 6.0 Statistics 
Inkscape, Version 0.92.1 
Java Tree View, Version 1.1.6r4 
NEXUS Copy Number, Version 8.0 
Photoshop, CS2 
PowerPoint 2016 
Pyro Q-CpG Software 
PyroMark Assay Design Software 
REST, Relative Expression Software Tool 2009 
Venn Diagram Plotter, Version 1.5.5 
Word 2016 
http://www.bioconductor.com 
BioView, Rehovot, Israel 
http://www.dbcat.cgm.ntu.edu.tw 
http://www.vincenthee.github.io/DotEditor/ 
http://www.ensembl.org 
Microsoft, Redmond, WA, USA 
Agilent, Santa Clara, CA, USA 
ftp://ftp.ncbi.nlm.nih.gov/pub/FISHtrees 
http://www.genecards.org 
Laboratory of DNA Information Analysis, 
University of Tokyo, Japan 
https://www.ncbi.nlm.nih.gov/geo/ 
http://software.broadinsti-
tute.org/gsea/msigdb/annotate.jsp 
Illumina, San Diego, CA, USA 
GraphPad Software, La Jolla, CA, USA 
http://www.inkscape.org/en/ 
http://www.jtreeview.sourceforge.net 
BioDiscovery, El Segundo, CA, USA 
Adobe Systems, San Jose, CA, USA 
Microsoft, Redmond, WA, USA 
Qiagen, Hilden, Germany 
Qiagen, Hilden, Germany 
Qiagen, Hilden, Germany 
https://omics.pnl.gov/software/ 
Microsoft, Redmond, WA, USA 
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2.2 Patient samples 
Formalin-fixed paraffin embedded (FFPE) tissue samples were collected from the tis-
sue archive of the Institute of Pathology of the University Medical Centre Mannheim 
between 2002 and 2014. In total, 87 (68 biological individuals) FFPE colorectal ade-
noma specimens (and three additional normal mucosae samples) were obtained. The 
selection was performed by reviewing the electronic clinical database of the Central 
Interdisciplinary Endoscopy Unit of the University Medical Centre Mannheim of pa-
tients who underwent endoscopic resection of adenomas during sigmoidoscopies or 
colonoscopies (Table 7). Polyp size was determined by the endoscopist or by patho-
logical measurement. Due to the fragmentation of nearly all samples, pathological eval-
uation of in toto polypectomy was not feasible. However, endoscopic removal of polyps 
was indicated as complete for all lesions by experienced endoscopists. H&E-stained 
tissue sections were utilized for histopathological diagnosis by experienced board-cer-
tified pathologists blinded for the clinical data and based on the current WHO classifi-
cation (Bosman et al., 2010). Thus, conventional colorectal adenomas were classified 
by histological subtypes into tubular, tubulo-villous or villous with low-grade dysplasia 
(LGD) (Figure 14A) or high-grade dysplasia (HGD) (Figure 14B). The endoscopists 
defined and categorized the localizations of polyps by segments: the right hemicolon 
(cecum, ascending colon, hepatic flexure, transverse colon), the left hemicolon (splenic 
flexure, descending colon and sigmoid colon) and the rectum, respectively. 
Colorectal adenoma samples were categorized by the status of recurrence into 
three groups (Table 8): (i) primary adenomas without documented recurrence in the 
follow-up period (n=30), (ii) primary adenomas presenting adenoma recurrence at the 
same location within the follow-up period (n=19) and (iii) matched pairs (n=19) consist-
ing of the primary adenoma and the corresponding recurrent adenoma, respectively. 
The study was approved by the local board of ethics (Medizinische Ethikkomission 
II, University of Heidelberg, ethics approval identifier: 2012-608R-MA) and was con-
sistent with the Declaration of Helsinki (World Medical Association, 2013). Further-
more, the use of the subsequently coded and de-identified data was granted by the 
National Institutes of Health’s “Office of Human Subjects Research” (OHSR #13220).  
With regards to limited tissue material and increased labor-intensity of the methods, 
not all assays utilized in this study could be performed on each specimen (Figure 15).  
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Table 7. Clinicopathological features of specimens of the adenoma cohort. Clinical parameters of 
primary adenomas without recurrence, primary adenomas with recurrence, recurrent adenomas 
(matched pairs) and normal mucosae are listed below. F, female; M, male; ND, not determined. 
Continued next page.  
 
Sample 
ID 
Gender 
Age at di-
agnosis 
(y) 
Grade of 
dysplasia 
Recurrence 
Observation 
time / recur-
rence (m) 
Histology Localization 
Size 
(mm) 
P
ri
m
a
ry
 a
d
e
n
o
m
a
 w
/o
 r
e
c
u
rr
e
n
c
e
 
A 1 M 66.7 Low-grade no 27.1 Tubulo-villous Ascending 20 
A 2 M 66.0 Low-grade no 12.1 Tubular Cecum 18 
A 3 M 50.3 Low-grade no 14.1 Tubulo-villous Rectum 35 
A 4 M 67.2 Low-grade no 38.0 Tubular Descending 20 
A 5 M 67.3 Low-grade no 47.2 Tubulo-villous Hepatic flexure 20 
A 6 M 68.6 Low-grade no 19.6 Villous Rectum 40 
A 7 F 63.9 Low-grade no 23.9 Tubulo-villous Cecum 25 
A 8 M 70.3 Low-grade no 45.4 Tubulo-villous Sigmoid 12 
A 9 F 68.2 Low-grade no 21.9 Tubulo-villous Ascending 20 
A 10 M 62.8 Low-grade no 20.4 Villous Rectum 10 
A 11 F 68.5 Low-grade no 47.5 Tubulo-villous Sigmoid 30 
A 12 M 66.3 Low-grade no 3.4 Tubular Cecum 40 
A 13 F 71.8 Low-grade no 12.5 Tubulo-villous Ascending 12 
A 14 M 50.9 Low-grade no 10.9 Tubular Transverse 15 
A 15 M 66.6 Low-grade no 36.5 Tubular Ascending 25 
A 31 F 66.3 Low-grade no ND Tubulo-villous Rectum 20 
A 32 F 83.6 Low-grade no 50.6 Tubulo-villous Transverse 20 
A 33 F 69.7 Low-grade no ND Tubulo-villous Cecum 30 
A 34 M 67.3 Low-grade no ND Tubular Rectum 10 
A 35 F 75.4 Low-grade no ND Tubular Sigmoid 8 
A 36 M 76.0 Low-grade no ND Tubulo-villous Sigmoid 5 
A 37 M 67.9 Low-grade no ND Tubular Rectum 12 
A 38 M 74.1 Low-grade no ND Tubulo-villous Ascending 20 
A 39 F 84.4 Low-grade no ND Tubulo-villous Caecum 20 
A 40 F 62.9 Low-grade no ND Tubulo-villous Ascending 15 
A 41 F 63.4 Low-grade no ND Tubulo-villous Hepatic flexure 20 
A 42 F 58.2 Low-grade no ND Tubular Cecum 12 
A 43 F 55.7 Low-grade no ND Tubulo-villous Rectum 23 
A 44 F 71.0 Low-grade no ND Tubular Sigmoid 12 
A 45 M 69.0 Low-grade no ND Tubular Descending 20 
P
ri
m
a
ry
 a
d
e
n
o
m
a
 w
/ 
re
c
u
rr
e
n
c
e
 
A 16 M 69.2 Low-grade Primary 24.2 Tubulo-villous Ascending 15 
A 17 M 68.5 Low-grade Primary 7.7 Tubulo-villous Rectum 20 
A 18 M 55.1 Low-grade Primary 30.4 Tubulo-villous Sigmoid 42 
A 19 M 64.9 Low-grade Primary 6.6 Tubulo-villous Cecum 20 
A 20 F 70.2 Low-grade Primary 41.8 Tubulo-villous Hepatic flexure 40 
A 21 M 62.7 Low-grade Primary 21.0 Tubular Ascending 20 
A 22 M 73.0 Low-grade Primary 8.0 Tubulo-villous Rectum 25 
A 23 F 64.9 Low-grade Primary 17.2 Tubular Transverse 6 
A 25 M 61.9 Low-grade Primary 5.3 Tubulo-villous Transverse ND 
A 26 F 79.0 Low-grade Primary 60.1 Tubulo-villous Transverse 20 
A 28 F 55.9 Low-grade Primary 8.4 Tubulo-villous Rectum 35 
A 30 M 78.0 Low-grade Primary 14.5 Tubulo-villous Rectum 30 
A 46 F 52.3 Low-grade Primary 3.1 Tubulo-villous Rectum 63 
A 47 F 58.8 Low-grade Primary 54.2 Tubulo-villous Cecum 40 
A 48 M 52.0 Low-grade Primary 7.0 Tubulo-villous Ascending ND 
A 49 M 63.6 Low-grade Primary 52.7 Tubular Ascending 7 
A 50 F 72.9 Low-grade Primary 26.6 Tubulo-villous Cecum 12 
A 51 F 70.7 Low-grade Primary 36.3 Tubular Cecum 18 
A 52 M 63.5 Low-grade Primary 3.2 Tubulo-villous Rectum 40 
N
o
rm
a
l 
N 1 M 51.7 Low-grade Normal ND ND Descending ND 
N 2 M 52.6 Low-grade Normal ND ND Transverse ND 
N 3 M 69.1 Low-grade Normal ND ND Transverse ND 
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Table 7. (continued). 
 
 
Table 8. Patient groups. ND, not determined. 
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A 24 F 45.3 Low-grade Primary 
19.9 
Tubulo-villous Ascending 25 
A 24b F 46.8 Low-grade Recurrent Tubular Ascending 10 
A 27 M 87.9 Low-grade Primary 
19.1 
Tubulo-villous Rectum 94 
A 27b M 89.3 Low-grade Recurrent Tubulo-villous Rectum ND 
A 29 M 37.9 Low-grade Primary 
24.9 
Tubulo-villous Cecum 40 
A 29b M 39.8 Low-grade Recurrent Tubular Cecum ND 
A 53 F 69.8 Low-grade Primary 
32.6 
Tubulo-villous Cecum 35 
A 53b F 72.5 Low-grade Recurrent Tubulo-villous Cecum 15 
A 54 F 64.3 Low-grade Primary 
1.9 
Tubulo-villous Rectum 20 
A 54b F 64.4 Low-grade Recurrent Tubulo-villous Rectum ND 
P 1a F 81.9 Low-grade Primary 
26.4 
Tubulo-villous Rectum 84 
P 1b F 84.1 Low-grade Recurrent Tubulo-villous Rectum 20 
P 2a F 53.6 Low-grade Primary 
29.1 
Tubulo-villous Sigmoid 45 
P 2b F 56.0 Low-grade Recurrent Tubulo-villous Sigmoid ND 
P 3a F 54.4 Low-grade Primary 
12.8 
Tubulo-villous Sigmoid 20 
P 3b F 55.4 Low-grade Recurrent Tubulo-villous Sigmoid ND 
P 4a M 63.8 Low-grade Primary 
47.4 
Tubulo-villous Cecum 30 
P 4b M 67.6 Low-grade Recurrent Tubulo-villous Cecum 30 
P 5a F 73.8 Low-grade Primary 
11.8 
Tubulo-villous Sigmoid 30 
P 5b F 74.7 Low-grade Recurrent Tubulo-villous Sigmoid 20 
P 6a M 87.1 Low-grade Primary 
9.5 
Tubulo-villous Cecum 40 
P 6b M 87.9 Low-grade Recurrent Tubulo-villous Cecum 19 
P 7a F 72.1 Low-grade Primary 
6.0 
Tubulo-villous Ascending 20 
P 7b F 72.6 Low-grade Recurrent Tubulo-villous Ascending 20 
P 8a F 64.2 High-grade Primary 
7.6 
Tubulo-villous Rectum 50 
P 8b F 64.9 High-grade Recurrent Tubulo-villous Rectum 15 
P 9a F 78.7 High-grade Primary 
20.8 
Tubulo-villous Rectum 15 
P 9b F 80.4 High-grade Recurrent Villous Rectum 20 
P 10a M 69.9 High-grade Primary 
9.8 
Tubulo-villous Sigmoid 15 
P 10b M 70.8 High-grade Recurrent Tubulo-villous Sigmoid 15 
P 11a F 72.7 High-grade Primary 
5.0 
Tubular Ascending 30 
P 11b F 73.0 High-grade Recurrent Tubular Ascending 12 
P 12a M 64.1 High-grade Primary 
15.1 
Tubulo-villous Cecum 15 
P 12b M 65.3 High-grade Recurrent Tubulo-villous Cecum 10 
P 13a F 68.2 High-grade Primary 
24.1 
Tubulo-villous Rectum 25 
P 13b F 70.2 High-grade Recurrent Tubular Rectum 8 
P 14a M 52.3 High-grade Primary 
95.9 
Tubulo-villous Sigmoid 60 
P 14b M 60.2 High-grade Recurrent Tubular Sigmoid 10 
 
Sample 
ID 
Gender 
Age at di-
agnosis 
(y) 
Grade of 
dysplasia 
Recurrence 
Observation time 
/ recurrence (m) 
Histology 
Localiza-
tion 
Size 
(mm) 
Group  Definition Gender Age at diagnosis (y) Size (mm) Observation time (m) 
Male Female 
mean ± SD mean ± SD mean ± SD 
median (IQR) median (IQR) median (IQR) 
I (n=30) 
Primary adenomas 
without recurrence 
16 14 
67.3 ± 7.5 19.6 ± 8.8 26.9 ± 15.2 
67.3 (63.8-70.5) 20 (12-23.5) 22.9 (12.9-43.6) 
II (n=38) 
Primary adenomas 
with recurrence 
18 20 
65.8 ± 10.9 31.8 ± 19.6 22.3 ± 19.6 
64.9 (58.1-72.8) 27.5 (20-40) 18.2 (7.7-29.4) 
III (n=19) 
Recurrent adenomas 
(matched pairs) 
7 12 
68.2 ± 13.0 16 ± 5.9 22.1 ± 21.1 
70.2 (60.2-74.7) 15 (10-20) 19.1 (9.5-26.4) 
IV (n=3) Normal mucosa 3 0 
57.8 ± 9.8 ND ND 
52.6 (51.7-69.1) ND ND 
Ʃ (n=90) Cohort 44 46 
66.5 ± 10.4 24.5 ± 15.8 23.3 ± 19 
67.3 (62.5-72.5) 20 (15-30) 19.9 (9.5-29.8) 
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A 
B 
Figure 14. Histological images of colorectal adenomas. (A) Representative overview (left) of 
a conventional colonic adenoma (A24) with tubulo-villous histologic architecture and low-grade 
dysplasia. Zoom-in (right) highlights the hyperchromatic cells with a markedly shifted nuclei-to-
cytoplasm ratio. (B) Representative overview (left) of a conventional colonic adenoma (P14a) of 
tubulo-villous histology and high-grade dysplasia. Zoom-in (right) magnifies the multilayered ir-
regular nuclei in atypical crypts with a visibly distorted cytology. Images were captured with 
PreciPoint Microscope & Scanner. Scale bars overview, 500 µm; Scale bars zoom, 100 µm. 
Figure 15. Patient samples analyzed by individual genetic and epigenetic assays. Adenoma 
(n=87) and normal (n=3) specimens were targets of analysis by two epigenetic approaches, i.e., 
HM450K BeadChip array and pyrosequencing of GREM2, and additionally by two (cyto-)genetic assays, 
i.e., aCGH and miFISH, and IHC to determine microsatellite status. Norm., normal mucosa. 
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2.3 DNA extraction from FFPE tissue 
Archived FFPE tissue blocks were cut into four consecutive sections by a microtome. 
Tissue sections were carefully applied onto Duran® microscopy slides with the aid of a 
paintbrush prior to incubation at 62°C for 30 min for drying. The first section (4 µm-
thick) was stained by H&E to mark the region of interest, comprising at least 70% of 
adenoma cells, by an experienced board-certified pathologist. The next three un-
stained sections (each 10 µm-thick) were deparaffinized by repeated incubation in xy-
lene for 10 min. Dehydration was continued by exposing the tissue twice to 100% EtOH 
for 10 min. Tissues slides were then taken for conscientious macro-dissection with a 
scalpel guided by the markings of the formerly H&E-stained slide. Scraped tissues 
were collected in 1.5 ml tubes and air-dried overnight at RT. DNA was extracted utiliz-
ing the Gentra Puregene Tissue Kit (Qiagen) following the manufacturer’s protocol. 
The procedure started by adding 300 µl cell lysis solution into the tube and followed by 
incubation (65°C for 60 min at 1,100 rpm). Subsequently, 1.5 µl Puregene proteinase 
K was added to the tube which was then 25x inverted until mixed thoroughly. The vial 
was incubated in a Thermomixer (55°C overnight at 450 rpm). The next day 1.5 µl 
RNase A was added into the solution which was 25 times inverted prior to incubation 
(37°C for 60 min). Samples were chilled on ice for 1 min. 100 µl protein precipitation 
solution were added and the tube was mixed on a “Vortex” for 2 min. Proteins were 
pelleted by spinning the tube (13,000 g for 3 min at RT). If the formed pellet was not 
tight, the sample was incubated on ice for 5 min and centrifugation was subsequently 
repeated. The supernatant was subsequently poured into another vial which contained 
300 µl isopropanol. The tube was inverted up to 50 times and spun (13,000 g for 3 min 
at RT). The supernatant was discarded while the remaining pellet was washed by add-
ing 500 µl of 70% EtOH and thorough mixing. The tube was centrifuged (13,000 g for 
1 min at RT), the supernatant was pipetted off and the tube was inversely drained on 
absorbent cleaning tissue for 15 min. Residual liquid was taken off by carefully wiping 
an absorbent lens paper around the vial’s walls. DNA was eluted by repeatedly pipet-
ting up and down 22 µl of ddH2O. The vial was mixed (“Vortex” for 0.5 min) and incu-
bated on a Thermomixer (65°C for 60 min at 450 rpm) to completely dissolve the DNA. 
Extracted DNAs were gently shaken at RT overnight. The following day, extraction-
yield and 260/230-ratio were spectrophotometrically quantified by NanoDrop ND-1000. 
The DNAs were stored at -20°C. 
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2.4 CpG dinucleotides methylation analysis 
2.4.1 Real-time-PCR quality check 
The quality of extracted DNAs (chapter 2.3) was assessed by performing the Infinium 
HD FFPE QC Real-time PCR assay (Illumina). Briefly, DNAs were diluted to 1 ng/µl in 
ddH2O, and the 100-fold QC-template reagent was aliquoted (10 µl QC-template and 
990 µl ddH2O). The assay was performed in triplicates (3 wells/sample). Wells were 
either pipetted with 2 µl 100-fold QC-template (standardized control template), 2 µl ge-
nomic DNA (sample DNA) or 2 µl ddH2O (NTC), respectively. To each well, 8 µl of the 
qPCR premix (5 µl SYBR Green MM, 1 µl QC-primer, 2 µl ddH2O) were added. The 
plate was sealed and spun at 280 g prior to placing it in the qPCR thermal cycler  
(Table 9). The quality of the amplification was evaluated by the melting curve. If more 
than one specific PCR product existed, the different GC content would generate two 
independent melting curves. Obtained data on threshold cycles (Ct) was analyzed fol-
lowing the MIQE guidelines (Bustin et al., 2009; Livak and Schmittgen, 2001). Sample 
DNA would pass the QC test to be selected for further experiments if the ΔCt value 
ranged below 5, which was recommended by the manufacturer’s protocol (Illumina). 
 
       Table 9. Thermal profile real-time-PCR. 
Cycles Temperature Time 
1 x 50°C 2 min 
1 x 95°C 10 min 
40 x 
95°C 30 sec 
57°C 30 sec 
72°C 30 sec 
1 x 4°C ꝏ 
 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑡 =  
𝐶𝑡1+ 𝐶𝑡2+ 𝐶𝑡3
3
     (1) 
 
∆𝐶𝑡 =  𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑡Sample −  𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝐶𝑡QC template  (2) 
 
2.4.2 Bisulfite conversion 
Extracted FFPE DNAs that passed the quality check were treated by sodium bisulfite 
conversion using the EpiTect Plus DNA Bisulfite Kit to convert unmethylated cytosines. 
The bisulfite mix was dissolved in 800 µl ddH2O and heated to 60°C. The bisulfite 
reactions were set up in PCR tubes in a distinct order (Table 10). The vials were mixed 
thoroughly and incubated in a thermal cycler (Table 11). Subsequently, bisDNAs were 
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transferred into 1.5 ml reaction tubes and cleaned-up by adding 310 µl buffer BL (in-
cluding 10 µg/ml carrier RNA) and 250 µl 100% EtOH. Upon mixing on a “Vortex” and 
spinning of the tubes, the content was transferred onto the MiniElute DNA spin columns 
prior to centrifugation (13,000 g for 1 min). Flow through was discarded, the columns 
were washed with 500 µl buffer BW and spun (13,000 g for 1 min). Again, the flow 
through was discarded and 500 µl buffer BD incubated on the column for 15 min at RT. 
The columns were spun (13,000 g for 1 min) and a repetitive wash step by adding 
500 µl buffer BW and subsequent centrifugation (13,000 g for 1 min) were performed. 
250 µl 100% EtOH were added and the tubes centrifuged (13,000 g for 1 min). Spin 
columns were incubated at 60°C for 5 min to evaporate residual liquids. DNAs were 
eluted with 15 µl buffer EB for 1 min at RT and centrifugation (15,000 g for 1 min). 
Purified bisDNA was stored at -20°C. 
 
Table 10. Bisulfite reaction setup. 
Reagent Per reaction 
DNA solution 
ddH2O 
Bisulfite mix 
DNA protect buffer 
X µl (maximum 20 µl)  
DNA solution ad 20 µl  
85 µl 
35 µl 
Final volume 140 µl 
 
      Table 11. Thermal profile bisulfite conversion. 
Cycles Temperature Time 
1 x 95°C 5 min 
1 x 60°C 25 min 
1 x 95°C 5 min 
1 x 60°C 85 min 
1 x 95°C 5 min 
1 x 60°C 175 min 
1 x 20°C ꝏ 
 
2.4.3 DNA methylation microarray: HumanMethylation450K BeadChip 
DNA methylation array 
Sixty-nine colorectal adenoma DNAs and three normal tissue DNAs were selected for 
genome-wide methylation analysis by HM450K array (Figure 15). The assay com-
prises 485,577 probes of CpG sites which allows the quantification of DNA methylation 
in >99% of RefSeq genes with an average correlation of technical replicates of 
R2=0.992 (Bibikova et al., 2011). Performed steps were conducted in strict accordance 
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with the detailed manufacturer’s standard protocol for FFPE samples (Illumina user 
guide, 2012). Very briefly, DNA samples were quantified by Qubit fluorometer, bisulfite-
converted (approx. 250 ng), whole-genome amplified (WGA), enzymatically frag-
mented and then precipitated prior to re-suspension in the hybridization buffer 
(Bibikova et al., 2011). Subsequently, DNAs were hybridized onto six Infinium Hu-
manMethylation450K BeadChip arrays (Illumina) in a hybridization oven for 20h. Aim-
ing to minimize the technical bias of the array (Dedeurwaerder et al., 2011), sample 
DNAs were hybridized, subsequently after bisulfite conversion took place, in a random 
distribution to avoid batch effects. After the hybridization procedure, the array was 
treated with a primer extension and immunohistochemically detected before a coating 
step was performed. The arrays’ probe signals were detected by an iScan array scan-
ner (Illumina), and the raw data idat-files were exported with GenomeStudio software 
prior to data processing. 
 
(Bioinformatical) data processing and analysis 
Idat-files were loaded into GenomeStudio software to assess quality control metrics for 
both specimens and probes. Normalization of signal intensities, background level cor-
rection, and color adjustment were performed via Subset-quantile within array normal-
ization (SWAN) method (Maksimovic et al., 2012), which is incorporated in the Biocon-
ductor R-package minfi (Aryee et al., 2014). Methylation of CpG positions was meas-
ured on the array by fluorescent signals from the methylated (M) and unmethylated (U) 
alleles. Levels of methylation were then assessed per sample and CpG site by calcu-
lation of the ratio of signal intensities (beta) as described by Bibikova et al. (2011): 
 
𝑆𝑖𝑔𝑛𝑎𝑙 𝑖𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 β =
intensity (methylated)
intensity (unmethylated+intensity (methylated)+100
  (3) 
 
The β-value reflects a quantitative measure ranging from zero to one, i.e., fully un-
methylated to fully methylated (Martin-Subero et al., 2009). 
Prior to DNA methylation analysis, probes which harbor potential biological and/or 
technical bias had to be bioinformatically excluded (Dedeurwaerder et al., 2014). A 
total of 156,004 probes were removed as the following criteria applied (multiple probes 
overlap across lists): (i) cross-reactive polymorphic CpG positions (Chen et al., 2013), 
(ii) non-specific probes (Chen et al., 2013), (iii) age-dependent CpG sites (Rakyan et 
al., 2010) and (iv) probes containing SNPs at/near the targeted CpG position (Wang et 
al., 2012). Thus, 329,573 probes remained for further analysis.  
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Statistical analysis 
Methylation levels were evaluated to identify significantly differentially methylated CpG 
positions (DMPs) when comparing primary adenomas without recurrence, primary ad-
enomas with recurrence, recurrent adenomas, and normal mucosa. Significant differ-
entially hyper- or hypomethylated sites were defined by applying Benjamini Hochberg-
corrected (i.e., multiple testing corrected) false discovery rates (FDR q-value) below 
0.05 and 0.01 (Mann-Whitney U test), respectively, and at the same time a fold change 
(Δ β-value) showing a difference of >10% (see Galamb et al. 2016). Although this 
threshold seems comparably low (Dedeurwaerder et al., 2011; Sharma et al., 2016), 
the sample set comprised an adequate number (comparisons included tumor vs tumor) 
to reduce biased (i.e., false positive) discoveries. Additionally, pre-selected CpG sites 
were further categorized into “top genes,” i.e., most differentially hyper/-hypomethyl-
ated sites, which not only applied to criteria mentioned above but also showed absolute 
changes in Δ β exceeding ±0.1. Among the top genes probes targeting CpGs on sex-
chromosomes were excluded to avoid gender-specific bias. Calculations were per-
formed utilizing the bioinformatics software R. 
DMPs were compared for overlaps across defined sample groups using Venn Dia-
gram Plotter software. The distribution of DMPs was studied by plotting the CpG posi-
tions according to their linear location within CpG islands (CGI; stretch of 0.5-2kb), 
CpG shores (<2kb from CGI), CpG shelves (2-4kb from CGI) or open sea (>4kb from 
CGI), respectively (Bibikova et al., 2011; Schneider et al., 2016). The distribution of 
DMPs was also analyzed by association within gene regions (proximal promoter re-
gions, gene body, and 3’UTR) and by chromosomal location (Schneider et al., 2016, 
Sharma et al., 2016). Identified top gene-DMPs were further used to analyze whether 
site-specific DNA methylation correlates with distinct biological pathways. A gene set 
enrichment analysis (GSEA) using the molecular signatures database (MSigDB of the 
Broad Institute) was carried out to compute the overlaps of gene-associated DMPs 
with curated gene sets involving pathways listed in BioCarta, KEGG, NABA, PID, RE-
ACTOME, and SIG, respectively. Evaluated were pathways only which scored FDR 
q<0.001 to guarantee highly significant discoveries. 
Unsupervised hierarchical clustering of samples was performed by probes reaching 
P<0.05 using two-way cluster analysis (Euclidean distance and Ward’s group linkage 
method). Cluster associations were correlated with clinicopathological data applying 
Spearman’s correlation coefficient. Principal component analysis (PCA) was carried 
out to investigate the distance of samples via average DNA methylation.  
Materials and Methods 
44 
2.4.4 Pyrosequencing 
Assay-design and pre-PCR 
Results obtained by methylation analysis of the HM450K (2.4.3) were orthogonally val-
idated using pyrosequencing (Tost et al., 2003) by quantifying the methylation levels 
of selected CpG sites within the gene body of GREM2 (Figure 16A). The gene was 
chosen due to the pivotal role in the BMP pathway whose alteration influences tumor-
igenesis (Kosinski et al., 2007; Loh et al., 2008). The PyroMark Assay Design Software 
was used to design assays by incorporating the selected differential CpG dinucleotides 
in the sequence to analyze (Table 12). Pre-PCR for initial fragment amplification was 
performed by adding the reagents into a PCR tube (Table 13). Samples were amplified 
in a PCR thermal cycler (Table 14). PCR products were verified by running 5 µl per 
sample mixed with 1 µl loading dye on an agarose-gel electrophoresis (1% agarose in 
50 ml TAE buffer with 3 µl GelRed) for 30 min with 120 V. GeneRuler 100 bps DNA 
ladder (1 µl) was used as reference and the gel was analyzed using an UV-transillumi-
nator. If a PCR product were visible, the sample would qualify for the sequencing re-
action. 
 
Table 12. Pyrosequencing primers for pre-PCR and sequencing. 
Assay Primer DNA sequence 5’→ 3’ (ºbiotinylated) Length 
GREM2 
(FOR-Assay) 
Forward AGTATTTTAAGAGTGATTGGTGTAA 
158 bp 
Reverse ºCTAAAAAAACTCCTCCTCCTTCTTCA 
Sequencing TGAGYGAGGAGGGTTG  
GREM2 
(REV-Assay) 
Forward ºAAGGAGGAGGAGTTTTTTTAGT 
135 bp 
Reverse ACCRACACTACTTCACCTTCTAAATTTTCT 
Sequencing CTTCACCTTCTAAATTTTCTTA  
 
Table 13. Pyrosequencing pre-PCR setup. 
Reagent Per reaction 
REDTaq ready mix 
Primer mix 
MgCl2 
bisDNA 
 HPLC-grade ddH2O 
12.5 µl   
1 µl (10 µM For/10 µM Rev) 
1 µl (25 µM) 
2 µl (~100 ng) 
8.5 µl 
Final volume 25 µl 
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       Table 14. Thermal profile pyrosequencing pre-PCR. 
Cycles Temperature Time 
1 x 95°C 15 min 
45 x 
94°C 30 sec 
56°C 30 sec 
72°C 30 sec 
1 x 72°C 10 min 
1 x 4°C ꝏ 
 
Sequencing 
PCR product was purified utilizing the biotinylated strand which was then analyzed in 
a sequencing reaction. Sequencing of GREM2 covered by the FOR-assay a 37-bp 
sequence of interest (TYGGAGTYGTATTATTTTTAATYGTTTTTGTTAYGGT) analyz-
ing four sequential CpG sites, while the REV-assay covered a 47-bp sequence of in-
terest (AATCRAAAAAATAAATCCAAACCRAAACACTCRAACTCCACRAAAAC) in-
corporating four sequential CpG sites (Figure 16A). Bisulfite-converted DNA of glio-
blastoma cell lines (LN229; T98G) served as technical replicates for assay validation. 
Each pyrosequencing run was additionally performed with these controls, e.g., hyper-
methylated CpGs, to confirm the reliability and robustness of the obtained pyrograms. 
Performing the sequencing reactions started by setting up (multiplied by n samples) 
the bead-solution (5 µl beads with 35 µl binding buffer) and the primer-solution (0.8 µl 
primer [20 pM] with 39.2 µl annealing buffer), respectively. The latter one was applied 
(40 µl) into the wells of the sequencing plate. Instead, bead-solution (40 µl) and pre-
PCR product (40 µl) were mixed in the wells of a cell culture plate and shaken for 5 min. 
The mix was soaked up by the vacuum pump of the PyroMark vacuum prep station, 
subsequently and sequentially immersed in EtOH (70%), NaOH and washing buffer 
prior to setting off the vacuum pump to release the bead-bound product onto the se-
quencing plate, which was heated at 80°C for 2 min and cooled to RT. Meanwhile, 
suitable volumes (determined by software Pyro-Q-CpG) of enzyme, substrate, and 
dNTPs were added into the cartridge which was then placed in the PyroMark Q24 
device. The sequencing plate was set into the PyroMark device, and the reaction was 
started by programming the assay using Pyro Q CpG software. Once the sequencing 
reaction was completed, “pyrograms” were evaluated for mean CpG methylation of the 
sequenced CpG positions (Figure 16B). 
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Figure 16. GREM2 gene card and representative “pyrogram”. (A) Schematic map of the human 
GREM2 gene displaying excerpts of both gene body and promoter including the relative positions of pyro-
sequenced CpG sites (black boxes and circles). Grey boxes and white circles show non-pyro-sequenced 
CpGs. GREM2 consists of seven exons and 23 predicted CpG islands within 122,577 bases from tran-
scription start site (+1). CpG1, cg.id=cg01809217; CpG15, cg.id=cg02577267. (B) Representative “py-
rogram” of the GREM2 Forward-assay displaying the relative luminescence in relation to the dispersed 
sequence to analyze. Blue highlighted peaks show the expected ratio. CpG sites are highlighted in blue 
while highlighted bases in orange reflect bisulfite controls. Percentage values atop CpG sites display the 
average degree of methylation detected by sequencing (blue, very good confidence; yellow, medium con-
fidence; red, poor confidence/needs to be evaluated). CpGs within “pyrograms” of not evaluable dispen-
sion peaks were excluded from analysis.  
B 
A 
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2.5 Array-based comparative genomic hybridization (aCGH) 
2.5.1 DNA purification 
Extracted gDNAs were purified from salt/wash buffers using the Genomic DNA Clean 
& Concentrator Kit to obtain >500 ng of DNAs (DNA-recovery rate 70-95%) eligible for 
downstream analysis. Consequently, 2 µg of extracted DNA (1x volume) were mixed 
briefly in a 1.5 ml tube with DNA binding buffer (7x volume). The mixture was applied 
to the spin column placed in collection tubes. Samples were spun (13,000 g for 0.5 min 
at RT), the flow-through was discarded, and the column was repeatedly washed with 
200 µl of DNA wash buffer prior to centrifugation (13,000 g for 0.5 min at RT). The 
column was transferred to a new collection tube. Afterward, 21 µl of ddH2O was applied 
to the column matrix to eluate the bound DNA. The column tube was incubated (3 min 
at RT) prior to centrifugation of the column (13,000 g for 1 min). Ultra-pure DNA was 
spectrophotometrically quantified by NanoDrop ND-1000. 
 
2.5.2 DNA labeling 
Adenoma samples were prepared for hybridization onto the SurePrint G3 Human Ge-
nome CGH microarray 8x60K (comprising probes covering 55,077 distinct biological 
features, 1,000 replicated biological features and 3,886 internal QC) with a median 
overall probe spacing of 41 kb. Following the manufacturer’s protocol (Agilent user 
guide, 2015), previously purified gDNAs were prepared for hybridization onto the mi-
croarray by non-enzymatically labeling both the reference DNA and the sample gDNA 
with the fluorescent dyes Cy3 (excitation peak=550 nm) and Cy5 (excitation 
peak=650 nm), respectively. 500 ng of purified sample gDNA and corresponding hu-
man reference DNA (female/male) were added to sterile PCR tubes, respectively. Vol-
umes were adjusted to 8 µl per sample by either adding ddH2O or vacuum concentra-
tion of the DNA. Reference DNAs only were then incubated at 95°C in a thermal cycler 
with heated lids for 10 min to heat fragment the DNAs. Subsequently, samples were 
chilled on ice for 3 min. Tubes were then spun in a microfuge (6,000 g for 0.5 min). 
Labeling reactions were started by adding 2 µl of the respective labeling master mix 
(Cy3-dUTPs for reference DNA, Cy5-dUTPs for gDNA) to each tube (Table 15). A 
thermal cycler incubated the samples at 85°C for 30 min prior to cool down on the ice 
(3 min). Non-reacted ULS-cyanines were removed with KREApure purification col-
umns to avoid interference (e.g., background noise) when hybridizing the DNAs onto 
the microarray. KREApure columns were mixed, bottom closures snapped off, and 
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columns were placed in collection tubes before centrifugation was performed (16,000 g 
for 1 min). While the flow-through was discarded, 300 µl of ddH2O was applied to the 
column matrix. Again, the vial was spun (16,000 g for 1 min) prior to the discarding of 
the collection tube. Columns were placed into sterile collection tubes, and 10 µl of the 
ULS-labeled DNAs were added onto the matrix. A centrifugation step followed (16,000 
g for 1 min). Here, the flow-through contained the purified ULS-DNA. By spectropho-
tometrically quantifying 1.5 µl of purified ULS-DNA per sample using NanoDrop ND-
1000 (“MicroArray Measurement”/sample type: DNA-50) degree of labeling, specific 
activity and yield were determined. Matching ULS-Cy3- and ULS-Cy5-labeled DNAs 
were combined equaling 17 µl per pair of gDNA and reference DNA. Volumes were 
vacuum concentrated to 9 µl per couple utilizing a SpeedVac centrifuge. 
Table 15. aCGH labeling master mix. 
Reagent Per reaction Per 9x array  
ddH2O 
ULS Cy3 or ULS Cy5 
10x Labeling solution 
0.5 µl 
0.5 µl 
1 µl 
4.5 µl 
4.5 µl 
9 µl 
Final volume 2 µl 18 µl 
 
𝐷𝑒𝑔𝑟𝑒𝑒 𝑜𝑓 𝑙𝑎𝑏𝑒𝑙𝑖𝑛𝑔 =
340 x pmol per µl dye
ng per µl gDNA x 1000
 x 100%            (4) 
 
            𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 =  
pmol per µl dye
ng per µl gDNA
    (5) 
 
𝑌𝑖𝑒𝑙𝑑 (µg) =  
DNA concentration (ng µl⁄ ) x sample volume (µl)
1000 ng µl⁄
  (6) 
 
2.5.3 Microarray processing 
Hybridization 
As described in the manufacturer’s protocol (Agilent user guide, 2015), ULS-labeled 
genomic and reference DNAs (9 µl) were thoroughly mixed with 25 µl hybridization 
buffer (Table 16). Samples were incubated in a thermal cycler (95°C for 3 min, then 
37°C for 30 min). Tubes were spun in a microfuge (6,000 g for 1 min) prior to addition 
of 11 µl of Agilent-CGHblock (equilibrated to RT). The sample-hybridization mixture 
(40 µl) was dispensed onto the respective well on the gasket slide. The probe-labeled 
surface of the microarray slide was aligned onto the gasket slide without causing air 
bubbles. The “slide-sandwich” was sealed with the cover of the “SureHyb chamber” 
and set in the rotisserie of the hybridization oven (65°C for 40 hours at 20 rpm).  
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 Table 16. aCGH hybridization master mix. 
Reagent Per hybridization Per 9x array  
Cot-1 DNA 
100x aCGH blocking agent 
2x Hybridization buffer 
2 µl 
0.5 µl 
22.5 µl 
18 µl 
4.5 µl 
202.5 µl 
Final volume 25 µl 225 µl 
 
Washing 
When the hybridization was completed, the SureHyb chamber was disassembled in 
an ozone-free environment performing the following steps under an ozone-controlled 
enclosure due to cyanines being susceptible to ozone degradation. The “microarray-
gasket sandwich” was removed from the SureHyb chamber and quickly submerged 
into the slide-staining dish #1 containing oligo aCGH/ChIP-on-chip wash buffer 1 (RT). 
After disassembly, the microarray-slide was washed in dish #2 containing oligo 
aCGH/ChIP-on-chip wash buffer 1 (RT) for 5 min with a magnetic stir. The second 
wash was performed by transferring the microarray into dish #3 containing oligo 
aCGH/ChIP-on-chip wash buffer 2 (warmed to 37°C) for 1 min. The slide was slowly 
removed from the dish to minimize droplets and loaded in the slide holder. 
 
Scanning 
The slide holder loaded with the microarray was placed in the SureScan microarray 
scanner. Scanning of the slide was performed using protocol AgilentG3_CGH with the 
following parameters: dye channel R+G, scan region 61x21.6 mm, scan resolution 
3 µm and Tiff file dynamic range 16 bit. Agilent Feature Extraction software was applied 
for data extraction from the scanned microarray image. Agilent’s Microarray QC Met-
rics (e.g., background noise, signal intensity, and derivative log ratio spread) were as-
sessed per sample. However, the quality of starting gDNA was drastically reduced for 
several samples due to FFPE tissue storage. Thus, eligibility for analysis was further 
evaluated by loading the processed sample data into Nexus Copy Number. The soft-
ware was used for visualization by applying the rank segmentation algorithm on the 
CN profiles, which were manually reviewed according to the baseline noise. Overall, a 
rather conservative CNA threshold was applied >0.25. Data were filtered by excluding 
(i) CNAs comprising ≤1.5 Mbp, (ii) sex-determining chromosomes and (iii) aberrations 
in copy number variant (CNV)-overlapping regions. Microarray data was stored online 
at NCBI’s Gene Expression Omnibus database (data accession no. GSE110221).  
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2.6 Multiplex-interphase fluorescence in situ hybridization (miFISH) 
2.6.1 DNA probe production 
The single-cell analysis of adenoma cells by miFISH was performed with self-made, 
non-commercially available fluorophore probes. The selection of locus-specific identi-
fier probes was based on (i) published data on chromosomal aberrations in CRC 
(Bomme et al., 1994; Hermsen et al., 2002; Meijer et al., 1998; Ried et al., 1996) and 
on the (ii) aCGH landscape of copy number alterations identified in this study. Conse-
quently, data assessment obtained the following genes: COX2 (1q31.1), PIK3CA 
(3q26.32), APC (5q22.2), CLIC1 (6p21.33), EGFR (7p11.2), MYC (8q24.21), CCND1 
(11q13.3), CDX2 (13q12.2), CDH1 (16q22.1), TP53 (17p13.1), HER2/ERBB2 (17q12), 
SMAD7 (18q21.1), SMAD4 (18q21.2), and ZNF217 (20q13.2). Additionally, a commer-
cially available probe (CytoTest) targeting the centromere of chromosome 10 (CEP10) 
was included for ploidy estimation since this chromosome is rarely altered in the colo-
rectal tumorigenesis according to aCGH analyses (see above for references). The pro-
cedures of design and production of the probe sets are described below. 
 
Bacterial artificial chromosome (BAC) clone contigs 
BAC clones were picked from the University of California, Santa Cruz (UCSC) Genome 
Browser (http://genome.ucsc.edu/) querying the genome assemblies dated to 
Feb.09/hg19 and Dec.13/hg39. Each probe contig comprised approximately 300-
700 kb and was assembled by three to four overlapping BAC clones which overlapped 
and centered around the genes of interest (Supplemental Table 1). BAC clones were 
purchased from BACPAC Resources Center (http://bacpacresources.org). Probe con-
tigs were assorted into three panels consisting of five genes each. The clone contigs 
were directly labeled with fluorophores (Dyomics) with an excitation peak of 415 nm 
(blue; DY-415-dUTP), 505 nm (green; DY-505-dUTP), 547 nm (gold; DY-547P1-
dUTP), 590 nm (red; DY-590-dUTP), and 651 nm (far red; DY-651-dUTP), respec-
tively. Panel 1 (Figure 17) consisted of MYC (blue), CCND1 (green), SMAD4 (orange), 
CDX2 (red), and PIK3CA (far red), whereas panel 2 (Figure 18) was composed of 
EGFR (blue), COX2 (green), APC (gold), CLIC1 (red), and SMAD7 (far red). Finally, 
panel 3 (Figure 19) combined the locus-specific probes for ZNF217 (blue), CDH1 
(green), TP53 (gold), HER2 (red), and centromere probe CEP10 (far red). 
  
Materials and Methods 
51 
  
Figure 17. miFISH probe panel 1. Chromosomal location of each probe (MYC, CCND1, SMAD4, 
CDX2, PIK3CA) within panel 1 sorted by fluorophore wavelengths ranging from blue (415 nm) to far 
red (651 nm). A detailed map for the respective probe is illustrated in the zoomed-in box (proximal to 
distal flanking BAC clone sequences; 12.5 kb per column). The target gene is highlighted by a bold 
red frame. The box underneath gives an approximation of the final FISH probe size. Gene annota-
tion/prediction is shown by UCSC Genes. Chromosome sizes are schematic and not to scale. 
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Figure 18. miFISH probe panel 2. Chromosomal location of each probe (EGFR, COX2, APC, CLIC1, 
SMAD7) within panel 2 sorted by fluorophore wavelengths ranging from blue (415 nm) to far red (651 
nm). A detailed map for the respective probe is illustrated in the zoomed-in box (proximal to distal flank-
ing BAC clone sequences; 12.5 kb per column). The target gene is highlighted by a bold red frame. The 
box underneath gives an approximation of the final FISH probe size. Gene annotation/prediction is 
shown by UCSC Genes. Chromosome sizes are schematic and not to scale. 
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Figure 19. miFISH probe panel 3. Chromosomal location of each probe (ZNF217, CDH1, TP53, HER2, 
CEP10) within panel 3 sorted by fluorophore wavelengths ranging from blue (415 nm) to far red (651 
nm). A detailed map for the respective probe is illustrated in the zoomed-in box (proximal to distal flank-
ing BAC clone sequences; 12.5 kb per column). The target gene is highlighted by a bold red frame. The 
box underneath gives an approximation of the final FISH probe size. Gene annotation/prediction is 
shown by UCSC Genes. Chromosome sizes are schematic and not to scale. 
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BAC clone cultivation and DNA extraction 
BAC clones were propagated in DH10B E.coli and shipped in LB agar (containing 
12.5 µg/ml chloramphenicol) stab cultures at 4°C distributed by BACPAC Resources 
Center (Children’s Hospital Oakland Research Institute, Oakland, CA, USA). Bacterial 
cultures were streaked to single colonies with a sterile loop on LB agar plates (contain-
ing 12.5 µg/ml chloramphenicol). Plates were incubated agar-side up at 37°C over-
night. The day after a single colony was picked with a sterile loop to inoculate a starter 
culture in a 250-ml-flask containing 25 ml of LB medium and 25 µl chloramphenicol. 
The flask was incubated (37°C for 5 hours shaking at 300 rpm). Subsequently, 1 ml of 
the starter culture was taken off to inoculate an overnight culture in a 1 l flask with 
250 ml LB medium and 250 µl chloramphenicol incubated overnight (37°C for 16-18 
hours at 350 rpm). The overnight culture was pelleted (6,000 g for 15 min at 4°C) prior 
to pouring off the supernatant. The pellet was frozen at -80°C. 
DNA extraction was performed using the Plasmid Maxi Kit starting by resuspending 
the bacterial pellet with 10 ml of chilled buffer P1. Subsequently, 10 ml buffer P2 was 
added, the tube was inverted 4-6 times and incubated at RT for 5 min. The mixture 
turned blue as an indicator of proper homogeneity. Buffer P3 was added (10 ml), the 
tube was repeatedly inverted and left on ice for 30 min when the mixture’s color 
changed to white. The tube was centrifuged (20,000 g for 30 min at 4°C). 
Meanwhile, the genomic-tip was equilibrated with 10 ml buffer QBT by gravity flow. 
The flow-through was discarded, and 30 ml of the supernatant were applied to the 
column. When the supernatant had entered the column matrix by gravity flow, the tip 
was washed twice with 30 ml of buffer QC. The flow-through was discarded, and the 
plastic tube was exchanged for a glass collection tube. DNA was eluted with 15 ml of 
the pre-warmed (65°C) buffer QF. DNA was precipitated by adding 10.5 ml isopropanol 
to the eluate. The tube was sealed with Parafilm M, inverted until entirely mixed and 
spun (15,000 g for 30 min at 4°C). The supernatant was aspirated, the residual pellet 
was washed with 5 ml cold 70% EtOH and subsequently centrifuged (15,000 g for 
10 min at 4°C). When the supernatant was aspirated, the pellet was air-dried on a 
napkin for 5 min upside-down and right-side-up, respectively. The DNA pellet was re-
dissolved in 200 µl dH2O by pipetting up and down for 10 min. Dissolved DNA was 
transferred into a 1.5 ml microcentrifuge tube, whereas the glass tube was centrifuged 
(5,000 g for 3 min) before the repetition of the previous step. DNA yield was measured 
on a spectrophotometer and stored at -20°C prior to further use.  
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Nick translation 
Probe DNA was simultaneously fragmented and labeled with fluorophores by nick 
translation. In this procedure, exonuclease activity of the added DNA polymerase in-
duces single-strand breaks in the probe-DNA. Consequently, the DNA was nicked and 
a fluorophore-labeled dUTP was incorporated using the intact DNA strand as a tem-
plate. Additionally, human Cot-1 DNA (containing repetitive sequences) was added to 
the reaction to reduce the hybridization of FISH probes onto repetitive sequences 
within the genome and therefore reducing background signals. 
The nick translation reaction was performed in small-scale if the clone-DNA had to 
be tested, or in large-scale, if the clone-DNA was previously tested before. Consecu-
tively, probe clone-DNA, NT master mix, and dUTP mixture were added into a tube 
(Table 17). The volume was adjusted by ddH2O prior to addition of polymerase and 
1:1,000 DNase I (1 mg/ml). The solution was mixed on a “Vortex”, spun down and 
incubated in a thermocycler (2 hours at 15°C). DNA fragments were verified by running 
5 µl per sample mixed with 1 µl loading dye on an agarose-gel electrophoresis (1% 
agarose in 50 ml TAE buffer with 3 µl GelRed) for 30-40 min with 100 V. DNA molecular 
weight marker II (1 µl mixed with 1 µl loading dye) and GeneRuler 100 bps DNA ladder 
(1 µl) were used as references. If the product displayed appropriate length of approxi-
mately 300-600 bps using an UV-transilluminator, nick translation would be terminated 
by adding 1-2 µl EDTA (0.5 M, pH=5.2). The tube was incubated (65°C for 10 minutes), 
and translated DNAs were frozen at -20°C. 
 
Table 17. Nick translation input volumes per probe clone. 
Reagent Small scale Large scale  
DNA 
NT master mix 
dUTP 
ddH2O 
Polymerase 
DNase (1:1,000) 
2 µg 
30 µl 
10 µl 
 X µl 
2 µl 
4 µl 
10 µg 
150 µl 
50 µl 
X µl 
10 µl 
14 µl 
Final volume 100 µl 500 µl 
 
10x NT buffer:     500 µl Tris-HCl (1 M), pH = 8.0 
       100 µl MgCl2 (0.5 M) 
       350 µl ddH2O 
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DNase I stock solution:     10 mg DNase 
       1.5 ml NaCl (1 M) 
          5 ml Glycerol 
                 ad 10 ml ddH2O 
 
dUTP mixture (0.5 mM):  1.25 µl dUTP (1 nmol/µl) 
     3.75 µl dTTP (1 mM) 
          5 µl ddH2O 
 
Master mix (single reaction):    10 µl NT buffer (10x) 
        10 µl dATP-dCTP-dGTP mix (0.5 mM) 
        10 µl β-Mercaptoethanol (0.1 M) 
 
Precipitation 
Fluorophore-labeled clone DNAs were pooled per gene probe and further high salt 
concentrated by DNA precipitation. Clone DNAs labeled by nick translation were in-
serted to the reaction in equal volumes per clones and probe. However, due to the 
varying intensity and detectability of probe fluorophores, the volume of probe clone 
DNA diverged for probes with an excitation peak at 415 nm and 651 nm, respectively 
(Table 18). In general, human Cot-1 DNA was added comprising 1/3 of the labeled-
probe DNA and 3 µl salmon testes DNA. Moreover, sodium acetate (1/10 of the DNA 
mixture’s volume) and 100% EtOH (threefold of the DNA mixture’s volume) were added 
to the reaction tube which was subsequently incubated at -20°C overnight. The vial 
was centrifuged (14,000 rpm for 30 min at 4°C) prior to removal of the supernatant. 
The pellet was washed twice (2 ml cold 70% EtOH). After thorough mixing, the tube 
was spun (14,000 rpm for 15 min at 4°C). The supernatant was taken off carefully, and 
the tube was dried upside-down at 15°C. If residual liquid remained, a clean lens clean-
ing tissue was used to wipe the tube dry. Furthermore, the tube was incubated on a 
Thermomixer at 37°C for 1 min with an open lid. Probes labeled with green- or gold-
fluorophores were then resuspended with equal volumes of formamide and master mix 
to obtain a final contig volume of 30 µl. Other probes were concentrated more rigor-
ously with 6 µl and 20 µl, respectively (Table 18). An appropriate volume of pre-
warmed deionized formamide (3-15 µl) was added for resuspension. The tube was 
incubated on a Thermomixer (700 rpm for 30 min at 37°C). Resuspension was com-
pleted by adding the appropriate volume of precipitation master mix (3-15 µl). The tube 
was shaken on a Thermomixer (700 rpm for 30 min at 37°C). Hybridizing the probe on 
a lymphocyte test slide evaluated the probe quality.  
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Table 18. Large-scale DNA precipitation scheme. Note, if the number of BAC clones diverged from 
three the input volumes for the additional reagents would be adjusted. 
Fluorophore excitation 415 nm 505 nm 547 nm 590 nm 651 nm 
Number of clones 
Labeled-probe DNA per clone 
Sum 
 
Human Cot-1 DNA 
Salmon testes DNA 
Na-Acetate 
100% EtOH 
Sum volume 
 
Final contig volume 
3 
400 µl 
1,200 µl 
 
400 µl 
3 µl 
160.3 µl 
4,408.3 µl 
6,171.6 µl 
 
20 µl  
3 
300 µl 
900 µl 
 
300 µl 
3 µl 
120.3 µl 
3,308.3 µl 
4,631.6 µl 
 
30 µl 
3 
300 µl 
900 µl 
 
300 µl 
3 µl 
120.3 µl 
3,308.3 µl 
4,631.6 µl 
 
20 µl 
3 
300 µl 
900 µl 
 
300 µl 
3 µl 
120.3 µl 
3,308.3 µl 
4,631.6 µl 
 
30 µl 
3 
420 µl 
1,260 µl 
 
420 µl 
3 µl 
168.3 µl 
4,628.3 µl 
6,479.6 µl  
 
6 µl 
 
Master mix:           40 ml Dextran sulfate (50%) 
             20 ml SSC (20x) 
            ad 100 ml ddH2O 
      pH adjusted to 7.0 by HCl (1 M) 
 
2.6.2 Cytospin preparation 
The procedure was a modification of the previously published Hedley technique 
(Heselmeyer-Haddad et al., 2012; Heselmeyer-Haddad et al., 2014): FFPE tissue 
blocks were cut into three consecutive sections. The first section (4 µm-thick) was 
stained by H&E to mark the region of interest by an experienced board-certified 
pathologist. The next two sections (each 50 µm-thick) were taken for conscientious 
macro-dissection with a scalpel guided by the formerly H&E-stained slide. Scraped 
tissue was collected in a 1.5 ml tube. Deparaffinization began by adding 1 ml xylene 
(20 min at RT). Xylene was removed by pipetting off the supernatant after spinning the 
tube (3,000 rpm for 3 min). These steps were repeated three times. The tissue was 
dehydrated by subsequently adding 1 ml of 100% (twice), 90% and 70% EtOH, re-
spectively. The tube was respectively incubated for 5 min at RT prior to centrifugation 
(3,000 rpm for 3 min). The supernatant was removed. Finally, 1 ml 50% EtOH was 
added and the tube incubated at RT for 5 min. The tissue was spun (14,000 rpm at 
4°C for 15 min) before EtOH was taken off and 1 ml dH2O was added (20 min at RT). 
The tube was spun (4,000 rpm at 4°C for 15 min) prior to removal of the dH2O. Macro-
dissected tissue was then digested with 500 µl 0.1% protease in 1x PBS (800 rpm at 
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45°C for 60-120 min; case-specific). The degree of disintegration was periodically 
(every 15 min) monitored by taking off 5 µl of the tissue solution and mixing it with 5 µl 
of staining solution on a microscope slide. The tissue sample was evaluated under a 
fluorescence microscope using the 16x objective field view. Optimal criteria for disin-
tegration included approximately 30 nuclei per field and intact nuclei exhibiting little to 
no cytoplasm while the DAPI stain was intense. In case of incomplete disintegration, 
the incubation of the tissue in the tube was continued. When the nuclei were of di-
gested as desired, the reaction was stopped by adding 500 µl of 1x PBS before the 
vial was spun (2,500 rpm for 5min at RT). The supernatant was removed leaving 100 
µl of residual volume. Disintegrated single cells were resuspended in a case-specific 
volume of sterile 1x PBS to obtain a concentration which allows the production of ten 
or more cytospin-slides. Meanwhile, cytology funnel filters were filled with 80 µl 1x PBS 
and loaded onto the cytospin centrifuge (1,400 rpm for 5 min) accompanied by a mi-
croscopy adhesion slide (SuperFrost™). Filters were then filled with 80-160 µl cell sus-
pension and spun in the cytospin centrifuge (1,400 rpm for 5 min). The density of the 
cytospin-slides was evaluated with a phase contrast microscope, and the cell suspen-
sion was further diluted or concentrated as needed, respectively. Obtained single-layer 
cytospin-slides were dehydrated by subsequent exposure to 100 ml Coplin jars con-
taining 70% EtOH (5 min), 90% EtOH (5 min) and 100% EtOH (10 min), respectively. 
Slides were air-dried and stored (4°C) until used further. 
 
DAPI (1 mM):     1 mg DAPI in 27 ml dH2O 
 
Sulforhodamine (5 mM):  50 mg Sulforhodamine in 16.5 ml dH2O 
 
Staining solution:      2 ml DAPI solution 
       2 ml Sulforhodamine solution 
    Ad 98 ml PBS (1x), pH = 7.4 
 
2.6.3 MiFISH 
The following chapter will depict the steps of the procedure of multiplex-interphase 
fluorescence in situ hybridization (miFISH) including the slide’s pretreatment, hybridi-
zation, detection, scanning, and re-hybridization, respectively.  
Materials and Methods 
59 
Pretreatment 
Prior to hybridize the locus-identifier probes onto the previously prepared FFPE ade-
noma cell single-layer cytospin slides the nuclei had to be pretreated to obtain analyz-
able results of the hybridization procedure. Hereinafter, the pretreatment procedure is 
described for cytospin case slides first, while the modified pretreatment of lymphocyte 
slides (used to test probe quality) are described in the second part of this chapter. 
Desired slides were examined under a phase contrast microscope to identify the 
appearance and shape of the nuclei. Additionally, the area of interest comprising the 
nuclei was marked by a glass pen. Slides were equilibrated in a Coplin jar with 2x SSC 
for 10 min at RT and transferred into 1x PBS for 2 min. Subsequently, slides were 
placed in a hybridization chamber on a plastic grid covering paper tissues soaked in 
dH2O. The proteolysis of peptide bonds in membrane proteins of the adenoma cells 
was performed by applying 120 µl proteinase solution (0.1%) on top of the cytospin 
slide. The hybridization chamber was incubated (37°C for 15 min). Slides were trans-
ferred into a Coplin jar containing 1x PBS to stop the digest temporarily and to check 
the nuclei under the phase contrast microscope. If the cells exhibited an excess of 
cytoplasm which was determined by a grey haze surrounding the nuclei, the slide was 
pre-incubated with 120 µl proteinase solution (0.1%; 100 mg/ml dissolved in ddH2O) 
for a more extended period. The specific pretreatment intervals ranged from 15-120 
min in regard of the case and slide age. 
In contrast, if the cells showed a significant fading of the grey haze by reduction of 
cytoplasm, the reaction would be stopped. Slides were washed three times in Coplin 
jars containing 1x PBS. Finally, the slides were dehydrated in an increasing EtOH se-
ries comprising of 70%, 90% and 100% for 5 min, respectively. Slides were air-dried 
prior to performing the hybridization procedure. 
Nevertheless, the pretreatment protocol for lymphocyte slides was slightly modified 
to ensure somewhat moderate proteolysis to avoid over-digest. Lymphocyte slides 
were equilibrated in 2x SSC for 20 min while the proteolysis was performed by adding 
5 µl pepsin solution (0.1%; 100 mg/ml dissolved in ddH2O) in a pre-warmed (37°C) 
Coplin jar which was filled up with 100 ml HCl (0.01 M; pH=2.0). The slide was incu-
bated for 30-120 sec (variance per batch). The additional steps were performed as 
described beforehand.  
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Hybridization 
Previously prepared locus-identifier probes were assorted into three panels of five 
probes (see 2.6.1 DNA probe production). Panels were set up in 1.5-ml-tubes in 10 µl 
batch volume comprising a 415 nm-probe (2 µl), a 505 nm-probe (2 µl), a 547 nm-
probe (2 µl), a 590 nm-probe (2 µl), a 651 nm-probe (1 µl) and, additionally, forma-
mide/precipitation master mix solution (1 µl). The desired probe was prepared for hy-
bridization by denaturing the probe DNA (73°C for 5 min). Subsequently, the probe 
was pre-annealed by shaking on a Thermomixer (37°C for 1 hour at 350 rpm) covered 
with aluminum foil for light-protection. Noteworthy, if probe panel 3 was prepared for 
hybridization, centromere probe CEP10 was solely denatured and added to the probe 
mix when pre-annealed. 
Meanwhile, pretreated and air-dried single-cell adenoma suspension cytospin-
slides were denatured. Therefore, 120 µl of 70% formamide/2x SSC were applied on 
a 24x60 mm2 coverslip. The cytospin-slide was touched to the coverslip strictly avoid-
ing the formation of air bubbles. The slide was incubated at 72°C on a ThermoBrite 
StatSpin hot plate for 3 min. As soon as this procedure was performed, the coverslip 
was slipped off gently. The slide was quickly transferred into an ice-cold increasing 
ethanol series comprising of 70%, 90% and 100% for 3 min, respectively. Slides were 
air-dried under the laboratory fume hood. The pre-annealed probe (2 µl) was applied 
to the slide’s nuclei and covered by a round coverslip strictly avoiding the formation of 
bubbles. Drops of rubber cement sealed the edges after drying for approximately 
3 min. Cytospin-slides were placed in the humid, light-impenetrable hybridization 
chamber and incubated at 37°C for 16 hours. 
Contrary to the adenoma FFPE cytospin slides, lymphocyte slides were denatured 
at 65°C for 30-60 sec, which was batch-dependent. 
 
70% formamide/2x SSC:     10 ml SSC (20x) 
        20 ml ddH2O 
              ad 100 ml Formamide, deionized; pH = 7.0 
 
Detection 
Overnight-hybridized cytospin-slides were taken off the hybridization chamber to per-
form a stringent wash. Rubber cement was removed gently utilizing a tweezer. The 
slides were immersed into a Coplin jar of pre-warmed (48°C) 2x SSC/0.3% NP-40 
buffer. With the aid of a tweezer, the coverslips were slid carefully into the solution. 
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The slides were washed by gentle and periodical shakes while incubated in another 
Coplin jar with pre-warmed (48°C) 2x SSC/0.3% NP-40 buffer for 2 min. Subsequently, 
slides were transferred into 2x SSC/0.1% NP-40 buffer for 1 min at RT prior to a wash 
in 2x SSC for 0.5 min and 1x PBS for 2 min, respectively. The Coplin jars were kept 
away from light. Slides were then exposed to the DAPI solution for 1 min at RT. Wash-
ing the slides three times with 2x SSC for 2 min removed excessive residues with ad-
ditional agitation. An increasing EtOH series comprising of 70%, 90% and 100% for 
2 min, respectively, dehydrated the slides at RT. Stored in a drawer slides were dried 
while hidden from light-exposure. Finally, 1-2 drops Vectashield fluorescence mounting 
medium without DAPI were applied on a coverslip which was subsequently touched 
onto the cytospin-slide under strict avoidance of bubble formation. The slides were 
ready for imaging and scanning. 
Nevertheless, lymphocyte slides were washed less stringently. The utilization of the 
detergent NP-40 was eluded. Instead, the slides were washed three times in 2x SSC. 
 
DAPI solution:      50 µl of DAPI stock (5 mg/ml) 
       50 ml PBS (1x) 
       mix and store light-protected at 4°C 
 
Scanning 
The detected cytospin-slides were subsequently placed onto the DUET scanning im-
aging workstation (BioView Ltd.). This workstation comprised of a fluorescence micro-
scope accompanied by an automated stage with a loading capacity of up to 8 slides 
(Olympus). Ready-to-image slides were prepared for scanning by adjusting the scan-
ning parameters using an exemplary field of view with several nuclei of the respective 
slide. Therefore, the plane of focus was adjusted by exciting the slide with the excitation 
peak of DAPI (ᴧ=358 nm; ultra-violet) by the mercury fluorescence lamp integrated into 
the microscope. Consecutively, all probes were tested by reviewing the chosen field of 
view. Probe excitation and image acquisition were adjusted by brightness, exposure 
time, intensity and plane of focus to obtain precise and intense probe signals with a 
reduced background, respectively. The modified parameters were adapted for the re-
spective channels and applied for the entire scan. A 2448x2048 monochrome digital 
camera took high-quality images. Recorded probe signals were automatically re-col-
ored by the software according to the probe’s respective excitation peak (i.e., 
blue=415 nm; green=505 nm; gold=547 nm; red=590 nm; far red=651 nm). The 
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software located an upper limit of 12,000 targets per cytospin-slide. If the scanned slide 
were too sparse, the whole slide would be scanned. 
If a slide were re-scanned after re-hybridization with panel 2 or 3, respectively, the 
additional scan would start via re-localizing the previously scanned targets by the 
DUET software. Nevertheless, the process had to be monitored and reviewed manu-
ally to assure exact overlap. If the target nuclei were successfully retrieved, scanning 
of the probe panel would be conducted by revisiting all targets formerly scanned by the 
fluorescence microscope. Prior to the scan parameters were adjusted as described 
before. Images of the current signals were taken before sorting these images to the 
corresponding image of each target nucleus. Thus, signal counts for all 15 miFISH 
probes could be collected for each targeted nucleus assorted into three panels. 
 
Re-Hybridization 
After scanning and imaging a previously hybridized slide, the probe could be washed 
off to perform a novel miFISH on the same slide (up to four times). The desired probe 
panel was set up and prepared for hybridization by denaturing the probe DNA at 73°C 
for 5 min. Subsequently, the probe was pre-annealed by shaking in a Thermomixer 
(37°C for 1 hour at 350 rpm) covered with aluminum foil. 
Meanwhile, the slide was immersed into 2x SSC, and the coverslip was slid off gen-
tly (with a tweezer). Slides were washed three times (2x SSC for 2 min). By combining 
washing and denaturation, the slide was exposed to pre-warmed (80°C) 50% forma-
mide/2xSSC for 1 min. Slides were then dehydrated in an ice-cold increasing EtOH 
series comprising of 70%, 90% and 100% for 2 min, respectively. Slides were air-dried 
in the laboratory fume hood prior to application of 2 µl of the pre-annealed probe panel. 
As described before (see 2.6.3 miFISH: Hybridization), slides were covered by a round 
coverslip strictly avoiding the formation of bubbles. Drops of rubber cement sealed the 
edges after drying for approximately 3 min. Cytospin-slides were placed in the humid, 
light-impenetrable hybridization chamber and incubated (37°C for 16 hours) until slide 
detection was performed. 
 
50% formamide/2x SSC:      10 ml SSC (20x) 
        40 ml ddH2O 
              ad 100 ml Formamide, deionized; pH = 7.0 
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2.6.4 Data assessment 
Signal enumeration 
The recorded images of the probe signals within the three probe panels were analyzed 
when the scanning of all probes was successfully performed. The nuclei were sorted 
by target number with each target comprising three panels. Each panel showed a 
merged image of the nucleus which combined all five probe channels within a scanned 
panel. Moreover, the panel presented a DAPI image and a single image for each of 
the five probes. The signal counts were manually counted for accuracy using the SOLO 
satellite workstation (BioView) with the customized software. Counting was performed 
consecutively reviewing the scanned targets starting with target number one. When 
reviewing the targets, a nucleus was excluded from analysis if a criterion for exclusion 
applied (Table 19). Split probe signals were cautiously enumerated concerning the un-
derlying ploidy. Targets were assorted into the following categories: 
(i) nuclei with an unchanged signal count for each probe (i.e., non-aneuploid) 
(ii) nuclei with any changed signal count (i.e., aneuploidy) 
(iii) nuclei with signal counts suggesting a triploid/tetraploid set of chromosomes 
(iv) nuclei excluded from analysis. 
 
Counting proceeded until 350 altered nuclei were identified (cut-off). If this were not 
applicable, the whole slide would be enumerated. Consequently, counting was stopped 
when the last target was reviewed no matter how many altered cells were identified. 
On average, 10,398 targets were scanned per adenoma cytospin-slide (limit of 12,000 
targets). Signal evaluation within all specimens revealed a mean final count of 180 
aberrant (range, 5-350) and 342 non-aberrant interphase nuclei (range, 18-867), re-
spectively. Enumerated signal counts were recorded in an excel-spreadsheet. 
 
Table 19. Criteria of an exclusion of nuclei from the miFISH analysis. 
criteria description 
i the nucleus overlapped with other nuclei 
ii 
the nucleus was of non-epithelial morphology (i.e., non-ellipsoid nucleus) 
suggesting an immune cell 
iii the nucleus was visibly damaged indicating a truncated or cut nucleus 
iv 
the nucleus exhibited indistinguishable probe signals indicating an artifact 
or failed panel hybridization 
v 
the nucleus lacked a centromere signal which was likely due to a trun-
cated artifact 
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Processing of data files 
Signal counts were recorded in raw data tab-delimited text files saved separately per 
case. The raw data file contained each scanned target which was further assorted by 
the assigned categories of nuclei while counting. Analyzed nuclei possessed a signal 
count denoted separately for each probe. Based on these raw data files, analyzed cells 
were re-sorted by an excel macro application. Rows were lexicographically ordered 
ranging from low signal numbers towards increased signal numbers. Columns were 
sorted by the probe’s chromosome location in ascending order. The combination of 
probe signal counts is called the signal pattern. The macro application grouped multiple 
nuclei which exposed the same signal pattern into one row and annotated the count of 
nuclei in the respective column. Nuclei with a diploid signal count within each analyzed 
probe (non-altered) were also listed in the table. Data files were used for the further 
analysis described at a later point. 
 
Ploidy annotation and determination of gain and loss 
An overall ploidy was assigned to each analyzed nucleus to determine copy number 
gains and losses further. Cells were classified as either diploid (2N), triploid (3N) or 
tetraploid (4N). Higher polyploidies (>4N) were not observed in our cohort. Centromere 
10 (CEP10) was chosen as an indicator of DNA ploidy since aCGH analyses have 
revealed that copy number alterations exceptionally rarely targeted this chromosome 
in the colorectal tumorigenesis. The annotation of ploidy per signal pattern was inferred 
by assessing the signal count of CEP10. However, the landscape of additional gene 
probe counts was also considered for ploidy estimation using the empirical knowledge 
of which probes represented oncogenes and tumor suppressors, respectively. 
Moreover, an average ploidy was calculated for each adenoma case by dividing the 
sum of ploidy values per signal pattern from the sum of cells analyzed. Among adeno-
mas analyzed, 94.8% (55/58) were inferred to possess a diploid (2N) average ploidy 
whereas 5.1% (3/58) of cases showed conclusive evidence for the presence of poly-
ploid sets (4N) of chromosomes (case 13, 30 and P7b). Albeit, polyploid samples were 
excluded from further statistical analysis due to their severity of genomic instability 
compared to diploid lesions (2N). 
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CN gain and loss, respectively, were annotated for each gene probe regarding the 
underlying ploidy of the respective signal pattern (Figure 20). Consistently, copy num-
bers exceeding two signals would not, per se, indicate a gain. Neither would the ob-
servation of two signals inevitably imply an unchanged signal number if the ploidy of 
the signal pattern was not considered. CN gains and losses were not only separately 
evaluated per nucleus but also in total per adenomatous lesion. As such, copy number 
alterations were considered if the respective alterations were present in at least 10% 
(threshold) of the counted cell population per adenoma lesion.   
Figure 20. Exemplarily translation 
of probe signal counts into gain and 
loss signal pattern displays. The 
flow chart exemplarily depicts the first 
15 analyzed nuclei of adenoma case 
A1. First, signal probe counts were re-
viewed and stored in an excel spread-
sheet for each nucleus. Second, probe 
counts were translated into copy num-
ber status neutral (N), gain (G) or loss 
(L) in accordance to the annotated and 
inferred ploidy, respectively. Finally, 
copy number information were color-
coded to display hundreds of single 
cells within a graph quickly assessing 
clonal populations. Columns represent 
all probe signal counts per individual 
nucleus while rows display the counts 
for a certain probe within the nuclei 
fraction. Copy number color-code: 
neutral (blue), gain (green), loss (red). 
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Tumor heterogeneity by (ecological) measures of diversity 
With the scope of a quantitative assessment of inter- and intratumor heterogeneity 
within the adenomas the following four measures of diversity were calculated:  
(i) Instability index (Heselmeyer-Haddad et al., 2012 and 2014) 
(ii) Shannon entropy (Martinez et al., 2016; Wangsa et al., 2016),  
(iii) Simpson diversity index (Martinez et al., 2016; Wangsa et al., 2016) 
(iv) Accumulated pairwise genetic diversity (Rogers, 2015). 
 
First, the frequencies of signal patterns (i.e., “genetically divergent clones”) were 
determined. To calculate the diversity measures, let pi (i.e., allele frequency) be the 
frequency of the ith count pattern of kth (i.e., allele number) different loci expressed by 
probe-specific copy numbers. The total pattern count was defined as N of n nuclei. 
Additionally, the number of altered count patterns was expressed as XK while the num-
ber of diploid (non-altered) count patterns was given as YK. 
 
(i) The ecological diversity measure of species richness was transferred into 
clonal richness, here defined as “instability index” I. The index comprises the 
number of observed patterns per sample divided by the total number of enu-
merated clones within a sample. The value is multiplied by 100 to obtain a 
range of 0-100 patterns. 
𝑔𝑒𝑛𝑜𝑚𝑖𝑐 𝑖𝑛𝑠𝑡𝑎𝑏𝑖𝑙𝑖𝑡𝑦 𝑖𝑛𝑑𝑒𝑥 𝐼 =
(𝑁∗100)
𝑛
   (7) 
 
(ii) Shannon entropy H’ is a measure of richness and evenness in information 
theory which puts more weight on the sheer number of genetically different 
clones. The dimensionless index usually gives values in the range of 1-3 
(low to high heterogeneity), although the scale is unlimited.  
𝑆ℎ𝑎𝑛𝑛𝑜𝑛 𝑒𝑛𝑡𝑟𝑜𝑝𝑦 𝐻′ = − ∑ 𝑝𝑖𝑙𝑜𝑔2(𝑝𝑖)   (8) 
 
(iii) Simpson diversity index D’ is a measure of dominance in population genetics 
which puts more weight on more frequently observed clones. The dimen-
sionless index is in the range of 0-1 (low to high heterogeneity). 
𝑆𝑖𝑚𝑝𝑠𝑜𝑛 𝑑𝑖𝑣𝑒𝑟𝑠𝑖𝑡𝑦 𝑖𝑛𝑑𝑒𝑥 𝐷′ = 1 − ∑ 𝑝𝑖
2    (9) 
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(iv) Genetic diversity metrics can assess genetic distance, here defined as ac-
cumulated pairwise genetic diversity D. The dimensionless index estimates 
the genetic distance among clones within a tumor sample typically in a range 
of 1-6 (low to high clonal distance). Each copy number alteration increases 
the genetic distance away from the diploid signal pattern - no matter whether 
caused by copy number gain or loss, respectively.  
𝐴𝑐𝑐𝑢𝑚𝑢𝑙𝑎𝑡𝑒𝑑 𝑝𝑎𝑖𝑟𝑤𝑖𝑠𝑒 𝑔𝑒𝑛𝑒𝑡𝑖𝑐 𝑑𝑖𝑣𝑒𝑟𝑠𝑖𝑡𝑦 𝐷 =
2
𝑁(𝑁−1)
 ∑ (𝑥𝐾
15
𝑘=1 ∗ 𝑦𝐾) (10) 
 
Phylogenetic miFISH trees 
The clonal evolution of subclones identified by single-cell miFISH can be modeled by 
tumor phylogenies using the algorithm of the publicly available FISHtree software 
(Chowdhury et al., 2013; Chowdhury et al., 2014). The updated version of FISHtree 
3.0 inferred a model with the possible clonal evolution not only within a single tumor 
but also from the primary to the secondary tumor by building a consensus tree (Gertz 
et al., 2016). In the study presented herein, the clonal evolution of subclones within 
paired primary adenoma and recurrent adenoma was modeled to obtain a consensus 
graph. However, each paired adenoma lesion (i.e., primary and recurrent adenoma) 
was also modeled separately to obtain the probabilities of copy number changes for 
the respective edge. The heuristic algorithm considers the change of probe counts 
which represent different copy number alterations within the clonal population of the 
adenoma lesions. Thus, the algorithm was designed to infer the most likely relation 
and distance of copy number changes across the entire lesion based on the total num-
ber of copy number alterations observed. The approach used in this study modeled 
the distance of copy number alterations irrespective of the ploidy. Excel data files sep-
arated per lesion contained the probe signal counts for each analyzed nucleus. These 
nuclei were incorporated by the FISHtree algorithm which obtained a dot-file per ade-
noma lesion. The respective graph description file was exported to a vector graph file 
by DotEditor and visualized by Inkscape. Tree models were then manually translated 
into PowerPoint graphs precisely adopting the clone distances and tree levels. 
Created tree models display the diploid (all probe counts equal 2) copy number-
neutral signal pattern (“root”) at the top of the graph (Figure 21). Edges leading away 
from the root signal pattern represent the minimum of copy number alterations required 
to form the copy number-wise distantly closest clone populations, whose tree-nodes 
are defined as children of the root. Edges within the tree correspond to the 
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accumulation of an additional copy number alteration connecting the nodes of the pro-
genitor and the descendant, respectively. Nodes within the tree represent a particular 
signal pattern based on the observed CNA. While trees derived from a single lesion 
also displayed the probability value for the connection between two copy number 
changes annotated at the respective edge, consensus trees did not provide this infor-
mation as a matter of lucidity. With the aim to simplify the consensus tree, clone frac-
tions exclusive to the primary adenoma or the recurrent adenoma were marked by a 
circularly or rectangularly shaped node, respectively. If both lesions shared a popula-
tion, the node would be shown as a diamond. Additionally, major clone populations of 
both the primary and the recurrent adenoma were color-coded. Moreover, if the most 
significant clone population within the primary tumor corroborated by the most sub-
stantial fraction of cells within the recurrent tumor, the node would be highlighted. A 
dotted node marked signal patterns which were observed once within an individual 
adenoma. A bold node showed signal patterns counted twice (or more). 
Statistical analysis of the tree-based model provided the opportunity to assess the 
degree of tumor heterogeneity and the amassment (i.e., complexity) of copy number 
changes within the clones. Consequently, the number of tree levels away from the 
neutral root node defined the “node depth” which was previously identified as a poten-
tial measure for the prediction of tumor progression (Heselmeyer-Haddad et al., 2014).  
Figure 21. A representative example of a signal pattern miFISH tree. The phylogenetic tree shows 
the inferred clonal evolution of an adenoma. Top node (“root of the tree”) represents the diploid, un-
changed CN pattern (blue). The two children of the root are nodes with the distantly closest alteration 
pattern (quasi, “trunk of the tree”) Every node shows a signal pattern present in the adenomatous lesion 
and each edge stands for a change in CNs away from the root cell. The probability value for a certain 
alteration is annotated to the edge. CN gains are shown in green while copy number losses are shown 
in red. Signal pattern frequencies are shown below the line separating each node-box. Probe order 
within the signal pattern: COX2, PIK3CA, APC, CLIC1, EGFR, MYC, CEP10, CCND1, CDX2, CDH1, 
TP53, HER2, SMAD7, SMAD4, ZNF217. 
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2.7 Immunohistochemistry 
2.7.1 Microsatellite instability detection 
Although adenomatous polyps are reported to be rarely affected by losses of MMR 
proteins (Gaiser et al., 2013; Petko et al., 2005), the microsatellite phenotypes of col-
orectal adenoma samples not displaying any CNAs in the previous analyses were as-
sessed indirectly by the loss of MMR protein expression (Gaiser et al., 2013).  
Therefore, four FFPE tissue sections (3 µm-thick) per case were mounted on Su-
perFrost microscope slides followed by deparaffinization in xylene (3x 5 min). Slides 
were rehydrated in a decreasing ethanol series comprising 100% (2x), 96% and 80% 
for 2 min, respectively, before rinsing in dH2O (2x). Antigen retrieval was performed via 
heat-induction by immersing the slide in a Coplin jar of Target Retrieval Solution (pH 
9.0; Tris/EDTA; 1:10) in a steamer (95°C for 20 min). Subsequently, sections were 
washed with TBS buffer. Peroxidase Blocking Solution was added for 7 min which was 
then removed by washing with TBS buffer. Primary antibodies MLH1 (1:25) and PMS2 
(1:50) were diluted with Antibody Diluent, while primary antibodies MSH2 and MSH6 
were ready-to-use and applied to the tissue slides for 30 min. Sections were washed 
with TBS buffer and detection was performed with the EnVision Detection System, 
Peroxidase/DAB, rabbit/mouse. The peroxidase-labeled secondary antibody was incu-
bated for 30 min. Sections were rinsed, and chromogen-DAB was applied for 6 min 
prior to rinsing the slides. Slides were counterstained by immersion into hematoxylin 
solution for 2 min followed by rinsing in tap-water for 2 min. Dehydration of the sections 
was carried out in an increasing EtOH series comprising of 80% (2x), 96% and 100% 
for 2 min, respectively, and subsequent incubation in xylene for 2 min. A coverslip and 
Pertex mounting medium covered the sections. 
Experienced pathologists evaluated the immunohistochemical staining. Evaluation 
criteria followed Gaiser et al. (2013): positive nuclear staining in basal crypts of normal 
epithelium and inflammatory cells was considered for expression evaluation of the mis-
match repair genes MLH1, MSH2, MSH6, and PMS2. Distinct expression of each 
marker in tumor cells was classified as microsatellite stability, whereas a loss of MLH1, 
MSH2, MSH6 or PMS2 indicated microsatellite instability for the respective adenoma. 
Staining was validated in comparison to positive and negative controls, respectively. 
Slides were imaged by a digital microscope and an accompanied scanner.  
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2.7.2 CDX2 expression 
Immunohistochemistry on tumor samples was performed with a primary antibody 
(mouse) targeting CDX2. In general, the procedure was carried out as described be-
fore (see 2.7.1 Microsatellite instability detection) with slight modifications using the 
CDX2 primary antibody (dilution 1:50) and performing an antigen retrieval with EDTA 
(pH=9). An experienced pathologist evaluated immunohistochemical staining. Positive 
nuclear staining in normal epithelium and nuclear/cytoplasmic staining in tumor cells 
were evaluated as controls. Intensities of staining were evaluated by the pathologist 
as an indication of putative relatively high or low expression of CDX2 per adapted im-
munoreactive score (Remmele and Stegner, 1987). 
 
2.8 Statistical analysis 
Statistical identification and interpretation of differentially methylated CpG positions 
(DMPs) in adenoma specimens analyzed by HM450K were described in detail before 
(see 2.4.3 DNA methylation microarray: Human Methylation 450K Array). 
In general, statistical analyses were performed using the statistical software 
GraphPad Prism, and R. Continuous data were tested by Shapiro-Wilk-normality test 
to assess whether values were Gaussian distributed. Unpaired, parametric variables 
were then analyzed by Student’s t test comparing the columns by the mean and the 
standard deviation (SD), while non-parametric data were analyzed by Mann-Whitney 
U test comparing the columns by medians with interquartile ranges (IQR). Compari-
sons of paired variables were performed by Wilcoxon matched-pairs signed rank test. 
If three or more columns were compared, significance was tested by either one-way 
ANOVA (parametric) or Kruskal-Wallis (non-parametric) for non-grouped data, 
whereas two-way ANOVA compared grouped variables. Categorical variables were 
tested in 2x2-contingency tables by Fisher’s exact test while more variables were 
tested with the Freeman-Halton test. Recurrence-free time was statistically assessed 
using Kaplan-Meier analysis calculating the significance via log-rank (Mantel-Cox) test 
and hazard ratio (HR) with 95% confidence intervals (CI). Cohen’s kappa (with 95% 
CI) quantitatively determined inter-observer agreement of CN status detected by 
aCGH and miFISH. Clinicopathological features were correlated by Spearman’s non-
parametric correlation coefficient. Fractions of a whole were displayed by frequencies. 
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Statistical significance was defined as P<0.05 and displayed throughout the thesis 
with three significant digits. Performed tests were carried out exploratory and two-sided 
without multiple test correction (if not mentioned otherwise: e.g., HM450K data) de-
manding careful interpretation of the data. 
The profile of copy number alterations (CNAs) detected by aCGH was tested for 
fitting Gaussian distribution or rather Poisson distribution when P>0.10. To compare 
CNAs among different sample groups the average number of copy alterations (ANCA) 
was calculated (Ried et al., 1999).  
Chromosomal instability and tumor heterogeneity were quantitatively assessed (see 
2.6.4 Data Assessment: Tumor heterogeneity by (ecological) measures of diversity). 
Tumor heterogeneity and clonal evolution in recurring adenomas were further investi-
gated by modeling phylogenetic trees based on single-cell miFISH utilizing FISHtree 
software (Chowdhury et al., 2013). The node depth of the respective trees was meas-
ured as a parameter to compare the degree of copy number alterations within the 
clonal population of the samples. Based on observed CNAs by single-cell miFISH, the 
average signal number (ASN) per gene identifier probe and per sample were calcu-
lated. Adenoma samples were unsupervised clustered by Gene Cluster software com-
paring the ASNs of probe markers to generate a heat map with the following criteria 
(Wangsa et al., 2016):  
(i) genes were normalized 
(ii) genes were centered by the mean 
(iii) genes and arrays were non-centered correlated 
(iv) genes and arrays were clustered via complete linkage 
The obtained tree was visualized by Java Tree View which color-coded copy num-
ber gain, loss, and neutrality, respectively. The cluster tree was divided into distinct 
cluster groups. 
Moreover, the bp-length of CNAs in relation to affected chromosome arms of colo-
rectal adenomas detected by aCGH were clustered as heat map (applying the above-
mentioned criteria). Neutral copy numbers were annotated as 0%, while focal CNAs 
were expressed as ≤10%. More extensive alterations were annotated in accordance 
to the respective bp-length in steps of 20%, i.e., whole-chromosome aberrations 
equaled 100%. 
  
Results 
72 
3 RESULTS 
3.1 CpG methylation in colorectal (recurring) adenomas 
3.1.1 Methylation array analysis 
Sixty-nine colorectal adenoma samples and three additional normal mucosa speci-
mens of 62 biological individuals were evaluated for DNA methylation utilizing the 
HM450K. Prior to analysis, the data was normalized and checked for technical artifacts 
(2.4.3). The array’s 485,577 probes were filtered, leaving 329,573 CpGs for analysis. 
Excluding putative batch effects, samples were correlated with one of the six HM450K 
assays. Indeed, a batch-effect was ruled out as confirmed by random distribution. 
First, a principal component analysis (PCA) of the mean β-value per sample showed 
a wide-spread distribution (i.e., the distance of component scores) (Figure 22A). Based 
on PCA, it was not possible to differentiate between primary adenoma without recur-
rence, primary adenoma with recurrence, recurrent adenoma, and normal mucosa. 
Second, an unsupervised hierarchical cluster analysis based on the mean β-value 
per sample was performed seeking to distinguish the adenoma subgroups (Figure 
22B). Cluster analysis revealed three cluster groups; however, cluster 3 was sharply 
different from the remaining clusters 1 and 2. The sample annotation was tested for 
recurrence association, i.e., primary adenomas without recurrence, primary adenomas 
with recurrence and recurrent adenomas, and showed only a tendency (P=0.171; Fig-
ure 22C). The strong divergence of cluster 3 was, however, not associated with ade-
noma recurrence. Aiming to reveal an explanation for this divergence cluster associa-
tions based on mean β-values were dichotomized (i.e., cluster 1 and 2 versus 3) and 
correlated with clinical parameters (Spearman’s correlation coefficient). Neither patient 
age (P=0.496), nor adenoma localizations (P=0.837), nor right- and left-sided location 
(P=0.869), nor adenoma size (P=0.671), nor gender (P=0.511) showed an association 
with the separation between clusters 1 and 2 versus 3. Nevertheless, dichotomized 
clustering was significantly associated with the histological subtype (P=0.008; Figure 
22D). This finding implies that the histological phenotype is also associated with a spe-
cific epigenetic DNA methylation pattern. As a side note, trichotomized cluster assign-
ment showed a trend of divergent distribution of females and males (P=0.052; Figure 
22E); although patient genders were balanced throughout the cohort (n=34 vs n=38). 
Altogether, the mean β-value per sample was not capable of discriminating the ade-
noma subgroups. This finding demanded further analysis of the DNA methylation data.  
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Figure 22. DNA methylation in colorectal adenomas: PCA, cluster analysis, and correlations. (A) 
PCA projection of the entire sample set analysed by HM450K (mean β-value). Defined is an orthogonal 
coordinate system in which the variance of the samples is plotted and given by the component score. 
The analysis did not reveal personal associations with the adenoma subgroups. (B) Unsupervised hier-
archical clustering (Euclidean distance and Ward’s group linkage) of the sample set was performed by 
mean β-values per sample. Cluster analysis exhibited three cluster groups. Cluster 3 diverged stronger 
from the other clusters. (C) Separation of clusters failed short of an association with the adenoma sub-
groups (Freeman-Halton test). (D) Dichotomized clustering was significantly associated with the histo-
logic subtype (Freeman-Halton test). Tubular adenomas were enriched in cluster 3. (E) Cluster groups 
displayed a trend of a non-equal distribution of males and females (Freeman-Halton test). 
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3.1.2 Identification of differentially methylated CpG positions 
The filtered 329,573 probes were used for the detection of differentially methylated 
CpG positions (DMPs) when comparing the adenoma groups (Table 20). For explora-
tory analysis, false discovery rates (FDR; multiple-testing adjusted P-values) were de-
tected using stringent criteria of q≤0.01, q≤0.05, and q≤0.1, respectively. Neither did 
computing the differences of primary adenomas without recurrence compared to pri-
mary adenomas with recurrence unveil any significant DMP, nor did the comparison of 
matched pair adenomas, i.e., primary versus corresponding recurrent adenomas (Ta-
ble 20). Comparing primary adenomas without recurrence versus adenomas associ-
ated with recurrence (primary and recurrent) failed to reveal any DMP (Table 20). 
Nevertheless, the comparison of recurrent adenomas versus primary adenomas 
with recurrence (matched and non-matched) exhibited 2,415 (0.7%) DMPs of 329,573 
assessed sites (q≤0.05; Table 20). Twenty-two DMPs were very significantly different 
(q≤0.01) in this comparison. 99% of DMPs were hypermethylated in recurrent adeno-
mas compared to the primary adenomas with recurrence (Figure 23A). Next, recurrent 
adenomas were compared versus the complete set of primary adenomas, i.e., adeno-
mas without and with recurrence, which resulted in 575 (0.2%) DMPs (q≤0.05; Table 
20). Fifty-four DMPs differed very significantly (q≤0.01). Hypermethylation of recurrent 
adenomas versus all primary adenomas was observed in 99% of these 575 DMPs 
(Figure 23B). Finally, colorectal adenomas were compared to normal mucosa which 
exhibited 9,266 (2.8%) DMPs (q≤0.05; Table 20), of which 5,457 (1.6%) were very 
significant differential (q≤0.01). Notably, 73% of DMPs were hypomethylated in ade-
nomas compared to normal mucosa (Figure 23C). 
 
Table 20. Significant differentially methylated CpG positions (DMPs) in adenoma groups. 
# Specimen groups 
Sample 
number 
Description Significant DMPs (n) 
FDR ≤0.01 FDR ≤0.05 FDR ≤0.1 
1 
Primary adenomas without 
recurrence vs Primary  
adenomas with recurrence 
30 vs 29 
  
0 0 0 
2 
Matched pairs: Primary  
adenomas with recurrence 
vs Recurrent adenomas 
10 vs 10 
  
0 0 0 
3 
Primary adenomas without 
recurrence vs Primary ade-
nomas with recurrence and 
recurrent adenomas  
30 vs 39 
  
0 0 0 
4 
Recurrent adenomas vs  
Primary adenomas with  
recurrence (matched and  
non-matched) 
10 vs 29 Comparison A 22 2,415 14,855 
5 
Recurrent adenomas vs Pri-
mary adenomas with and 
without recurrence 
10 vs 59 Comparison B 54 575 2,667 
6 
Colorectal adenomas vs 
Normal mucosae 
69 vs 3 Comparison C 5,457 9,266 19,065 
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The provided number of 12,256 DMPs (total of all comparisons; q≤0.05) was tested 
for CpG sites which were shared or non-shared across the comparisons (Figure 24A). 
Seventeen probes were common across the three comparisons with the following ten 
most significant (q<0.04) genes: MPPED1, AACS, FARP1, SMARCA4, TTC25, SIDT2, 
NUMBL, ABCC12, TBC1D12, and ZNF655. However, these common CpG dinucleo-
tides did not necessarily overlap regarding hyper-/hypomethylation as this was defined 
depending on the comparisons. For instance, gene ZNF655 was hypermethylated in 
colorectal adenomas versus normal mucosa (20.8% vs 13.5%), but hypomethylated in 
recurrent adenomas compared to primary adenomas (5.3% vs 17.8%). 
With the objective to identify the most differential and biologically truly relevant meth-
ylated CpG positions, obtained DMPs were filtered once again excluding probes with 
fold changes <10%. Reassuringly, 12,256 DMPs were reduced to 5,094 DMPs of 
which 2,824 (55.4%) probes were hypermethylated, and 2,270 (44.6%) were hypo-
methylated. DMPs composed of comparison A (674; 98% hypermethylated), compari-
son B (241; 98% hypermethylated) and comparison C (4,179; 54% hypomethylated), 
respectively (Figure 24B). These DMPs were finally stringently filtered for an absolute 
change (i.e., Δβ) ≥|0.1| providing 35 top gene-DMPs (97% hypermethylated) for com-
parison A (Supplemental Table 2), 7 top gene-DMPs (71% hypermethylated) for com-
parison B (Supplemental Table 3) and 347 top gene-DMPs (68% hypomethylated) for 
comparison C (top50: Supplemental Table 4). Candidates were subsequently selected 
from the list of top gene-DMPs for technical validation via pyrosequencing (see 2.4.4). 
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Figure 23. Scatter plot distribution of DMPs identified by HM450K. (A) Scatter plot of DMPs in recur-
rent adenomas versus primary adenomas with recurrence (matched and non-matched). Each DMPs is 
plotted by the ratio of the mean β-value per group. The apparent shift of probes towards the y-axis is the 
result of hypermethylation in recurrent adenomas compared to the primary adenomas. (B) Scatter plot of 
DMPs in recurrent adenomas versus the complete set of primary adenomas. Each DMPs is plotted by the 
ratio of the mean β-value per group. Most probes were stronger methylated (i.e., hypermethylated) in 
recurrent adenomas. (C) Scatter plot of DMPs in adenomas versus normal mucosa. Each DMPs is plotted 
by the ratio of the mean β-value per group. Here, 73% of DMPs are hypomethylated (dots below the 
diagonal line) and 27% are hypermethylated in adenomas compared to normal mucosa. 
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Among the top genes-list of the comparison of recurrent adenomas versus primary 
adenomas with recurrence (matched and non-matched; comparison A), 30 of 35 
(85.7%) DMP-associated genes were listed only once. Two DMPs in an open sea were 
associated with TMEM85 (transmembrane protein 85). Interestingly, three DMPs were 
in a CpG island which is located in the gene body of the GREM2 (gremlin 2) gene, a 
member of the differential screening-selected gene in neuroblastoma (DAN) family of 
bone morphogenetic protein (BMP) antagonists and TGF-β modulators. Additionally, 
another member of the TGF-β/BMP-axis was among the 35 identified top gene-DMPs, 
namely BMP3 (bone morphogenetic protein 3). This supported the ultimate selection 
of the GREM2-associated CpGs cg01809217 (Δβ=0.103; q=0.026) and cg02577267 
(Δβ=0.101; q=0.048) as validation targets. The biological function, the relevance, and 
the statistical significance of three DMPs (i.e., hypermethylated in recurrent adenomas) 
in this locus seemed striking (see 3.1.5 Validation of GREM2 by pyrosequencing). 
 
3.1.3 Genome-wide distribution of DMPs 
Genomic localizations of the DMPs were classified in regions defined by the closest 
CpG island (see 2.4.3), including information about the genomic direction as upstream 
(i.e., north) or downstream (i.e., south), to get an impression of the distribution of DNA 
methylation. The total count of 5,094 DMPs (4,917 when overlaps between compari-
sons were filtered out), identified by FDR≤0.05 and fold change >10% (Figure 24B), 
Figure 24. Venn-diagram and distribution of DMPs by multiple comparisons. (A) Venn-diagram depicts 
the overlaps of DMPs across the three comparisons (A, B and C) of sample groups. (B) The upper pie-
chart displays the distribution of DMPs within the three comparisons. Included are DMPs only which 
scored FDR≤0.05 with fold change >10%. These DMPs are further distributed on the three comparisons 
as shown in the lower panel of pie-charts. Comparisons A and B exhibited an evident hypermethylation 
in recurrent adenomas. Comparison C was more balanced. 
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demonstrated an unequal distribution across the genome with an enrichment of hyper-
methylated DMPs in CpG islands (33.7%; 1,655/4,917). Contrary, DMPs in open sea 
regions were hypomethylated (24.1%; 1,186/4,917; Figure 25A). Shore and shelf re-
gions exhibited a low number of DMPs independent whether hyper- or hypomethyl-
ated. Note, the average number of probes located in shelf regions was lower than CpG 
islands (4.1 vs 5.6). Comparing the DMP-localizations by ratios of hypermethylation 
versus hypomethylation revealed that more than 75% of DMPs were hypomethylated 
in open sea and shelf regions, respectively (Figure 25B). However, the most frequent 
abundance (86%) was documented for hypermethylated CpG island DMPs, while 
shore regions seemed balanced with a slight excess of hypermethylation (Figure 25B). 
The distribution of DMPs was analyzed per comparison which exhibited an excess of 
DMPs located in CpG islands of comparison A (i.e., recurrent adenomas versus pri-
mary adenomas with recurrence; 47%) and comparison B (i.e., recurrent adenomas vs 
the complete set of primary adenomas; 66%; Figure 25C). Interestingly, comparison C 
(i.e., adenomas vs normal mucosa) showed a more homogeneous distribution of 
DMPs across islands (37%), shores (27%) and open sea (31%; Figure 25C). 
The distribution of the 4,917 DMPs was further analyzed regarding functional ge-
nomic regions: proximal promoter (i.e., upstream of the transcription start site, 5’UTR 
and 1st exon), gene body and 3’UTR (Figure 25D). Proximal promoter DMPs were most 
frequently hypermethylated, whereas DMPs in the gene body were in total numbers 
most abundant and more frequently hypomethylated (Figure 25D). However, the mean 
number of probes per functional region on the HM450K needs to be considered: prox-
imal promoters 15.2 probes, gene bodies 9.9 probes and 3’UTR 1.5 probes. The non-
random distribution of hyper-and hypomethylation was further confirmed by analyzing 
the ratio of hypermethylated versus hypomethylated DMPs per functional region (Fig-
ure 25E). DMPs of the proximal promoter were more frequently hypermethylated (ex-
ceeding 50% in each subregion), and DMPs in the gene body and 3’UTR were more 
frequently hypomethylated. The DMP-distribution of gene regions per individual com-
parison confirmed a large excess of DMPs located in promoter regions with the highest 
percentage (74%) in comparison B (i.e., recurrent adenomas vs the complete set of 
primary adenomas; Figure 25F). 
Finally, the distribution of DMPs was plotted by chromosomal location (sex-chromo-
somes excluded) which exhibited the highest frequencies of DMPs located on chr1 
(10.8% hypermethylated, 11.3% hypomethylated; Figure 25G). However, this is also 
the largest chromosome and has the highest gene-density.   
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Figure 25. Legend on next page. 
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3.1.4 Functional pathway enrichment of DMPs 
The DMPs identified per individual comparison (Figure 24B) were annotated by path-
ways and biological functions via gene set enrichment analysis (GSEA; Figure 26). 
The input of 674 DMPs of comparison A resulted in 632 individual genes found in the 
database which provided 25 different pathways and gene ontologies highly significantly 
(q≤0.001) associated with 340 genes (Figure 26A). The most significant were genes 
involved in the immune system (n=44; q=2.9x10-9) and the adaptive immune system 
(n=32; q=4.8x10-9) as well as in inflammation-mediated chemokine and cytokine path-
ways, e.g., IL2 pathway (n=9; q=2.1x10-5; Figure 26A). Interesting targets in adenoma 
recurrence might also be genes associated with cellular survival, growth and differen-
tiation via signaling by neural growth factor (NGF; n=15; q=6.9x10-5), mTOR pathway 
(n=9; q=6.9x10-5) and cell cycle pathways (n=19; q=7.3x10-4; Figure 26A). 
Comparison B provided of 241 DMPs of 233 individual genes which were found in 
the database, however only two pathways/ontologies were highly significantly associ-
ated with 31 genes (Figure 26B): again, genes involved in the immune system (n=21; 
q=2.1x10-5) and cytokine signaling in the immune system (n=10; q=9.3x10-4; Figure 
26B). Note that eighteen other pathways, e.g., cell cycle checkpoints, reached q≤0.01. 
Finally, 4,179 DMPs of comparison C had to be filtered by q≤0.001 (resulting in 
n=1584) to reduce the data input. These DMPs provided 1,396 individual genes of 
which 34 pathways were highly significantly associated with 1,022 genes (Figure 26C). 
Genes encoding not only extracellular matrix (ECM) and ECM-associated proteins 
(n=84; q=5.8x10-13) and core ECM-proteins (n=32; q=2.4x10-8) but also “classical tar-
gets of tumorigenesis” such as pathways in cancer (n=39; q=3.4x10-10), MAPK signal-
ing (n=34; q=1.0x10-9) or p53 signaling (n=13; q=1.3x10-5; Figure 26C) appeared to be 
the most striking. Genes involved in the immune system (n=60; q=5.7x10-6) and adap-
tive immune system (n=39; q=5.1x10-5) were also enriched as described before. 
Figure 25. Distribution of DMPs by genome localizations and chromosomes. (A) Distribution of 
DMPs in regards of CpG content in the linear genome. Shown percentages are computed with the total 
number of DMPs (ntotal=4,917). (B) Depicted is the ratio of hypermethylated vs hypomethylated DMPs 
in multiple genomic regions defined by CpG content. (C) Distribution of DMPs in regard to genomic 
regions defined by CpG content and sorted by individual comparisons. (D) Distribution of DMPs in gene-
associated regions defined as 200-1,500 bp upstream from transcription start site (TSS1500), up to 
200 bp upstream from transcription start site (TSS200), 5’untranslated region (5’UTR), 1st exon, gene 
body and 3’untranslated region (3’UTR), respectively. Shown percentages are computed in relation to 
the total number of DMPs (ntotal=4,917). (E) Ratio of hypermethylated versus hypomethylated DMPs in 
different gene-associated regions. (F) Distribution of DMPs in regards of gene-associated regions and 
sorted by individual comparisons. (G) Chromosomal distribution (sex chromosomes excluded) of DMPs 
categorized as hyper- or hypomethylated, respectively. Note that chr8 showed the lowest ratio of hy-
permethylation/hypomethylation (i.e., hypomethylation enriched), while chr19 showed the highest ratio. 
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Figure 26. Legend 
on next page. 
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3.1.5 Validation of CpG methylation by pyrosequencing 
Methylation frequencies detected by HM450K were sought to be validated by selection 
(i.e., highly significant p-values across group comparisons, differential methylation fold 
change exceeding 10%, located in CpG island) of a candidate gene. Pyrosequencing 
validated the locus-specific methylation alterations of CpG sites in CpG islands of the 
gene. Three CpG sites within GREM2 (Gremlin 2) diverged when comparing primary 
adenomas with/without recurrence to recurrent adenomas (see 3.1.2) suggesting this 
antagonist of the BMP (bone morphogenetic protein) pathway as a potential target. 
Highly specific probe design incorporated two CpG sites (i.e., CpG position 
1=cg01809217 and CpG position 15=cg02577267) covered by HM450K (Figure 16A). 
Assays were firstly validated by technical replicates to test the array reproducibility 
(Figure 27A; see 2.4.4 Pyrosequencing): methylation status of GREM2 forward- and 
reverse-assay were 8-times and 4-times, respectively, measured in glioblastoma cell 
lines, which confirmed a high validity (Figure 27A). Bisulfite-converted DNAs of primary 
adenomas with (n=15) and without (n=9) recurrence and recurrent adenomas (n=4) 
were analyzed for GREM2 gene body methylation frequencies (Figure 15; Figure 27B). 
While GREM2 methylation frequencies were highly variable across samples, methyla-
tion ratios of analyzed CpG sites were detected to be low (i.e., hypomethylated; ≤33%) 
in 14.6% (28/192), medium (>33-66%) in 49.5% (95/192) and high (i.e., hypermethyl-
ated; >66%) in 35.9% (69/192) of specimens, respectively. Addressing the compara-
bility of GREM2 CpG dinucleotide methylation patterns across adenomas with and 
without recurrence the mean methylation frequencies per CpG site was calculated 
(Figure 27C, D). Interestingly, primary adenomas showed very similar ratios across 
CpG sites 1-4 whereas recurrent adenomas tended to exhibit slightly higher mean 
methylation frequencies (Figure 27C). On the contrary methylation ratios of CpG sites 
12-15 were found to be more heterogeneous across adenoma groups: recurrent 
Figure 26. Distribution of DMPs according to pathway analysis/gene ontology. (A) Circle plot 
shows the frequency of genes (picked from DMPs of comparison A) associated with the respective 
pathways/gene ontologies, which are listed in the legend. Results show that genes involved in inflam-
matory-pathways were differentially methylated in this comparison. (B) Circle plot shows the frequency 
of genes (picked from DMPs of comparison B) associated with the respective pathways/gene ontolo-
gies, which are listed in the legend. Here, immunologic pathways only were identified to be highly 
significantly associated with the DMPs. (C) Circle plot shows the frequency of genes (picked from 
DMPs of comparison C) associated with the respective pathways/gene ontologies, which are listed in 
the legend. Results document the tumor-related differential methylation of multiple cellular signaling 
pathways and extracellular matrix proteins. Not that genes may be assorted to several pathways. 
All pathways were ordered by significance and not by the frequency of genes involved. Pathway 
annotations relate to database entry: 1=NABA; 2=KEGG; 3=REACTOME; 4=PID; 5=SIG; 6=BioCarta. 
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adenomas unveiled the lowest frequencies while primary adenomas showed, on aver-
age, the higher methylation frequencies (Figure 27D). As a side note, methylation ra-
tios of CpG 2 and CpG 13, respectively, had the highest (mean, 70% ± 18%) and the 
lowest (mean, 38% ± 15%) ratios across specimens. 
In-depth analysis conducted by calculating the average methylation frequency per 
sample based on cumulated GREM2 CpG dinucleotides 1-4 showed no difference 
comparing the adenoma groups (P=0.814; Figure 28A). Despite that, mean methyla-
tion ratios of cumulated GREM2 CpG dinucleotides 12-15 seemed to tend weakly to-
wards lower average methylation frequencies in primary adenomas with recurrence 
compared to primary adenomas without recurrence (P=0.172; Figure 28B). Comparing 
the median methylation frequencies of individual CpG dinucleotides 1-4 sorted by ad-
enoma groups failed to reveal a difference across primary adenomas with and without 
recurrence and recurrent adenomas (P=0.590; Figure 28C), although recurrent ade-
nomas seemed to be hypermethylated compared to primary adenomas without 
(P=0.406) and with (P=0.312) recurrence. However, the comparison of median meth-
ylation frequencies of individual CpG dinucleotides 12-15 unveiled a significant differ-
ence comparing primary adenomas with recurrence to adenomas without recurrence 
(P=0.042; Figure 28D). Moreover, methylation ratios of CpG sites 12-15 were highly 
significantly different across primary adenomas with recurrence, primary adenomas 
without recurrence and recurrent adenomas (P=0.002; Figure 28D). Here, recurrent 
adenomas were hypomethylated compared to primary adenomas without (P=0.004) 
and with (P=0.003) recurrence. According to our data, the combination of GREM2 CpG 
dinucleotides 12-15 provides the most reliable statistical power to discriminate primary 
adenomas without recurrence, primary adenomas with recurrence and recurrent ade-
nomas via differential methylation. 
Average percentages of GREM2 DNA methylation of CpG position 1 (cg01809217) 
were measured on the HM450K as β=0.716 for recurrent adenomas (n=10) and 
β=0.613 for primary adenomas with recurrence (matched and non-matched; n=29). 
Pyrosequencing showed values of β=0.753 for recurrent adenomas (n=4) and β=0.687 
for primary adenomas with recurrence (matched and non-matched; n=14) (Figure 
27C). These values are in line with the array results, although a smaller number of 
samples was investigated by pyrosequencing (ΔβHM450K=0.103 versus ΔβPyroseq=0.066) 
(Figure 27C, D).  
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Figure 27. CpG methylation validation by pyrosequencing. (A) Quantitative GREM2 gene body 
methylation analysis (mean ± SEM) of glioblastoma cell line LN229 (served as the technical control) 
confirms the reliability and reproducibility of results obtained by pyrosequencing. (B) Detected meth-
ylation values are depicted as lollipops resembling the color-coded degree of methylation from high 
to low (i.e., hypermethylation to hypomethylation) in trichotomized order (yellow > orange > red). CpG 
sites of the reverse-assay whose methylation levels were not determined (N.D.) are shown as straight 
lines. CpG number 1-4 were determined by the forward-assay whereas CpG number 12-15 were 
analyzed by the reverse-assay. (C) Quantitative GREM2 gene body methylation analysis of four CpG 
dinucleotides (for-assay) in primary adenomas with and without recurrence and recurrent adenomas, 
respectively. Data points in the pyrogram represent the mean methylation frequency per CpG and 
subgroup. (D) Quantitative GREM2 gene body methylation analysis of four CpG dinucleotides (rev-
assay) in primary adenomas with and without recurrence and recurrent adenomas, respectively. Data 
points in the pyrogram represent the mean methylation frequency per CpG and subgroup. 
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Figure 28. GREM2 gene body methylation in colorectal adenoma subgroups. (A) Computing the 
mean methylation frequency of cumulated CpG sites 1-4 of the GREM2 pyrosequencing assay per ade-
noma did not reveal differences (median with IQR) across primary adenomas with and without recurrence 
(Mann-Whitney U test) or recurrent adenomas (global, Kruskal-Wallis test), respectively. (B) Mean meth-
ylation frequencies of cumulated CpG sites 12-15 of the GREM2 pyrosequencing assay showed a trend 
to differ (median with IQR) not only when comparing primary adenomas with and without recurrence 
(Mann-Whitney U test), but also when including recurrent adenomas in the comparison (Kruskal-Wallis 
test). (C) Plotting the methylation frequencies of CpG sites 1-4 individually per primary adenoma with and 
without recurrence and recurrent adenoma did not show differences (median with IQR; Mann-Whitney U 
test; global, Kruskal-Wallis test). (D) Median (with IQR) methylation frequencies of GpG sites 12-15 plotted 
individually per subgroup showed a significant difference across primary adenomas with and without re-
currence (Mann-Whitney U test). Differences were strongly divergent when comparing primary adenomas 
with and without recurrence and recurrent adenomas (Kruskal-Wallis test). 
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3.2 Landscape of CNAs in colorectal (recurring) adenomas 
3.2.1 Overall aCGH analysis 
Analysis of aCGH results detected a total of 178 copy number changes among the 
non-tetraploid colorectal adenomas (n=51) (Figure 15; Table 21). Overall, gains were 
more frequently observed than losses (means 1.9 ± 2.3 vs 1.6 ± 2.4; P=0.113, Mann-
Whitney U test). The proportion of whole-chromosome changes (defined as ≥90%; 
22.5%; 40/178) per adenoma was significantly lower than part-chromosome changes 
(defined as ≤50%; 77.5%; 138/178) (means 0.78 ± 0.20 vs 2.71 ± 0.50; P=0.004; Fig-
ure 29A). Frequencies of both whole-chromosome CNAs (z=0.88, P=0.379) and part-
chromosome CNAs (z=1.20, P=0.230) suggested a distribution by Poisson (P>0.100) 
indicating that CNAs are non-randomly distributed throughout the genome. However, 
there was no tendency visible that adenomas with larger numbers of whole-chromo-
some alterations also showed larger numbers of part-chromosome alterations 
(r=0.112; P=0.433; Spearman correlation). ANCA (average number of copy altera-
tions) values ranged from 0-16 with a mean of 3.5 ± 4.1 (Table 21). Evaluation of the 
clinicopathological parameters revealed a positive correlation between the presence 
of CNAs and the adenoma location (P=0.037; Figure 29B). In other words, rectal ade-
nomas showed more CNAs than colonic adenomas. However, none of the other clini-
copathological features (adenoma size, histology, gender, grading, time of recurrence, 
patient age) reached statistical significance when correlated with the number of CNAs.  
Figure 29. CNAs detected by aCGH. (A) Comparison (mean ± SD) of whole-chromosome aberrations 
and part-chromosome aberrations within all samples analysed (n=51) revealed that whole-chromo-
some changes occurred less frequently (Mann-Whitney U test). (B) CNAs by aCGH were not randomly 
distributed among colorectal adenomas (n=51) when separated by trichotomized localization (Free-
man-Halton test). All analyzed rectal adenomas displayed CNAs. 
A B 
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Table 21. Summary of copy number alterations detectable by aCGH. The table depicts the copy 
number changes in colorectal adenomas expressed as gain or loss of bps. Changes were of small 
magnitude, i.e., no amplifications or deep-deletions were detected. Aberrations <1,500kb, copy number 
variant (CNV)-overlapping regions and sex chromosomes were excluded. F, female; M, male; N.D., not 
determined; †, tetraploid adenoma; % genome changed, extracted from Nexus Copy Number. 
Sample 
ID 
Sex Gains Losses 
No. of 
CNAs 
Whole-chr. 
aberr.a 
Part-chr. 
aberr.b 
% genome 
changed 
A 1 M N.D. N.D. N.D. N.D. N.D. N.D. 
A 2 M - 4q28.3; 4q32.1-q32.3 2 0 2 0.66 
A 3 M 3p21.31-p21.1; 7q22.1; 
11q12.2-q13.4; 12q13.11-
q13.2 
1pter-p35.2; 1p33-p32.2; 
5q15-q21.1; 16q21 
8 0 8 6.25 
A 4 M - - 0 0 0 0.69 
A 5 M - - 0 0 0 0.00 
A 6 M 6p22.1; 17q12-q21.33; 
19pter-p13.11 
- 3 0 3 4.01 
A 7 F - - 0 0 0 0.00 
A 8 M 6p22.2-22.1; 8; 19 - 3 2 1 6.47 
A 9 F 8 - 1 1 0 4.80 
A 10 M 5; 6; 7; 14; 20 2p12-p11.2; 3q26.1-q26.2; 
4q28.3; 10q25.1; 16pter-13.2; 
16q21 
11 5 6 24.92 
A 11 F 6p22.2-22.1; 7; 20p13-p12.3 - 3 1 2 5.58 
A 12 M 6p22.1-p21.32; 7q22.1 14q21.1-q21.3 3 0 3 0.60 
A 13† F 20q 1; 4; 6; 10; 16; 17; 18 16 15 1 37.95 
A 14 M 7 3q26.1-q26.2; 16q21; 
18p11.31-p11.23; 18q11.2-
q12.1 
5 1 4 8.37 
A 15 M 7q11.23; 7q22.1; 19q 5q22.1-q23.2 4 0 4 0.66 
A 16 M 1q; 6p22.1; 6p21.33-p21.32; 
7q22.1; 8; 19q; 20 
13q21.1-q21.33; 16q21 9 2 7 10.93 
A 17 M 
3p21.31-p21.1; 6p22.2; 
17p13.1 
- 
3 0 3 2.18 
A 18 M 1pter-p33; 6p22.1; 6p21.33-
6p21.2; 7; 12q13.11-q14.1; 
13; 17pter-17q21.33; 19q 
2p12-p11.2; 4q28.3; 5p14.3-
p13.3; 8p12; 11p12; 14q24.3-
q31.3; 16q21 
15 2 13 13.54 
A 19 M N.D. N.D. N.D. N.D. N.D. N.D. 
A 20 F - - 0 0 0 1.07 
A 21 M 6p22.1 - 1 0 1 0.06 
A 22 M 6p22.1-p21.32; 7q22.1; 20q 1pter-p35.2; 5q21.1- q22.3; 
11q23.1-q24.2; 16p13.3-
p13.2; 16q21; 18; 20p 
10 1 9 6.69 
A 23 F 3; 6p22.1; 7p15.2-p15.1; 
11q12.2-q13.3; 17q 
5pter-p15.31; 5p14.3-p14.1; 
6p12.3-p12.2; 13q21.1-
q21.33; 16q21; 17p13.1-p12; 
18q12.2-q12.3 
12 1 11 10.60 
A 24 F - - 0 0 0 0.00 
A 25 M - - 0 0 0 0.00 
A 26 F 6p22.1; 12p13.2-p12.3 16q21 3 0 3 2.73 
A 27 M 6p21.33; 17q12-q21.32; 19p; 
20q 
16q21 5 0 5 5.48 
A 28 F 6p22.1 16q21 2 0 2 1.21 
A 29 M - 16q21 1 0 1 0.51 
A 30† M 6p22.2-p21.2 1; 2; 5; 8; 11; 15; 18 8 7 1 30.98 
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Case 
ID 
Sex Gains Losses 
No. of 
CNAs 
Whole-chr. 
aberr.a 
Part-chr. 
aberr.b 
% genome 
changed 
P 1a F 6p21.33; 7q22.1; 11q12.2-
q13.2 
16q21 4 0 4 2.52 
P 1b F 6p22.1-p21.33; 7q22.1; 
11q12.2-q13.2; 17q21.2-
q21.31 
16q21 5 0 5 1.62 
P 2a F - - 0 0 0 0.00 
P 2b F 13q21.33-q22.2 
4p15.33-p15.1; 16pter-13.2; 
19 
4 1 3 4.01 
P 3a F 12q12-q13.2 - 1 0 1 0.50 
P 3b F 3q26.2-q26.31; 4q21.1-
q21.21; 5q13.2-q13.3; 5q15-
q21.1; 6p21.33; 6q23.3; 
8p22-p21.3; 8p21.1-p12; 
8q24.21; 12p13.2-p13.1; 
13q21.33-q22.1 
5pter-p15.31; 15q11.2-q13.1; 
17q11.2-q12; 19q13.33-qter; 
22q13-qter 
16 0 16 5.61 
P 4a M N.D. N.D. N.D. N.D. N.D. N.D. 
P 4b M N.D. N.D. N.D. N.D. N.D. N.D. 
P 5a F - - 0 0 0 0.12 
P 5b F - 11q22.1-q22.3 1 0 1 1.04 
P 6a M 6p22.1-6p21.33; 7q22.1 18q22.3 3 0 3 1.03 
P 6b M 6p22.1 5p14.1-p13.3 2 0 2 0.71 
P 7a F 7 - 1 1 0 5.05 
P 7b† F 6p22.2-p21.1; 7q22.1; 17; 19 1p33-p13.3; 1q; 2; 4; 11q; 15; 
16q; 18 
12 6 6 25.46 
P 8a F - 1pter-p35.2 1 0 1 0.81 
P 8b F - 1pter-p35.2; 16q13-q24.3 2 0 2 1.96 
P 9a F 13 - 1 1 0 3.18 
P 9b F 13 - 1 1 0 3.11 
P 10a M 13; 20 1pter-p35.1; 1p34.1-p21.2; 4; 
6q16.1; 12; 14; 17p; 18; 22 
11 7 4 25.62 
P 10b M 5q; 13; 20 1pter-p35.1; 1p34.1-p21.2; 4; 
9q32-q33.2; 12q; 15; 17p; 18 
11 5 6 27.29 
P 11a F 7; 9 - 2 2 0 8.55 
P 11b F 7; 9 - 2 2 0 9.55 
P 12a M - - 0 0 0 0.19 
P 12b M - - 0 0 0 0.39 
P 13a F 13; 20 - 2 2 0 5.18 
P 13b F 13; 20 - 2 2 0 5.23 
P 14a M - 5q14.3-q22.1 1 0 1 0.77 
P 14b M - 5q14.3-q22.1 1 0 1 0.73 
aWhole-chromosome aberrations defined as alteration comprising ≥90 of the chromosome. 
bPart-chromosome aberrations defined as alteration comprising ≤50% of the chromosome. 
 
3.2.2 Genomic locations of CNAs 
CNAs were detected in 41/51 (80.4%) of the colorectal adenomas, i.e., 10/51 (19.6%) 
of the colorectal adenomas did not reveal a detectable copy number change. The most 
frequent changes observed applied to focal (≤10 Mb) copy number gains of 6p22.1-
p21.33 (17/51; 33.3%) and 7q22.1 (16/51; 31.4%; Table 21) followed by the focal loss 
of 16q21 (15/51; 29.4%). In contrast, chromosomal aberrations affecting entire 
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chromosomes and chromosome-arms were less frequent with chromosomes 7 (7/51; 
13.7%), 13q (7/51; 13.7%) and 20q (7/51; 13.7%) being most commonly changed in 
copy numbers (Figure 30A-D). The frequency plot revealed, in general, a low incidence 
(not exceeding 50%) of genomic imbalances in adenomas without and with recurrence. 
Figure 30. Chromosomal aberrations in colorectal adenomas identified by aCGH. (A) Frequency 
plot of CN gains (blue) and losses (red) distributed in the adenoma cohort (n=51). The most frequent 
focal alterations were observed on chr6, chr7 and chr16, respectively, while whole-chromosome CNAs 
were detected on chr7, chr13, chr18 and chr20, respectively. (B) Representative aCGH ideogram of 
genome-wide distributed chromosomal gains and losses (case A22). (C) Chromosome view of chr6 
which was affected by focal aberrations (zoomed-in: p-arm). Graph shows the distribution of probes via 
log2-ratio. (D) Chromosome view of chr20 which displayed arm-level aberrations (-20p, +20q). 
A 
B 
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3.2.3 Differential CNAs in primary (recurring) adenomas 
The investigated set of primary colorectal adenomas (n=39) exhibited at least one copy 
number alteration in 76.9% (10/13) of samples without recurrence whereas 80.7% 
(21/26) of adenomas with recurrence were affected by CNAs (Figure 31A; Table 21). 
Consequently, neither the average number of copy alterations (ANCA) of primary ad-
enomas without recurrence compared to primary adenomas with recurrence did show 
any difference (means 3.3 ± 3.2 SD vs 3.4 ± 4.3 SD; P=0.955, Figure 31B), nor did the 
percentage of changed genome per sample, which reflects the length of respective 
chromosomal aberrations (means 4.8 ± 6.7 SD vs 4.2 ± 5.8 SD; P=0.748, Figure 31C). 
Although the alteration patterns shared an immense proportion of chromosomal aber-
rations across colorectal adenomas without and with recurrence (Figure 31A), 
Figure 31. Chromosomal aberrations in primary colorectal adenomas without and with recur-
rence. (A) Frequency plot of CN gains (blue) and losses (red) of autosomal chromosomes distributed 
among primary adenomas without recurrence (upper panel) and with recurrence (lower panel). Despite 
visible differences on chr6, chr13, chr18 and chr20, none of the alteration patterns reached statistical 
significance (P>0.05). (B) Primary adenomas without recurrence and primary adenomas with recurrence 
did not show a difference in the number of copy alterations expressed by the ANCA index (mean ± SD; 
Student’s t test). (C) Percentage of changed genome (mean ± SD) failed to distinguish primary adenomas 
without recurrence from the ones with recurrence (Student’s t test). (D) Part-chromosome aberrations 
were more frequently observed than whole-chromosome aberrations (Mann-Whitney U test). +, mean; 
whiskers, Tukey. 
B D C 
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characteristic imbalances of the colorectal carcinogenesis were identified in both 
groups, e.g., copy number gains of chromosome 7 and chromosome 20. Of note, none 
of the chromosomal aberration loci reached statistical significance to distinguish pri-
mary adenomas with recurrence from adenomas without recurrence (Table 22). How-
ever, copy number events affecting chromosome 13 showed a trend to distinguish pri-
mary adenomas with recurrence with 23.1% (6/26) from non-recurring primary adeno-
mas with 0% (0/13; P=0.081, Fisher’s exact test). 
Interestingly, the number of whole-chromosome CNAs was lower than the number 
of observed part-chromosome aberrations per sample in both groups: primary adeno-
mas without (means 0.8 ± 1.4 vs 2.5 ± 2.5) and with recurrence (means 0.7 ± 1.5 vs 
2.7 ± 3.6), respectively (Figure 31D). However, the comparison was more significant 
in primary adenomas with recurrence (P=0.018, Student’s paired t test). 
 
Table 22. Differential CNAs in primary adenomas without and with recurrence. Genome wide dif-
ferential copy number alterations occurring in 2 or more cases in any of the groups. 
Cytoband Event 
Primary adenoma 
w/o recurrence 
Trend 
Primary adenoma 
w/ recurrence 
P value° 
1pter-p35.2 CN loss 7.7% (1/13) < 11.5% (3/26) 1.000 
3p21.31-p21.1 CN gain 15.4% (2/13) > 3.8% (1/26) 0.253 
3q26.1-q26.2 CN loss 15.4% (2/13) > 0% (0/26) 0.105 
4q28.3 CN loss 15.4% (2/13) > 7.7% (2/26) 0.589 
5p14.3-p14.1 CN loss 0% (0/13) < 7.7% (2/26) 0.544 
6p22.1-p21.33 CN gain 30.8% (4/13) < 42.3% (11/26) 0.728 
chr7 CN gain 23.1% (3/13) > 11.5% (3/26) 0.381 
7q22.1 CN gain 38.5% (5/13) > 30.8% (8/26) 0.725 
chr8 CN gain 15.4% (2/13) > 3.8% (1/26) 0.253 
chr13 CN gain 0% (0/13) < 15.4% (4/26) 0.281 
13q21.1-q21.33 CN loss 0% (0/13) < 7.7% (2/26) 0.544 
14q21.1-q21.3 CN loss 0% (0/13) < 7.7% (2/26) 0.544 
14q24.3-q31.3 CN loss 0% (0/13) < 7.7% (2/26) 0.544 
16q21 CN loss 23.1% (3/13) < 30.8% (8/26) 0.719 
17p CN gain 0% (0/13) < 7.7% (2/26) 0.544 
17p13.1-p12 CN loss 0% (0/13) < 7.7% (2/26) 0.544 
17q12-q21.32 CN gain 7.7% (1/13) < 15.4% (4/26) 0.648 
chr18 CN loss 0% (0/13) < 7.7% (2/26) 0.544 
18q12.2-q12.3 CN loss 0% (0/13) < 11.5% (3/26) 0.538 
18q22.3 CN loss 0% (0/13) < 11.5% (3/26) 0.538 
19pter-p13.11 CN gain 15.4% (2/13) > 3.8% (1/26) 0.253 
19q CN gain 15.4% (2/13) > 7.7% (2/26) 0.589 
20p CN gain 7.7% (1/13) < 11.5% (3/26) 1.000 
20q CN gain 7.7% (1/13) < 19.2% (5/26) 0.643 
°, Fisher’s exact test. 
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Furthermore, genome-wide aCGH profiles of primary adenomas were correlated 
with the clinicopathological features of these samples. Copy number changes corre-
lated with the dichotomized localization, i.e., colon or rectum, of the primary adenomas 
(P=0.040; Figure 32A), as seen in the complete sample-set (Figure 29B). Conse-
quently, at least one CNA was detected in each rectal adenoma analyzed by aCGH. 
Subsequently, numbers of CNAs per sample were tested for association with the di-
chotomized localization which revealed a strong trend (P=0.052; Figure 32B). Surpris-
ingly, primary adenomas of male patients harbored a more significant load of CNAs 
than their female counterpart (P=0.029; Figure 32C). None of the other clinicopatho-
logical parameters (adenoma size, histology, grading, time of recurrence, patient age) 
correlated significantly. 
 
3.2.4 Hierarchical clustering of colorectal adenoma CNA-profiles 
Unsupervised hierarchical clustering of aCGH-detected CNA-profiles expressed as 
chromosome arm-lengths separated the 51 samples into three distinct groups (Figure 
33). One of the groups (Cluster 1) contained samples with either several chromosome-
arm losses, e.g., chromosome 18 or whole-chromosome gains of chromosome 7 and 
8, respectively. The second group (Cluster 2) was defined by other copy number alter-
ations, i.a., whole-chromosome gains of 13 or part-chromosome aberrations on chro-
mosome arms 11q or 19p (Figure 33). The third group (Cluster 3) was composed of 
adenoma samples which either showed focal aberrations only or samples without any 
detectable CNA at all. Thus, the number of copy alterations per sample was strongly 
Figure 32. CNAs detected by aCGH correlate with the localization of the primary adenomas. (A) 
CN changes/neutrality in primary adenomas correlated with the dichotomized localization of either the 
colon or the rectum (Fisher’s exact test). (B) Numbers of CNAs per sample in primary adenomas were 
almost significantly different when separated by dichotomized localization (Mann Whitney U test). (C) 
Primary adenomas of male patients exhibited a larger number of CNAs (Mann Whitney U test). +, mean; 
whiskers, Tukey. 
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associated with the unsupervised clustering of the adenoma samples into Cluster 1 
(mean 6.5 ± 4.8), Cluster 2 (mean 3.7 ± 3.0) and Cluster 3 (mean 1.7 ± 3.3) (P<0.001; 
Figure 34A). Cluster-based groups were further evaluated by consideration of the sta-
tus of recurrence. However, cluster assignment did not discern primary adenomas 
without recurrence from primary adenomas with recurrence (P=0.449; Freeman-Halton 
test). Additionally, recurrent adenomas were not associated with a distinct cluster sep-
arating these samples from primary adenomas (P=0.653, Freeman-Halton test; Figure 
33 33).  
Figure 33. Heat map of CNAs in colorectal adenomas detected by aCGH. Heat map cluster analysis 
of 51 colorectal adenoma specimens including primary adenomas without recurrence (n=13), primary ad-
enomas with recurrence (n=26) and recurrent adenomas (n=13). Unsupervised hierarchical clustering was 
performed by calculating the bp-length of CNAs detected by aCGH expressed as a percentage of the 
affected chromosome arm p and q, respectively. Blue, red and black show CN gain, loss, and neutrality. 
Adenoma cases are plotted along the x-axis with chromosome arms plotted along the y-axis. However, 
acrocentric chromosomes (i.e., chr13, chr14, chr15, chr21 and chr22) are represented by the q-arm only. 
The heat map is divided into three well-defined clustering groups. However, these groups were not asso-
ciated with the status of recurrence but with the number of CNAs per sample. 
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Aiming to identify putative additional correlations of the cluster assignment, besides 
the number of CNAs per sample (Figure 34A), other clinicopathologic features of the 
cluster groups were evaluated. The sample distribution suggested by the heat map 
clustering failed short of a trend to be correlated with dichotomized lesion size sepa-
rating the tumors at the cohort’s median of 20 mm (IQR, 15-35 mm; P=0.108; Figure 
34B). Cluster group 3 consisted of more than 80% of adenomas which exceeded the 
median adenoma size of 20 mm (Figure 34B). More striking, cluster groups correlated 
negatively with dichotomized patient age considering the cohort’s median of 67.3 years 
(IQR, 61.9-72.7 years; P=0.027; Figure 34C). Smaller lesions tended to have fewer 
CNAs than larger lesions. While Cluster 1 was dominated by samples above the me-
dian of 67.3 years, Cluster 3 was dominated by samples from younger patients, i.e., 
below the median. Apart from that none of the other tested clinicopathological features 
(adenoma histology, gender, grading, time of recurrence) demonstrated a correlation 
with the heat map cluster assignment. 
 
3.2.5 Comparison of CN profiles of match-paired colorectal adenomas 
Matched adenoma pairs, consisting of the primary tumor and the corresponding recur-
rent tumor from the same patient, were compared between both samples by arm-level 
copy number aberration profiles identified via aCGH (Figure 35A). Among analyzed 
adenoma pairs, 38.5% (5/13) showed an identical copy number profile in the primary 
tumor and the corresponding recurrent tumor (P=1.000; Figure 35A). 23.1% (3/13) of 
Figure 34. Heat map cluster group correlations. (A) Heat map cluster adenoma groups were most 
significantly associated with the number of CNAs per sample, with Cluster 1 exhibiting the largest numbers 
of CNAs (Kruskal-Wallis test). +, mean; whiskers, Tukey. (B) Heat map cluster groups failed short of a 
trend being correlated with the dichotomized size of the adenomatous lesions (Freeman-Halton test). (C) 
Distribution of samples across the cluster groups was associated with dichotomized patient age (Freeman-
Halton test). While cluster 1 was dominated by samples equaling or exceeding 67.3 years, vice versa, 
cluster group 3 was dominated by samples of patients below 67.3 years (y). 
A B C 
Results 
94 
adenoma pairs differed, yet not statistically significant, genome-wide in a single CNA 
in the primary and the recurrent tumor (Figure 35A). Interestingly, the different aberra-
tion patterns comprised an additional focal CNA in the recurrent adenoma of pair P1 
and P5, respectively. Pair P8 showed an arm-level CN loss of 80% compared to the 
corresponding lesion, whereas P10 exhibited more changes (Figure 35A). However, 
the number of arm-level CNAs per patient varied drastically across these paired sam-
ples (range, 0-14) implicating the presence of intertumor heterogeneity. Remarkably, 
46.2% (P1, P5, P6, P8, P12, P14) of the pairs harbored none or only a few focal CNAs, 
while 30.8% (P9, P10, P11, P13) of the pairs were affected by various focal and arm-
level CNAs. Based on the detected CN profiles, ten adenoma pairs suggested none to 
a shallow level of variance between the primary tumor and the corresponding recurrent 
tumor. CN profiles were classified as either “stable” CN patterns in 53.8% (7/13) of 
cases, or as “simplification/complexity” patterns (if the patterns were more divergent) 
(Figure 35B). The most recurrent alterations (n>2) were the CN gains of 7q22 (30%) 
and 13q (30%), respectively. 
Although most match-paired cases exhibited a substantial overlap of the aCGH CN 
profiles across the primary and the recurrent tumor, 46.2% (6/13) of adenoma pairs 
revealed an acquisition of CNAs in the recurrent lesion (apart from P6 and P10): the 
simplification/complexity pattern (Figure 35B). Even though no CNA was detected in 
the primary adenoma of pair P2, the recurrent lesion harbored three focal aberrations 
and a gain of chromosome 19. Statistically, the comparison of CNAs of both lesions 
showed a trend for an accumulation of CNAs in the recurrent tumor (P=0.078; Figure 
35A). An even more significant increase in the number of CNAs was observed in the 
recurrent adenomas of pair P3 (P=0.006) and P7 (P<0.001), respectively (Figure 35A). 
Herein, pair P3 exhibited a significant acquisition of additional focal CNAs which indi-
cate an increase of the genomic instability from the primary tumor to the recurrent ad-
enoma. More striking, adenoma pair P7 exposed a primary lesion with a single gain of 
chr7 while the recurrent tumor was dominated by ten chromosome arm-level losses 
and four arm-level gains (Figure 35A). 
An association of any pattern with a longer time interval of adenoma recurrence was 
not observed (P=0.231; Figure 35C).  
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Figure 35. Comparison of chromosomal aberrations in matched adenoma pairs. (A) Matched 
adenoma pairs (consisting of the primary adenoma and the corresponding recurrent adenoma) are 
plotted by the bp-length of CNAs detected by aCGH. CNAs are expressed as a percentage of the 
affected chromosome arm p and q, respectively. Neutral copy numbers were annotated as 0%. Focal 
alterations were expressed as ≤10%. More extensive alterations are plotted in accordance to the 
respective bp-length in steps of 20%, i.e., a whole-chromosome arm aberration equaled 100%. Ac-
rocentric chromosomes are represented by the q-arm only. P value, student’s paired t test. (B) Dis-
tribution of matched pair adenomas by CN profiles comparing primary adenomas to the correspond-
ing recurrent adenoma. (C) There was no correlation observed between the time to recur and the 
CNA profiles detected via aCGH in the matched pair adenoma samples (median with IQR; Mann-
Whitney U test). 
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3.3 Single-cell analyses of CNAs in colorectal (recurring) adenomas 
3.3.1 Distribution of clinicopathological features 
Clinicopathological parameters were collected for all colorectal adenoma samples (Ta-
ble 7). The two-different recurrence groups of primary adenomas were matched in 
terms of the histopathological and clinical features (Table 23).  
 
Table 23. Clinicopathological features of primary adenomas without and with recurrence. 
    
Primary adenomas 
w/o recurrence 
Primary adenomas 
w/ recurrence   
Variable (n=15) (n=29) P value 
Age at diagnosis (y)     
  Mean ± SD 65.0 ± 6.3 66.6 ± 11.7 0.633a 
  Median (IQR) 66.7 (63.9-68.5) 68.2 (57.4-72.9)  
Sex 
  
  
  Female 4 14 0.208b 
  Male 11 15   
Localization 
  
  
  Right hemicolon 9 14 0.774c 
  Left hemicolon 3 6   
  Rectum 3 9   
Histology 
  
  
  Tubular 5 3 0.099b 
  Tubulo-villous / Villous 10 26   
Size (mm) 
  
  
  Mean ± SD 22.8 ± 9.7 32.5 ± 20.2 0.086a 
  Median (IQR) 20.0 (15.0-30.0) 27.5 (20.0-40.0)  
Observation time/  
recurrence-free time (m) 
  
  
  Mean ± SD 25.4 ± 14.4 21.7 ± 19.5 0.528a 
  Median (IQR) 21.9 (12.5-38.0) 17.2 (8.2-25.7)  
a Student’s t test; b Fisher’s exact test; c Freeman-Halton test 
 
3.3.2 Chromosomal instability in colorectal adenomas 
Fifty-eight colorectal adenoma samples were sequentially hybridized with three 
miFISH probe panels which allowed the simultaneous enumeration of fifteen probes 
per individual nucleus of the same specimen (Figure 15; Figure 36). Signals were 
manually counted/enumerated for on average 523 nuclei per case (range, 326-1164 
nuclei) including nuclei with two signals for all probes. Ploidy estimation was inferred 
based on CEP10 and on the average signal number of all probes, which were balanced 
regarding tumor suppressor genes and oncogenes.  
The enumeration of clonal aberration patterns was performed on a cell-to-cell basis. 
Each cell fitting a respective pattern had the identical signal count for all fifteen probe 
markers. These signal pattern clones were visualized by depicting each cell of the 
adenoma according to its copy number status of gain, loss or neutrality, respectively. 
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The clonal fractions are compared within each adenoma and between the individual 
specimens. Calculating the frequency of gains and losses for each probe marker in 
percentages of the total cell population aided to investigate recurrent patterns of CNAs 
(Figure 37; Figure 38-44). 
 
  
Figure 36. Representative image of a colorectal adenoma nucleus hybridized by miFISH. 
The image shows a nucleus which was consecutively hybridized with panel 1 (top row), panel 2 
(middle row) and panel 3 (bottom row). The merged image in each row displays the overlay of 
all respective channels. Gene probe names are annotated to each box. The nucleus presented 
here reveals a copy number gain for CDX2 and ZNF217 (signal count: three) while the other 
markers remained neutral (signal count: two). 
Figure 37. CNAs in colorectal adenomas identified by miFISH. Clinicopathological features (upper 
columns) and CNA status (lower columns) are plotted per individual adenoma. Polyploid adenomas 
were excluded from analysis due to the increased degree of genomic instability. Age at diagnosis and 
lesion size were dichotomized by the median considering the sample cohort, respectively. ND, not 
determined. 
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Figure 27. (continued). 
Figure 38. Summary of color displays of signal pattern clones in primary colorectal adenomas 
without recurrence (n=15). Depicted are the adenoma cases without recurrence (A1-A15). Green, CN 
gain; red, CN loss; blue, CN neutral. Nuclei are sorted horizontally according to their signal pattern from 
left to right by frequency and with the gene probes assorted vertically by chromosomal location from top 
to bottom. Vertical lines separate the clonal fractions whose prevalence of the aberrant clone population 
are noted in percentages. CN gains and losses are calculated as percentages of the total population. 
When applicable the pattern of the most abundant clone is annotated in brackets. Aberrant nuclei and 
nuclei without detected CNAs are displayed as separated clonal fractions. Average signal numbers, the 
number of observed signal patterns and the average ploidy are shown in the respective columns. Note-
worthy, case A13 displayed near-tetraploid (4N) signal counts compared to the other cases (2N). 
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Figure 38. (continued). 
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Figure 39. Summary of color displays of signal pattern clones in primary colorectal adenomas 
with recurrence (n=15). Depicted are the adenoma cases without recurrence (A16-A30). Green, CN 
gain; red, CN loss; blue, CN neutral. Nuclei are sorted horizontally according to their signal pattern from 
left to right by frequency and with the gene probes assorted vertically by chromosomal location from top 
to bottom. Vertical lines separate the clonal fractions whose prevalence of the aberrant clone population 
are noted in percentages. CN gains and losses are calculated as percentages of the total population. 
When applicable the pattern of the most abundant clone is annotated in brackets. Aberrant nuclei and 
nuclei without detected CNAs are displayed as separated clonal fractions. Average signal numbers, the 
number of observed signal patterns and the average ploidy are shown in the respective columns. Note-
worthy, case A30 displayed near-tetraploid (4N) signal counts compared to the other cases (2N). 
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Figure 39. (continued). 
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Figure 40. Summary of color displays of signal pattern clones in match-paired colorectal adenomas 
(Part I). Depicted are the adenoma pairs P1 (A), P2 (B), and P3 (C) consisting of the primary tumor (a) 
and the corresponding recurrent (b) lesion. Green, CN gain; red, CN loss; blue, CN neutral. Nuclei are 
sorted horizontally according to their signal pattern from left to right by frequency and with the gene probes 
assorted vertically by chromosomal location from top to bottom. Vertical lines separate the clonal fractions 
whose prevalence of the aberrant clone population are noted in percentages. CN gains and losses are 
calculated as percentages of the total population. When applicable the pattern of the largest clone is an-
notated in brackets. Aberrant nuclei and nuclei without detected CNAs are displayed as separated clonal 
fractions. Average signal numbers, the number of observed signal patterns and the average ploidy are 
shown in the respective columns. The clonal distribution of the primary and the recurrent adenoma of pair 
1 and pair 2, respectively, were similar. Pair 3 showed an accumulation of clones in the recurrent lesion. 
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Figure 41. Summary of color displays of signal pattern clones in match-paired colorectal adenomas 
(Part II). Depicted are the adenoma pairs P4 (A), P5 (B), and P6 (C) consisting of the primary tumor (a) 
and the corresponding recurrent (b) lesion. Green, CN gain; red, CN loss; blue, CN neutral. Nuclei are 
sorted horizontally according to their signal pattern from left to right by frequency and with the gene probes 
assorted vertically by chromosomal location from top to bottom. Vertical lines separate the clonal fractions 
whose prevalence of the aberrant clone population are noted in percentages. CN gains and losses are 
calculated as percentages of the total population. If applicable the pattern of the most abundant clone is 
annotated in brackets. Aberrant nuclei and nuclei without detected CNAs are displayed as separated clonal 
fractions. Average signal numbers, the number of observed signal patterns and the average ploidy are 
shown in the respective columns. Pair 4 exhibited a decrease of clone fractions from the primary towards 
the recurrent adenoma. The clonal distribution of the primary and the recurrent adenoma of pair 5 and 
pair 6, respectively, were similar. 
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Figure 42. Summary of color displays of signal pattern clones in match-paired colorectal adenomas 
(Part III). Depicted are the adenoma pairs P7 (A), P8 (B), and P9 (C) consisting of the primary tumor (a) 
and the corresponding recurrent (b) lesion. Green, CN gain; red, CN loss; blue, CN neutral. Nuclei are 
sorted horizontally according to their signal pattern from left to right by frequency and with the gene probes 
assorted vertically by chromosomal location from top to bottom. Vertical lines separate the clonal fractions 
whose prevalence of the aberrant clone population are noted in percentages. CN gains and losses are 
calculated as percentages of the total population. When applicable the pattern of the most abundant clone 
is annotated in brackets. Aberrant nuclei and nuclei without detected CNAs are displayed as separated 
clonal fractions. Average signal numbers, the number of observed signal patterns and the average ploidy 
are shown in the respective columns. Pair 7 showed a dramatic increase in CNAs from the primary towards 
the recurrent adenoma. Pair 8 exhibited an additional clonal loss of CDH1 in the recurrent adenoma. Pair 
9 demonstrated a very similar pattern across primary and recurrent adenoma. 
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Figure 43. Summary of color displays of signal pattern clones in match-paired colorectal adenomas 
(Part IV). Depicted are the adenoma pairs P10 (A), P11 (B), and P12 (C) consisting of the primary tumor 
(a) and the corresponding recurrent (b) lesion. Green, CN gain; red, CN loss; blue, CN neutral. Nuclei are 
sorted horizontally according to their signal pattern from left to right by frequency and with the gene probes 
assorted vertically by chromosomal location from top to bottom. Vertical lines separate the clonal fractions 
whose prevalence of the aberrant clone population are noted in percentages. CN gains and losses are 
calculated as percentages of the total population. When applicable the pattern of the most abundant clone 
is annotated in brackets. Aberrant nuclei and nuclei without detected CNAs are displayed as separated 
clonal fractions. Average signal numbers, the number of observed signal patterns and the average ploidy 
are shown in the respective columns. Pair 10 showed stable clonal fractions across the primary and the 
recurrent adenoma, which slightly progressed with an additional CNA of APC. Pair 11 and pair 12 displayed 
similar patterns of clonal compositions across the primary towards the recurrent adenoma, respectively. 
A 
B 
C 
Results 
106 
 
 
 
 
 
 
 
 
 
 
3.3.3 Patterns of genomic imbalances in colorectal adenomas 
Non-diploid (here: tetraploid) adenomas were excluded from overall analysis (samples 
A13, A30, P7b). Fifty-five adenoma samples were analyzed to reveal patterns of chro-
mosomal gains and losses. In general, probes targeting the oncogenes COX2 (1q), 
PIK3CA (3q), CLIC1 (6p), EGFR (7p), MYC (8q), CDX2 (13q), HER2 (17q), and 
ZNF217 (20q) were found to be affected by copy number gains (Figure 45A; Figure 
46A). Vice versa, probes which targeted the tumor suppressor genes APC (5q), CDH1 
(16q), TP53 (17p), SMAD7 (18q), and SMAD4 (18q) were rather lost than gained 
Figure 44. Summary of color displays of signal pattern clones in match-paired colorectal adenomas 
(Part V). Depicted are the adenoma pairs P13 (A) and P14 (B) consisting of the primary tumor (a) and the 
corresponding recurrent (b) lesion. Green, CN gain; red, CN loss; blue, CN neutral. Nuclei are sorted 
horizontally according to their signal pattern from left to right by frequency and with the gene probes as-
sorted vertically by chromosomal location from top to bottom. Vertical lines separate the clonal fractions 
whose prevalence of the aberrant clone population are noted in percentages. CN gains and losses are 
calculated as percentages of the total population. When applicable the pattern of the most abundant clone 
is annotated in brackets. Aberrant nuclei and nuclei without detected CNAs are displayed as separated 
clonal fractions. Average signal numbers, the number of observed signal patterns and the average ploidy 
are shown in the respective columns. Pair 13 and pair 14 displayed similar patterns of clonal compositions 
across the primary towards the recurrent adenoma, respectively. 
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(Figure 45A). The frequencies of aberrant (i.e., abnormal signal count which combines 
both gain and loss) cells separated per miFISH markers displayed an unequal distri-
bution in primary colorectal adenomas (Figure 45A). While CNAs most often affected 
the probes targeting EGFR (13.0%), CDX2 (10.9%), and ZNF217 (10.9%), followed by 
APC (6.6%), CLIC1 (6.1%), and MYC (6.5%). The remaining probes were affected by 
CNA by less than 5% with CCND1 (0.5%) being the probe most rarely altered in pri-
mary colorectal adenomas (Figure 45A). The comparison of abnormal signal counts in 
primary adenomas without recurrence to primary adenomas with recurrence revealed 
no significant difference (P=0.735, Wilcoxon signed rank test; Figure 45B). 
  
Figure 45. Average gain and loss frequencies of all miFISH gene markers. (A) The graph depicts 
the mean percentage values of aberrant cells in primary adenomas (n=42). Aberrant counts are 
expressed as gain (green), loss (red) and the combined abnormal counts (blue) sorted by gene 
markers and chromosomal location. (B) Abnormal signal counts (combining gain and loss) in primary 
adenomas without recurrence (n=14) compared to primary adenomas with recurrence (n=28). None 
of the analyzed probes reached statistical significance. However, the difference of the mean in 
abnormal nuclei counts for CDX2 in adenomas without recurrence compared to adenomas with 
recurrence showed a trend (P=0.082, Student’s t test). 
B 
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Despite visible differences in the frequencies of abnormal miFISH markers when 
comparing primary adenomas without recurrence to primary adenomas with 
recurrence, none of the probes reached statistical significance (P>0.05, multiple t tests; 
Figure 45B). However, the frequencies of cells displaying an abnormal signal count of 
CDX2 showed a trend to discriminate primary adenomas with recurrence from primary 
adenomas without recurrence (means 15.5 ± 21.7 vs 1.6 ± 1.5, P=0.082; Figure 45B). 
Nevertheless, the percentage values of aberrant cells are an insufficient parameter 
biased by cases of adenomas formed of large dominant clone fractions. Thus, 
analyzing the colorectal adenoma cohort (n=55) regarding the average signal number 
(ASN) per miFISH gene marker provides a more robust, yet arguably biased by 
dominant clones, overview of the frequency of CNAs (Figure 46A). Here, CDX2 
revealed the highest ASN (mean 2.17 ± 0.36), followed by EGFR (mean 2.12 ± 0.25) 
and ZNF217 (mean 2.11 ± 0.24). These ASNs demonstrate that these loci were prone 
to be gained (diverging from 2.00, i.e., 2N). While the ASNs of CLIC1 (mean 2.06 ± 
0.13) and MYC (mean 2.06 ± 0.18) ranged as fourth and fifth highest, the remaining 
probes displayed ASNs which hardly deviated from 2.00 (Figure 46A). In general, 
ASNs below 2.00 were distributed in a narrow range not exceeding 1.96. The 
distribution barely changed when analyzing the ASNs of primary colorectal adenomas 
(n=42) only (Figure 46B). Interestingly, EGFR (mean 2.13 ± 0.25) and CDX2 (mean 
2.12 ± 0.28) had the highest ASNs. More important, frequencies of ASNs were plotted 
to separate the colorectal adenoma samples by primary adenomas without recurrence, 
primary adenomas with recurrence and recurrent adenomas, respectively, and 
statistical differences were evaluated (Figure 46C; Table 24). Obtained ASNs of CDX2 
tended to be capable of discriminating the groups from each other (P=0.102, one-way 
ANOVA; Figure 46C): primary adenomas without recurrence exposed a lower ASN 
(mean 2.02 ± 0.03) compared to primary adenomas with recurrence (mean 2.18 ± 0.33) 
and recurrent adenomas (mean 2.32 ± 0.54). On the contrary, the ASN of CDX2 was 
slightly higher in recurrent adenomas compared to primary adenomas with recurrence, 
though not reaching statistical significance (P=0.382, one-way ANOVA with multiple 
comparisons; Figure 46C). Based on ASN it was not possible to discern the adenoma 
groups with statistical significance although ASNs of CLIC1, EGFR, MYC, and ZNF217 
slightly differed between the adenoma subgroups (Figure 46C; Table 24).  
Results 
109 
Table 24. Statistical evaluation of ASNs of miFISH analysis on adenomas. Comparison of primary 
adenomas without recurrence (n=14), with recurrence (n=28) and recurrent adenomas (n=13). Adjust-
ment for multiple testing was performed by Tukey’s multiple comparison test.  
  
One-way ANOVA  
p-value 
Tukey Tukey Tukey 
  
Primary adenoma 
w/o recurrence vs 
Primary adenoma 
w/ recurrence 
Primary adenoma 
w/ recurrence vs 
Recurrent ade-
noma 
Primary adenoma 
w/o recurrence vs 
Recurrent ade-
noma 
Marker 
not ad-
justed for 
multiple 
testing 
adjusted 
for mul-
tiple tes-
ting 
not ad-
justed for 
multiple 
testing 
adjusted 
for mul-
tiple tes-
ting 
not ad-
justed 
for multi-
ple test-
ing 
adjusted 
for mul-
tiple tes-
ting 
not ad-
justed for 
multiple 
testing 
adjusted 
for mul-
tiple tes-
ting 
COX2 0.622 0.798 0.808 0.900 0.615 0.900 0.900 0.900 
PIK3CA 0.780 0.910 0.900 0.900 0.743 0.900 0.900 0.900 
APC 0.941 0.941 0.900 0.900 0.900 0.900 0.900 0.900 
CLIC1 0.365 0.798 0.628 0.900 0.714 0.900 0.334 0.900 
EGFR 0.534 0.798 0.638 0.900 0.900 0.900 0.533 0.900 
MYC 0.158 0.798 0.256 0.900 0.833 0.900 0.169 0.900 
CCND1 0.627 0.798 0.598 0.900 0.890 0.900 0.900 0.900 
CDX2 0.102 0.798 0.382 0.900 0.463 0.900 0.084 0.900 
CDH1 0.321 0.798 0.900 0.900 0.350 0.900 0.392 0.900 
TP53 0.454 0.798 0.471 0.900 0.900 0.900 0.551 0.900 
HER2 0.928 0.941 0.900 0.900 0.900 0.900 0.900 0.900 
SMAD7 0.508 0.798 0.493 0.900 0.900 0.900 0.659 0.900 
SMAD4 0.485 0.798 0.457 0.900 0.900 0.900 0.704 0.900 
ZNF217 0.569 0.798 0.547 0.900 0.842 0.900 0.899 0.900 
 
  
A B 
C 
Figure 46. Legend on next page. 
Complete set of colorectal 
adenomas (n=55) 
Primary colorectal adenomas (n=42) 
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To assess the number of CNAs per case, we applied a 10% threshold, i.e., signal 
patterns present in less than 10% of the counted nuclei were not considered (Table 
25; Figure 47A). In the entire sample set the amplitude displayed that EGFR CN gain 
(n=13) was most abundant followed by gains of copy numbers of CDX2 (n=12) and 
ZNF217 (n=10), respectively (Figure 47A). While alterations of CLIC1 (n=6), MYC 
(n=5), and TP53 (n=5) were less common in the adenoma cohort, other probes 
displayed an even rarer abundance of CNAs (Figure 47A). The performance of gene 
markers among colorectal adenomas grouped by the status of recurrence was not 
linked with differential patterns of CNAs (P=0.372; Figure 47B). Differences in the 
percentages of CNAs in primary adenomas without and with recurrence were detected 
for CLIC1 (7.1% vs 14.3%), EGFR (42.9% vs 17.9%), MYC (21.4% vs 7.1%), and 
ZNF217 (7.1% vs 21.4%). Remarkably, CNAs of six of the gene markers (COX2, 
PIK3CA, CDX2, TP53, SMAD7, SMAD4) were exclusively reported in primary 
adenomas with recurrence (Figure 47B). Thus, primary adenomas without recurrence 
(n=14) reported a less broad distribution of different alterations across the miFISH 
markers than primary adenomas with recurrence (n=28). 6 of 14 miFISH-markers were 
affected in primary adenomas without recurrence versus 12 of 14 in primary adenomas 
with recurrence (P=0.046, Fisher’s exact test). Despite that, comparing the average 
number of CNAs per sample failed to discern primary adenomas without recurrence 
from primary adenomas with recurrence (means 1.0 ± 1.1 vs 1.39 ± 2.1, P=0.917; Fig-
ure 47C). CN status of CDX2 on 13q12.2, in contrast, evolved potential to discriminate 
25% (sensitivity) of the primary adenomas with recurrence from the non-recurring 
adenomas (100% specificity) (P=0.040; Figure 47D). Although the sensitivity seemed 
arguably low, the gain of this marker concurrently provided a specificity of 100% due 
to the absence of this CNA in primary adenomas without recurrence (n=14). 
Additionally, a probe set comprising CLIC1, CDX2, and ZNF217 would have detected 
39% (sensitivity) of the primary adenomas with recurrence via CN gain of at least one 
of the markers (P=0.036; Figure 47E). A decrease of test specificity to 93%, due to an 
adenoma without recurrence showing positivity for both CLIC1 and ZNF217 (case A10; 
Figure 38), would have admittedly altered the clinical value of this panel.  
Figure 46. Average signal numbers of miFISH markers in colorectal adenomas. (A) ASNs (mean) 
per miFISH marker (sorted by chromosome location) in the cohort of colorectal adenomas (n=55). Signal 
numbers above the baseline of 2.00 represent an average copy number gain (green) while signal num-
bers below resemble an average copy number loss (red). As expected, probes targeting oncogenes 
were, on average, gained whereas TSG probes were lost. (B) ASNs of primary colorectal adenomas 
(n=42) revealed a similar distribution. However, observed signal numbers of EGFR were, on average, 
higher than for CDX2. (C) Distribution of ASNs (mean) per miFISH marker in colorectal adenomas without 
recurrence, primary adenomas with recurrence and recurrent adenomas, respectively.  
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Table 25. Aberration frequencies detected by miFISH. 
Marker 
Gene 
location 
Primary adeno-
mas and  
recurrent lesions 
Primary  
adenomas 
Primary adenomas 
w/o recurrence 
Primary adenomas 
w/ recurrence 
Recurrent 
adenomas 
COX2 1q31 1/55 (1.8%) 1/42 (2.4%) 0/14 (0%) 1/28 (3.6%) 0/13 (0%) 
PIK3CA 3q26 1/55 (1.8%) 1/42 (2.4%) 0/14 (0%) 1/28 (3.6%) 0/13 (0%) 
APC 5q22 5/55 (9.1%) 4/42 (9.5%) 2/14 (14.3%) 2/28 (7.1%) 1/13 (7.7%) 
CLIC1 6p21 6/55 (10.9%) 5/42 (11.9%) 1/14 (7.1%) 4/28 (14.3%) 1/13 (7.7%) 
EGFR 7p11 13/55 (23.6%) 11/42 (26.2%) 6/14 (42.8%) 5/28 (17.8%) 2/13 (15.4%) 
MYC 8q24 5/55 (9.1%) 5/42 (11.9%) 3/14 (21.4%) 2/28 (7.1%) 0/13 (0%) 
CCND1 11q13 0/55 (0%) 0/42 (0%) 0/14 (0%) 0/28 (0%) 0/13 (0%) 
CDX2 13q12 12/55 (21,8%) 7/42 (16.6%) 0/14 (0%) 7/28 (25.0%) 5/13 (38.5%) 
CDH1 16q22 2/55 (3.6%) 0/42 (0%) 0/14 (0%) 0/28 (0%) 2/13 (15.4%) 
TP53 17p13 5/55 (9.1%) 3/42 (7.1%) 0/14 (0%) 3/28 (10.7%) 2/13 (15.4%) 
HER2 17q12 3/55 (5.4%) 3/42 (7.1%) 1/14 (7.1%) 2/28 (7.1%) 0/13 (0%) 
SMAD7 18q21 4/55 (7.3%) 3/42 (7.1%) 0/14 (0%) 3/28 (10.7%) 1/13 (7.7%) 
SMAD4 18q21 4/55 (7.3%) 3/42 (7.1%) 0/14 (0%) 3/28 (10.7%) 1/13 (7.7%) 
ZNF217 20q13 10/55 (18.2%) 7/42 (16.6%) 1/14 (7.1%) 6/28 (21.4%) 3/13 (23.1%) 
Ratio of CNAs 
per lesion 
1.29 1.21 1.00 1.39 1.57 
  
Figure 47. CNAs in primary adenomas without and with recurrence. (A) Distribution of CNAs across 
the miFISH gene markers in colorectal primary and recurrent adenomas (n=55). (B) Percentage of gains 
and losses for all miFISH gene markers observed in primary adenomas without recurrence and primary 
adenomas with recurrence (Wilcoxon signed-rank test). Percentages of gains are shown above the 0% 
line, and losses are shown below the 0% line. (C) Comparing primary adenomas without recurrence to 
primary adenomas with recurrence did not show a difference in the number of detected CNAs (Mann-
Whitney U test). +, mean; whiskers, Tukey. (D) Copy numbers of CDX2 were exclusively gained in 
primary adenomas with recurrence compared to primary adenomas without recurrence (Chi-square 
test), providing a 25% sensitivity and 100% specificity. (E) A probe panel consisting of CLIC1, CDX2, 
and ZNF217 detected primary adenomas with recurrence from primary adenomas without recurrence 
with 39% sensitivity while providing 93% specificity (Fisher’s exact test). 
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3.3.4 Hierarchical clustering of CNAs in colorectal adenomas 
Performing unsupervised clustering based on the fourteen miFISH gene identifier 
probes generated a heatmap of 55 colorectal adenoma samples which separated into 
four clustering groups (Figure 48A). Further examination of the assignment of clusters 
exhibited a strong relationship with the occurrence of CNAs (P<0.001; Figure 48B). 
Cluster 1 predominately combined adenomas with a gain of EGFR (r=-0.328, P=0.015, 
Spearman correlation) whereas Cluster 2 was mainly composed of adenomas without 
any detected CNAs (Figure 48A). Cluster 3 included adenomas with multiple different 
CNAs and Cluster 4 was strongly associated with the CN gain of CDX2 (r=0.497, 
P<0.001, Spearman correlation). Although the losses of SMAD7/SMAD4 were present 
only in a subset of samples of Cluster 4, there was no significant correlation (r=-0.101, 
P=0.463, Spearman correlation). Noteworthy, the CNA of ZNF217 correlated positively 
with the cluster assignment (r=-0.377, P=0.005, Spearman correlation), although both 
Cluster 3 and 4 contained samples affected by this alteration. Moreover, heatmap clus-
ter groups correlated positively with genetic heterogeneity expressed by the following 
measures of diversity (see 2.6.4 Data Assessment): instability index (r=0.360, 
P=0.021, Spearman correlation), Shannon entropy (r=0.390, P=0.011, Spearman cor-
relation) and Simpson diversity index (r=0.359, P=0.019, Spearman correlation). Clus-
ter 3 exhibited the highest diversity indices due to the increased number of CNAs (see 
3.3.5 Clonal composition). 
The distribution of primary adenomas without recurrence and with recurrence across 
the heatmap exhibited a very weak trend to separate both groups (P=0.193; Figure 
48C). Remarkably, cluster 4 was exclusively composed of primary adenomas with re-
currence. Further evaluation of the histopathological features and the cluster assign-
ment unveiled a relationship between the dichotomized localization, i.e., either colon 
or rectum, of the primary adenoma specimens (P=0.021; Figure 48D). Rectal samples 
were stronger associated with Cluster 3 and 4 compared to colonic adenomas domi-
nating Cluster 1 and 2. This observation is in line with the higher average number of 
CNAs in rectal compared to colonic adenomas detected by aCGH (see 3.2.1 Overall 
aCGH analysis). Nevertheless, consideration of additional clinicopathologic parame-
ters such as patient age at diagnosis, adenoma size, histology or grading did not un-
cover a statistically significant correlation with the heatmap cluster assignment based 
on the ASN of miFISH probe markers.   
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3.3.5 Clonal composition of primary (recurring) adenomas 
Tumor heterogeneity assessed by signal patterns and instability index 
Comparing the clonal composition within primary colorectal adenomas without recur-
rence and with recurrence, color displays of signal pattern clones were assessed. 
These visualized the clonal frequencies and appearances of CNAs (see Figure 38-44 
of chapter 3.3.2). The population size of the major clone fraction comprised on average 
62.8% (IQR, 39-88%) of the aberrant cell population within all analyzed adenoma 
(n=55) samples (Table 26). The median size of the major clone population did not differ 
when comparing primary adenomas without recurrence to primary adenomas with re-
currence (median 69.0% vs 68.0%; P=0.795; Figure 49A). Interestingly, recurrent 
Figure 48. Heat map clustering of 55 colorectal adenomas by CNAs of miFISH. (A) The heat map 
was generated by calculating the average signal number (ASN) per marker in each sample. Dendrogram 
correlation sorted genes and specimens. ASNs were assigned a green color representing CN losses, 
while black indicated CN neutrality and a red color depicted CN gains, respectively. The heat map sep-
arated the adenomas in four clustering groups (Cluster 1-4). (B) The heat map cluster assignment was 
apparently based on the occurrence of copy number changes within the colorectal adenoma specimens 
(Freeman-Halton test). (C) Cluster assignment tended to separate primary adenomas without recurrence 
from primary adenomas with recurrence (Freeman-Halton test). (D) Primary colorectal adenomas local-
ized in the rectum or colon revealed a relationship with the cluster assignment (Freeman-Halton test). 
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adenomas seemed to exhibit a slightly larger size of the major clone population (me-
dian 85.0%) than the primary adenomas. It might indicate a higher level of clonal se-
lection: however, the difference was statistically not significant (P=0.696; Figure 49A). 
 The analysis of CNAs (only considering clones >10%) within the group of primary 
adenomas without recurrence unveiled that 35.7% (5/14) of cases were not affected 
by a CNA of any of the gene markers. 42.8% (6/14) of cases showed a single alteration 
and 21.4% (3/14) of adenomas were detected with multiple CNAs (Figure 49B). Nev-
ertheless, within the primary adenomas without recurrence a major clone with four 
CNAs, i.e., APC, CLIC1, EGFR, and ZNF217) was present in adenoma case A10 only 
(Figure 38). In contrast, primary adenomas with recurrence were not affected by any 
CNA in 50.0% (14/28) of cases. However, 17.9% (5/28) of adenomas revealed a single 
CNA and 32.1% (9/28) of cases demonstrated multiple alterations (Figure 49B). The 
comparison of CNA frequencies across primary adenomas with and without recurrence 
showed merely a weak trend to separate the groups (P=0.263; Figure 49B). Yet, pri-
mary adenomas with recurrence harbored a substantially higher average number of 
CNAs per clone than primary adenomas without recurrence when only cases with 
clonal aberrations were considered (Figure 49C). Three and four CNAs were accumu-
lated in clones of primary adenomas with recurrence. Clone populations displaying 
more than four CNAs were exclusively observed in primary adenomas with recurrence. 
With the objective to quantitate the degree of genomic instability, an instability index 
was calculated by the number of aberrant FISH signals per 100 cells divided by the 
total number of nuclei (Table 26). Within the analyzed primary and recurrent adenomas 
(n=55) the average chromosomal instability index equaled 4.9 ± 5.1 patterns, suggest-
ing a low-level intratumor heterogeneity (ITH) across the adenoma samples. The in-
stability index as a measure of ITH could not discern primary adenomas without recur-
rence from primary adenomas with recurrence (means 4.8 ± 5.6 vs 4.8 ± 3.2; P=0.603; 
Figure 49D). Among the cohort of primary and recurrent adenomas, a fraction of 29.1% 
(16/55) samples did not harbor any aberrant clonal population exceeding 5% of the 
aberrant cells. However, in 23.6% (13/55) of samples, only a single clonal population 
was present while 47.3% (26/55) of adenomas were composed of multiple clonal pop-
ulations (Figure 49E). The number of clone populations was not a measure to discern 
primary adenomas without and with recurrence (P=0.675; Figure 49F). Noteworthy, 
more than half of the adenomas harbored multiple clonal populations indicating the 
presence of intratumor heterogeneity.  
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Table 26. Signal patterns of the largest aberrant clone populations and instability indices. 
 Sample 
ID 
Recurrence Largest clone populations with signal pattern° 
Instability 
index§ 
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A 1 no 99% 22223222222222 1.2 
A 2 no No 2.5 
A 3 no 30% 22222322222222; 20% 22223222222222; 6% 23222222222222 10.7 
A 4 no No 1.4 
A 5 no No 2.3 
A 6 no 41% 22222222223222; 6% 22232222222222 9.6 
A 7 no 35% 22222223222222; 8% 12222222222222 5.3 
A 8 no 69% 22222322222222; 6% 22233322222222 9.1 
A 9 no 82% 22222322222222; 8% 22232322222222 5.0 
A 10 no 66% 22333222222223; 25% 22333222222222 6.0 
A 11 no 71% 22223222222222; 11% 22233222222222 5.8 
A 12 no 27% 23222222222222; 22% 22232222222222 2.7 
A 13 † no 40% 34444444333224; 13% 34434444333224 22.6 
A 14 no 89% 22223222222222 1.5 
A 15 no 89% 21222222222222 4.3 
P
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A 16 Primary 68% 32222322222223; 13% 32222222222223 7.4 
A 17 Primary 24% 22232222222222; 15% 22222222223222; 11% 22222222122222 6.6 
A 18 Primary 65% 22223223222222; 17% 22223222222222 4.2 
A 19 Primary 71% 22233223222223; 11% 22233222222223 7.4 
A 20 Primary No 2.1 
A 21 Primary No 1.6 
A 22 Primary 45% 22122222222113; 34% 22122222222112 6.9 
A 23 Primary 44% 23222222222222; 38% 23222222213222 7.7 
A 24 Primary No 3.0 
A 25 Primary No 1.4 
A 26 Primary 34% 22232222222222; 17% 22222223322113 7.3 
A 27 Primary 31% 22232222222222; 21% 22222222222223; 8% 22223223222223 6.3 
A 28 Primary 85% 22232222222222; 6% 22222232222222 1.5 
A 29 Primary No 1.4 
A 30 † Primary 53% 34344334444334; 5% 34344334344334 21.7 
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P 1a Primary 76% 22222224222222; 16% 22232224222222 5.2 
P 1b Recurrent 94% 22222224222222 3.8 
P 2a Primary No 2.7 
P 2b Recurrent No 2.2 
P 3a Primary 48% 22222222122222 1.6 
P 3b Recurrent 5% 22122222222222 24.0 
P 4a Primary 12% 22222222212222; 8% 22222222213222; 7% 22222222222333;  
6% 22223222222333 
30.6 
P 4b Recurrent 50% 22222222212222; 25% 22222222213222 5.2 
P 5a Primary No 2.4 
P 5b Recurrent No 2.1 
P 6a Primary 69% 22232222222222 1.4 
P 6b Recurrent 15% 22222223222222; 12% 22232222222222; 10% 22222222212222;  
9% 22122222222222 
3.9 
P 7a Primary 85% 22223222222222 7.8 
P 7b † Recurrent 34% 33444434344334; 14% 34444434344334; 8% 22223222222222;  
5% 33443434344334 
24.9 
P 8a Primary 39% 22232222222222; 21% 22222222122222; 18% 22222223222222 2.3 
P 8b Recurrent 96% 22222222122222 2.7 
P 9a Primary 97% 22222223222222 2.9 
P 9b Recurrent 85% 22222223222222 6.4 
P 10a Primary 86% 22222223212113; 9% 22222223222113 1.7 
P 10b Recurrent 63% 22322223212113; 23% 22222223212113 4.2 
P 11a Primary 88% 22223222222222; 7% 22223222222223 3.8 
P 11b Recurrent 96% 22223222222222 2.5 
P 12a Primary No 0.8 
P 12b Recurrent No 1.8 
P 13a Primary 89% 22222223222223; 5% 22222223222222 4.2 
P 13b Recurrent 92% 22222223222223 4.7 
P 14a Primary No 2.6 
P 14b Recurrent No 2.0 
° Signal patterns are displayed in the following gene order: COX2, PIK3CA, APC, CLIC1, EGFR, MYC, CCND1, CDX2, CDH1, 
TP53, HER2, SMAD7, SMAD4, ZNF217. Clone populations (shown are clones exceeding 5%) are depicted as percentage of 
aberrant cells. Identical clone patterns in primary and recurrent adenomas are shown in bold. 
§ The instability index is calculated as described in Materials and Methods. † excluded from analysis due to DNA ploidy status 
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Figure 49. Clonal populations and instability indices of colorectal adenomas. (A) Major clone pop-
ulations are on average (median with IQR) of comparable size in primary adenomas without and with 
recurrence (Mann-Whitney U test). Recurrent adenomas displayed a larger major clone size, however 
statistically not relevant (Kruskal-Wallis test). Adenoma samples without identifiable clone population 
(≤35 nuclei) were not considered. (B) Distribution of the number of CNAs across primary adenomas 
without recurrence and with recurrence (Freeman-Halton test). (C) Shown is the distribution of CNAs 
per clone across primary colorectal adenomas without and with recurrence, respectively (Wilcoxon 
signed-rank test). Considered were cases with at least a single CNA. (D) Instability indices (median with 
IQR) of primary adenomas with and without recurrence were similar (Mann-Whitney U test). Recurrent 
adenomas did not show a different average instability index (Kruskal-Wallis test). (E) Fractions of clonal 
populations within primary and recurrent adenomas (n=55) uncovered that approximately half of the 
samples comprised of two or more clone populations. (F) Clonal populations in primary adenomas with-
out and with recurrence exposed similar fractions (Freeman-Halton test). 
A B 
C D 
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Tumor heterogeneity assessed by measures of diversity 
Seeking to quantitatively characterize and compare the colorectal adenomas regarding 
genetic intra- and intertumor heterogeneity, ecological diversity measures were applied 
(see 2.6.4 Data Assessment: Tumor heterogeneity). All analyzed adenomas (n=55) 
revealed genetically different clones, i.e., signal patterns (Figure 38-44) whose median 
number equaled 17 patterns (IQR, 10-25 patterns) in the cohort (n=55). A median of 
17 patterns (IQR, 11-33 patterns) was noted in primary adenomas (n=42), while recur-
rent adenomas (n=13) showed a median of 12 patterns (IQR, 9-23 patterns). 
Genetic diversity expressed by Shannon entropy (SE) considers the signal pattern 
quantity and their abundance. The values exhibited a heterogeneous distribution 
among primary adenomas with and without recurrence, respectively, and recurrent ad-
enomas (P=0.648; Figure 50A). Average SE of primary adenomas equaled a median 
of 1.1 (IQR, 0.4-1.9). SE was not capable of distinguishing primary adenomas without 
recurrence from primary adenomas with recurrence (P=0.516, Figure 50A; P=0.219, 
Figure 50B). Primary adenomas with recurrence tended to be associated with SE ex-
ceeding 2.0 (above 75% quartile) compared to primary adenomas without recurrence 
when only cases were considered which revealed CNAs (P=0.086; Figure 50C). 
Next, the Simpson diversity index (SI; range 0-1) was calculated which benefits 
abundant clones by more weight within the formula. Comparing the sample subgroups 
did not expose differential median SI (P=0.766; Figure 50D). The median SI of primary 
adenomas equaled 0.31 (IQR, 0.09-0.55). Median indices of primary adenomas with 
and without recurrence failed to distinguish the subgroups (P=0.531; Figure 50D). De-
spite that, the sample distribution range varied stronger in primary adenomas with re-
currence compared to primary adenomas without recurrence (grouped SI in intervals 
of 0.1, P=0.086; Figure 50E). Adenoma cases ranging in the top third range (0.66-1.00) 
of the index were exclusively associated with recurrence (P=0.052; Figure 50F). 
Additional to the diversity measures developed by Shannon and Simpson, the ge-
netic distance was assessed by calculating the accumulated pairwise genetic diversity 
for the adenoma subsets (P=0.648; Figure 51A). The utilized distance metric equaled 
a median of 2.65 (IQR, 2.17-4.36) in primary adenomas. However, comparing primary 
adenomas by recurrence status did not reveal statistical differences (P=0.516; Figure 
51A). Grouping primary adenomas with and without recurrence by the accumulated 
pairwise genetic diversity in intervals of 1.0 did not show a relevant difference 
(P=0.156; Figure 51B). Of note, the occurrence of tetraploid cells within diploid (2N) 
adenomas was identified to be very strongly correlated with the accumulated pairwise 
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genetic diversity, i.e., genetic distance (P<0.001; Figure 51C). Noteworthy, average 
numbers of signal patterns differed across primary adenomas without tetraploid cells 
(n=31; median 16, IQR 9-23) compared to primary adenomas with one or more tetra-
ploid cells (n=9; median 37, IQR 14-47) (P=0.016, Mann-Whitney U test). 
Ploidy was identified to be a fundamental cause for differential genetic diversity 
measures: adenomas with a tetraploid (4N) average ploidy showed higher values of 
instability index, SI and SE, respectively (P<0.001; Figure 51D-F), compared to ade-
nomas of diploid character (2N). This justified the exclusion of the polyploid adenoma 
samples (i.e., A13, A30 and P7b) regarding the advanced degree of genomic changes. 
Figure 50. Legend on next page. 
A B 
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Figure 51. Tumor heterogeneity assessed by genetic distance. (A) Accumulated pairwise genetic 
diversity values (median with IQR) of primary adenomas with and without recurrence were similar (Mann-
Whitney U test). Recurrent adenomas did not show a different average genetic distance index (Kruskal-
Wallis test). (B) Distribution of accumulated pairwise genetic diversity (grouped by intervals of 1.0, range 
0-7.0) across primary adenomas without and with recurrence, respectively (Wilcoxon signed-rank test). 
(C) Accumulated pairwise genetic diversity correlated strongly with the abundance of tetraploidized cells 
within the amassment of nuclei across primary adenomas with an average ploidy of diploid (2N) character 
(Mann-Whitney U test). (D) Adenomas with a near-tetraploid average ploidy (4N) exposed higher insta-
bility indices compared to diploid adenomas (2N; Mann-Whitney U test). (E) Near-tetraploid adenomas 
(4N) showed higher Shannon entropies compared to diploid adenomas (2N; Mann-Whitney U test). (F) 
Near-tetraploid adenomas (4N) exhibited higher Simpson diversity indices compared to diploid adenomas 
(2N; Mann-Whitney U test). Box plots in (C-F): +, mean; whiskers, Tukey. 
Figure 50. Tumor heterogeneity assessed by Shannon and Simpson diversity indices. (A) Shan-
non entropies (median with IQR) of primary adenomas with and without recurrence were similar (Mann-
Whitney U test). Recurrent adenomas did not show a different average Shannon index (Kruskal-Wallis 
test). (B) Distribution of Shannon indices (grouped by intervals of 0.5) across primary adenomas without 
and with recurrence, respectively (Wilcoxon signed-rank test). (C) Primary adenomas with recurrence 
tended to be associated with higher Shannon indices (dichotomized) compared to primary adenomas 
without recurrence (Freeman-Halton test). Considered were cases with at least a single CNA. (D) Simp-
son diversity indices (median with IQR) of primary adenomas with and without recurrence were similar 
(Mann-Whitney U test). Recurrent adenomas did not show a different average Simpson index (Kruskal-
Wallis test). (E) Distribution of Simpson indices (grouped by intervals of 0.1) across primary adenomas 
without and with recurrence, respectively (Wilcoxon signed-rank test). (F) Simpson indices in the upper 
third (trichotomized) of the range were exclusively associated with primary adenomas with recurrence 
(Freeman-Halton test). 
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3.3.6 Clonal evolution of paired primary and recurrent adenomas 
Subanalysis of miFISH ASNs of matched pair adenomas did not show a significant 
difference comparing primary to recurrent lesions (P=0.383; Figure 52). Nevertheless, 
43% (6/14) of pairs differed in CNAs across both lesions (Supplemental Table 5). 
Shedding light on the clonal evolution within the primary colorectal adenoma and the 
corresponding recurrent adenoma was a key feature of the presented study: CNAs 
observed in matched adenoma pairs were visualized by constructing consensus phy-
logenetic trees per matched pair utilizing the FISHtree software (Figure 53-56). The 
algorithm created FISH tress by applying a heuristic approach to minimize the number 
of CNAs across the tree. Emanating from the diploid root cell observed CNA-signal 
patterns were incorporated to form the tree nodes which are connected by edges re-
sembling the underlying genomic events. The primary adenoma-recurrence consen-
sus trees suggested four distinct clonal evolution patterns (Figure 53-56): first, a sim-
plification pattern was observed which is characterized by a primary tumor with a broad 
level of ITH expressed by the presence of multiple different signal pattern clone popu-
lations (Figure 53A). On the contrary, the recurrent tumor depicted a clonal composition 
which is dominated by a previously rare minor clone of the primary adenoma while 
other clones vanished and became extinct. Thus, there was a shift in ITH (here repre-
sented by different clone populations) decreasing from the primary adenoma towards 
the recurrent adenoma (Figure 53B). For instance, the primary adenoma of pair P4 
showed multiple clones, whereas only two fractions larger 5% dominated the recurrent 
lesion. Interestingly, a complexity pattern was observed which, vice versa to the sim-
plification pattern, was distinguished by a major clone in the primary tumor (Figure 54A, 
55A). However, the clone shrank to a minor clone in the recurrent adenoma which was 
instead dominated by several newly emerged clone populations (Figure 54B, 55B). 
Accordingly, the intratumor heterogeneity within the recurrent lesions increased dras-
tically. While the primary adenoma of pair P7 showed a very clonal pattern with a major 
clone affected by EGFR CN gain, the recurrent tumor was dominated by vast numbers 
of clones being targets of a whole genome duplication (WGD) event (Figure 54A, B). 
Clonal aberrations exhibited complex patterns of CN counts, i.e., trees developed mul-
tiple branches which increase the node depth. 
In opposition to these two clonal evolution patterns which show a shift in clone num-
bers and intratumor heterogeneity, adenoma pairs were observed which were extraor-
dinarily stable for measures mentioned above. Consequently, adenomas of the 
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stabilization pattern showed (relatively well) superimposing aberrant clone populations 
across the primary and the recurrent tumor considering both quantities of differential 
clones and population frequencies (Figure 56, 57A). Stabilization patterns were char-
acterized by trees with low node depths indicating less complex patterns of CNAs with 
the identical major clone present in the primary and recurrent adenoma, respectively 
(Figure 57A). Despite that, pair P10 resembled a modification of this pattern type: the 
major clone of the primary lesion is recognizable in the recurrent tumor (stabilization); 
however, a clone evolved with an additional CNA (progression) (Figure 56, 57A). 
Lastly, adenoma pairs which failed to expose copy number changes in more than 
10% of the counted total cell population were categorized into “zero” pattern (Figure 
57B). The lack of clonality and presence of few aberrant cells are emphasized by the 
failure to model phylogenetic trees for these cases. Since CNAs do not play a pivotal 
role in adenoma pairs of the “zero” clonal evolution pattern putatively other (epi)genetic 
mechanisms are drivers in these lesions (see 3.5.1 Immunohistochemical detection). 
Addressing the question whether primary adenomas are, in general, differential 
compared to the recurrent counterpart, non-consensus phylogenetic trees were ana-
lyzed considering the number of tree levels, i.e., the node depth (Figure 58A). As ex-
pected, a general trend of differential numbers of tree levels in primary lesions com-
pared to recurrent lesions was not confirmed (P=0.336). This fact was underpinned by 
the distribution of clonal evolution patterns across the fourteen adenoma matched pairs 
(Figure 58B), which showed an imbalance towards adenoma cases of “stability” (64%; 
stabilization and “zero” patterns) versus “shift” (36%; simplification and complexity pat-
terns). Interestingly, shifting patterns seemed to be associated with shorter adenoma-
recurrence free time than stable patterns (P=0.166; Figure 58C). In-depth analysis of 
CNAs in match-paired adenomas unveiled that copy number gains of CDX2 were ex-
clusively associated with the stabilization pattern (P=0.005; Figure 58D). 
Figure 52. ASNs in match-paired adenomas. Although ASNs varied across the probes, primary 
adenomas did not show alternating ASNs compared to recurrent lesions (Wilcoxon signed-rank test). 
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Figure 53. Phylogenetic trees of simplification pattern-adenomas. (A) Consensus phylogenetic 
trees depict the clonal distribution across the primary adenoma and the corresponding recurrent ade-
noma. Shown are pairs P4 and P8, respectively. Nodes (circle, square, rhomb) reflect the copy number 
profile of the fourteen gene identifier probes along CEP10. Genomic events which led to the formation 
of the major clone population (highlighted) are remarked to the edges. Adenoma pairs exhibiting the 
simplification pattern were characterized by vast numbers of diverging clone populations in the primary 
tumor compared to the recurrent adenoma (B) Schematic presentation of the simplification evolution 
pattern. The decline from multiple populations in the primary adenoma towards fewer numbers in the 
recurrent adenoma are visible in both cases (pairs P4 and P8, respectively). Graphs show populations 
only which exceeded 5% of the aberrant cells in the primary adenoma.  
A 
B 
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Figure 54. Phylogenetic tree of complexity pattern-adenoma P3. (A) Consensus phylogenetic tree 
depicts the clonal distribution across the primary adenoma and the corresponding recurrent adenoma 
of pair P3. Nodes (circle, square, rhomb) reflect the copy number profile of the fourteen gene identifier 
probes and CEP10. Genomic events which led to the formation of the major clone population (high-
lighted) are remarked to the edges. Although the primary adenoma was composed of a small number 
of clone populations the recurrent adenoma revealed an evident increase of clonal populations. (B) 
Schematic presentation of the complexity evolution pattern. Several newly emerged populations were 
present in the recurrent adenoma.  
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Figure 55. Phylogenetic trees of complexity pattern-adenomas. (A) Consensus phylogenetic trees 
display the clonal distribution across the primary adenoma and the corresponding recurrent adenomas 
of the pairs P6 and P7, respectively. Nodes (circle, square, rhomb) reflect the copy number profile of 
the fourteen gene identifier probes and CEP10. Genomic events which led to the formation of the major 
clone population (highlighted) are remarked to the edges. Pairs of the complexity pattern show an (dras-
tically) increasing number of clone populations from the primary to the recurrent adenoma. Notably, pair 
P7 was affected by a whole genome duplication in the recurrent adenoma. (B) Schematic presentation 
of the complexity clonal evolution pattern. The shift from large major clone populations in the primary 
tumor towards multiple emerging clone populations in the recurrent adenoma were visible in both cases.  
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Figure 56. Phylogenetic trees of stabilization pattern-adenomas. Consensus phylogenetic trees 
depict the clonal distribution along the primary adenoma and the corresponding recurrent adenoma of 
the pairs P1, P9, P10, P11 and P13, respectively. Nodes (circle, square, rhomb) reflect the copy number 
profile of the fourteen gene identifier probes and CEP10. Genomic events which led to the formation of 
the major clone population (highlighted) are remarked to the edges. Stabilization pattern-adenomas 
revealed similar clonal populations within the primary and the recurrent tumor underpinned by shared 
major clones in both lesions. However, pair P10 was a slight exception due to a clone population which 
accumulated an additional CNA. Therefore, this matched pair could be more precisely termed stabiliza-
tion(-progression) pattern. 
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Figure 57. Schematic presentations of the stabilization and “zero” clonal evolution patterns. 
(A) Adenoma pairs whose primary tumor clone populations persist in the recurrent tumor were 
classified as stabilization patterns. Graphs depict populations only which exceeded 5% of the ab-
errant cells in the primary adenoma. Although pair P10 showed characteristics of the stabilization 
evolution-type, the recurrent adenoma accumulated an additional CNA of the previous major clone 
population in the primary tumor suggesting a stabilization(-progression) pattern. (B) Matched pairs 
of colorectal adenomas which did not reveal any CNA across the miFISH panels were, therefore, 
allocated into the “zero” pattern group. 
A 
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Figure 58. Tree-levels and clonal evolution patterns in matched pairs. (A) Phylogenetic non-con-
sensus trees of primary adenomas and recurrent adenomas were compared by the depth of the trees 
(i.e., tree levels). Recurrent adenomas showed on average (mean ± SD) a statistically not significant 
higher number of tree levels (Student’s t test). (B) Distribution of adenoma clonal evolution patterns in 
matched pair adenomas (n=14) (C) Comparison of adenoma-recurrence time in adenoma cases of 
clonal evolution patterns which are differential across primary and recurrent adenoma (complexity and 
simplification patterns) and patterns of “stable” adenoma cases (stabilization and “zero” pattern). Re-
markably, non-shifted patterns, i.e., stabilization and zero patterns, weakly tended to be associated with 
a longer adenoma-recurrence time (Mann-Whitney U test). +, mean; whiskers, Tukey. (D) Copy number 
gains of CDX2 were exclusively observed in adenomas presenting the stabilization pattern (Fisher’s 
exact test). 
A B 
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3.3.7 Correlation of signal enumeration and clinicopathological data 
The clinical data annotated to the adenoma samples which were investigated by 
miFISH were analyzed (see Table 23 in chapter 3.3.1 and Figure 37 in chapter 3.3.2). 
The following passages present the highlights of these correlations per clinical param-
eter. However, correlations of the clinicopathological features and the signal enumer-
ation expressed by the calculated ASNs were not discussed in detail due to arguably 
low informative value (Supplemental Table 6). 
 
Size 
Adenoma size correlated with the histological subtypes (villous histologic architecture 
was not considered): smaller adenomas were more frequently observed with tubular 
histopathology while lesions of larger diameters were associated with tubulo-villous 
histology (medians 18 mm vs 20 mm, P=0.034; Figure 59A). Furthermore, lesion sizes 
correlated markedly with the assignment as primary or recurrent adenoma, respec-
tively, in matched pair samples (medians 30 mm vs 15 mm, P=0.003; Figure 59B). 
Larger diameters were frequently seen in primary adenomas compared to the recurrent 
adenomas being suggestive of tight surveillance intervals and immediate polypectomy. 
 
Histology 
The cohort of primary adenomas investigated in this study comprised three adenomas 
of villous histology indicating an underrepresentation compared to the other histologi-
cal subtypes. Accordingly, villous adenomas were combined into one group with ade-
nomas of tubulo-villous histology. The comparison of both histological subtype groups 
(i.e., tubular and tubulo-villous/villous) revealed that tubular adenomas were once ob-
served in left hemicolonic locations, and not present in the rectum (P=0.059; Figure 
59C). 
 
Grading 
Separating the primary colorectal adenomas by the grade of dysplasia exhibited a dif-
ference in the average number of clone populations within the tumors. Surprisingly, 
low-grade dysplastic lesions (LGD) frequently showed a higher number of clones 
compared to adenomas with high-grade dysplasia (HGD; medians 20 clones vs 10 
clones, P=0.016; Figure 59D).  
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Age at diagnosis 
Patient age at the time of primary adenoma diagnosis correlated with the genomic in-
stability index (P=0.026; Figure 59E). An advanced age (above the median of 66.7 
years, IQR 62.5-70.2 years) was associated with an increasing instability in the le-
sions compared to younger patients (medians 4.8 patterns vs 2.1 patterns). 
 
Time to recur 
Addressing the question whether the CNA of CDX2 was associated with an earlier re-
currence of adenomas, adenoma samples were analyzed by Kaplan-Meier (Figure 
59F). An increase of CDX2 copy numbers seemed, arguably, not associated with ad-
enoma-recurrence free survival (P=0.318).  
Figure 59. Correlations of clinical features in colorectal adenomas. (A) Larger adenoma samples 
were associated with tubulo-villous histology, whereas tubular adenomas were smaller (Mann-Whitney 
U test). (B) The average size of primary adenomas was larger than the corresponding recurrent ade-
noma size (Mann-Whitney U test). (C) Histological subtypes were associated with the trichotomized 
localization of the adenomas (Freeman-Halton test). (D) The number of clones (median with IQR) dif-
fered in adenomas with LGD compared to adenomas with HGD (Mann-Whitney U test). (E) Patients of 
advanced age displayed increased instability indices in the adenomatous lesions than younger patients 
(Mann-Whitney U test). Adenoma P4A was excluded as an outlier. (F) Kaplan-Meier analysis of ade-
noma recurrence-free survival time depending on the copy number status of CDX2 (χ=0.998, Log-rank 
test). CI, confidence interval; HR, hazard ratio. Box plots in (A), (B) and (E): +, mean; whiskers, Tukey. 
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Localization 
A potential unequal distribution of CNAs in adenomas across various colonic seg-
ments was assessed. Separating the large intestine into the colonic and the rectal 
fraction, respectively, exhibited that adenomas resected from the rectum were fre-
quently affected by CNAs (81.8%) while copy numbers in colonic adenomas re-
mained predominantly neutral (54.8%; P=0.036; Figure 60A). Moreover, copy num-
ber gain of CLIC1 was associated with the dichotomized location: 80% (4/5) of ade-
nomas affected by CLIC1 gains were found in the rectum (P=0.013; Figure 60B). 
 
Intratumor heterogeneity  
Diversities in the composition of intratumor populations were measured by the ob-
served number of divergent signal pattern clone populations. Considering a CNA to be 
present when more than 10% of the counted cells harbored an alteration, primary ad-
enomas were categorized into groups of copy numbers neutral and altered, respec-
tively. As expected, adenomas with distinct CNAs revealed a higher number of different 
clonal populations compared to adenomas without CNAs suggesting an increase of 
intratumor heterogeneity (medians 21 clones vs 11 clones, P=0.006; Figure 60C). 
Computing an instability index as a measure of diversity helped to assess intratumor 
heterogeneity while providing intertumoral comparability (see chapter 2.6.4 Data as-
sessment: Tumor heterogeneity). Primary adenomas which harbored a CNA of MYC 
were clearly associated with an increase of the intratumor heterogeneity indicating that 
this CNA accelerates chromosomal instability (medians 7.9 patterns vs 2.4 patterns, 
P=0.016; Figure 60D). Moreover, dichotomizing primary adenomas via low or high in-
stability index (median 2.92 patterns, IQR 1.69-6.46) revealed that CN gains of EGFR 
were predominately (80%) in line with a higher intratumor heterogeneity in the cases 
(P=0.036; Figure 60E). Interestingly, an increased average instability index was also 
observed in primary adenomas resected from the rectum in comparison to colonic lo-
cations (medians 6.0 patterns vs 2.6 patterns, P=0.045; Figure 60F). A similar obser-
vation was made when Shannon entropy was compared to the adenoma location con-
firming the increased intratumor heterogeneity across rectal cases (P=0.029; Figure 
60G). The larger the population size of the major clone within an adenoma, the lower 
was the value of the Simpson diversity index (P<0.001; Figure 60H). Dichotomizing 
primary adenomas by the median major clone population size (69%, IQR 38-85%) re-
vealed a negative linkage with accumulated pairwise genetic diversity (P=0.014; Figure 
60I).  
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Figure 60. Legend on next page. 
Results 
132 
 
3.4 Comparison of CNAs detected by aCGH and miFISH 
The results of copy number counts called by aCGH and miFISH in adenomas were 
correlated with an applied detection threshold of >10% of the cells for miFISH (Figure 
61A). Copy number status of aCGH findings and miFISH counts exhibited a “very 
good” strength of agreement of 97.3% (753/774 observations) which equaled κ=0.86 
(CI, 0.80-0.92; Cohen’s kappa coefficient). The few discrepancies in CNA-calls were 
predominantly observed for gains of CLIC1 called by aCGH but not seen (in equal 
numbers) by miFISH. In contrast, CN gains of CDX2, EGFR, MYC, and ZNF217 were 
less abundantly observed by aCGH as by miFISH analysis (Figure 61A). 
Next, CN profiles and signal patterns in match paired adenomas (n=13) detected by 
aCGH and miFISH were correlated (Figure 61B). Note that aCGH profiles were clas-
sified as stable or simplification/complexity due to the lack of clonal information. 84.6% 
(11/13) of pairs showed superimposable trends when comparing primary and recurrent 
adenoma by aCGH and miFISH, respectively. However, pair P2 showed a shift from 
primary adenoma towards an increase of CNAs in the recurrent adenoma by aCGH 
while miFISH detected no CNAs. However, called CNAs by aCGH were not covered, 
i.e., represented, by miFISH probe markers. Pair P10 resembled to be a complicated 
case as the aCGH profile showed differential CN losses of chr14 and chr15, respec-
tively. Any other alteration was shared across both lesions. However, miFISH targeted 
none of these chromosomes and clonal populations within this adenoma case seemed 
similar across the primary and the recurrent adenoma. 
Both methods call copy numbers of probe markers. However, aCGH data merely 
provides an average copy number profile (in comparison to a baseline) of the tumor 
bulk. In contrast, miFISH represents a direct single-cell approach whose quantification 
is not (ultimately) superimposable to aCGH (Lassmann et al., 2007). 
Figure 60. Correlations of clinical features and CNAs detected by miFISH. (A) Dichotomized loca-
tion of colorectal adenomas revealed an unequal distribution of CNAs in the different colonic segments 
(χ=4.404, Pearson’s χ2 test). (B) CLIC1 CN gain was predominately observed in adenomas of the rec-
tum. Adenomas of colonic segments were frequently observed with neutral CNs of the 6p-marker 
(Fisher’s exact test). (C) CN-altered primary adenomas exhibited an average higher number of clone 
populations within the tumors (Mann-Whitney U test). (D) Adenomas affected by MYC CN gain were 
associated with an increased instability index (Mann-Whitney U test). (E) EGFR CN gain is strongly 
associated with a high intratumor heterogeneity expressed by the instability index (Fisher’s exact test). 
(F) Instability indices were higher in rectal adenomas than in colonic counterparts (Mann-Whitney U 
test). (G) Rectal adenomas exhibited on average a higher Shannon entropy (Mann-Whitney U test). (H) 
The population size of the major clones correlates strongly with Simpson diversity indices across primary 
adenomas (Spearman correlation). (I) Primary adenomas divided by the median size of the major clone 
population differed for the accumulated pairwise genetic divergence. Cases without detectable major 
clones were not considered. Box plots in (C), (D), (F), (G) and (I): +, mean; whiskers, Tukey.  
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Figure 61. Correlation matrix of copy number results by aCGH and miFISH. (A) Obtained results 
of CNAs by aCGH and miFISH, respectively, were correlated with each other. A match would be con-
cordant (green) if both techniques showed the same results concerning the copy number status (gain, 
loss, neutral). Accordingly, an overlap would be discrepant (red) if copy number counts were unequal. 
CN status was statistically evaluated confirming a very good agreement of 97.3% (κ=0.86, Cohen’s 
kappa coefficient). (B) Comparison of clonal evolution patterns determined by aCGH CN profiles and 
miFISH probe counts, respectively. CN tendencies between the primary and recurrent adenoma were 
classified as either stable or simplification/complexity via aCGH. Patterns were compared to the miFISH 
recurrence patterns of stabilization, “zero,” simplification and complexity. “Zero” patterns were intro-
duced as no CNA was detected by miFISH and, accordingly, corresponding aCGH profiles are stable. 
An agreement was marked as either concordant (green), discrepant (red), or not determined (dark grey). 
N.D.; not determined. 
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3.5 Protein expression of MMR proteins and CDX2 in (recurring) adeno-
mas 
3.5.1 Immunohistochemical detection of microsatellite instability 
The cohort of colorectal adenomas analyzed by miFISH comprised a subgroup of 24 
samples (19 biological individuals) with no detectable CNAs in any of the fourteen gene 
identifier probes and centromere 10 probe, respectively (see chap. 3.3). Addressing 
the question whether these cases were instead affected by microsatellite instability 
instead of copy number alterations and/or chromosomal instability, expression status 
of mismatch repair proteins (namely MLH1, MSH2, MSH6, and PMS2) were immuno-
histochemically evaluated as indirect evidence of putative microsatellite instability (Fig-
ure 62). None of the tested DNA MMR proteins was lost in any of the specimens (n=24; 
Figure 15): IHC revealed distinct and clear nuclear expression of the proteins targeted 
by the antibodies (Table 27). Thus, immunohistochemical detection confirmed a mi-
crosatellite stable (MSS) phenotype in 100% (24/24) of the tested adenomas. 
 
Figure 62. Immunohistochemical detection of MMR proteins in colorectal adenomas. Repre-
sentative images of immunohistochemistry (IHC) detecting DNA mismatch repair proteins, i.e., MLH1, 
MSH2, MSH6, PMS2, in adenoma sample P14a. Positive immunoreaction was observed for all four 
protein markers. Scale bar, 100 µm. 
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3.5.2 CDX2 protein expression 
Detected CN gains of CDX2 in colorectal adenomas raised the question whether these 
genetic changes have a direct (measurable) impact on CDX2 expression. Therefore, 
IHC was applied to representative adenomas (n=8) comprising neutral and gained 
CDX2 CNs, respectively (Figure 63). IHC performance presented abundant nuclear 
CDX2 expression in 100% (8/8) of samples: not only in the adenomas with CN gain 
(i.e., A19, P9a, P10a, P13a) but also in the adenomas with neutral CN count for CDX2 
(i.e., A3, A9, A21, P5a). Statistical quantification of expression levels by immunoreac-
tive score was not performed due to the similarly strong intensities of IHC-staining and 
homogenous staining of tumor cells. 
Figure 63. CDX2 immunostaining of primary colorectal adenomas. (A) Strongly positive nuclear 
staining of CDX2 in epithelial cells of two representative adenoma cases with detected copy number 
gain of CDX2. (B) Similarly, a distinct expression of CDX2 in epithelial cells of two representative ade-
noma cases which exhibited neutral copy numbers concerning CDX2. A differential staining level across 
adenomas with and without CDX2 gain was not detectable. Scale bar, 100 µm. 
Table 27. IHC of DNA MMR proteins in colorectal adenomas. Adenomas not displaying any 
CNA by miFISH were tested for DNA MMR protein expression. +, stable nuclear protein expres-
sion; MSS, microsatellite stable. 
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4 DISCUSSION 
4.1 The lack of colorectal adenoma recurrence biomarkers 
Colorectal cancer (CRC) is the third most common cancer in men and the second most 
common cancer in females in Germany in 2013 (Zentrum für Krebsregisterdaten, 
2016). Thus, it denotes to be a dramatic health burden for patients and a tremendous 
cost factor for the health care system. As CRC is believed to develop in an interval of 
years to decades, a characteristic stepwise transition (from normal mucosa to ade-
noma and CRC) was proposed: the adenoma-carcinoma sequence (Fearon and Vo-
gelstein, 1990). Representing the most common neoplastic lesion in the colorectum 
(Eide, 1991; Levine and Ahnen, 2006), adenomatous polyps bear the opportunity to 
reduce CRC risk to up to 90% by resection, i.e., polypectomy, due to their intermediate 
role as precursor lesions (Winawer et al., 1993; Zauber et al., 2012). Although less 
than 5% of adenomas progress into CRCs (Eide, 1991; Shinya and Wolff, 1979), most 
CRCs indeed arise from adenomas. This circumstance confirms the rationale, and cur-
rently performed routine (Leitlinienprogramm Onkologie, 2014), to resect all adenomas 
after their detection during colonoscopy. However, recurrence of adenomatous polyps 
affects more than every third patient (Avidan et al., 2002; Bonithon-Kopp et al., 2004; 
Neugut et al., 1995; Winawer et al., 1993). This elevates both CRC risk and the risk of 
complications associated with the invasive colonoscopy (Corley et al., 2014). This em-
phasizes an urgent need for the identification of epigenetic and genetic biomarkers to 
infer and predict the individual risk for adenoma recurrences (“personalized medicine”). 
 
4.2 The role of CpG methylation in adenoma recurrence 
4.2.1 DMPs in colorectal adenomas 
The genetic landscape of cancers such as CRC is an extensively studied field ever 
since alterations were associated with cancer. It is well accepted that cancer is not 
caused by a “single hit” but rather by multiple hits, i.e., alterations (Knudson, 1971; 
Vogelstein et al., 2013). Since epigenetic phenomena were recognized to alter gene 
product expression without changing the DNA sequence, more and more studies shed 
light on epigenetic landscapes. Epigenetic variation in cancers is much higher than 
genetic variation (Bennett-Baker et al., 2003). The DNA methylation on CpG dinucleo-
tides, an epigenetic modification, is a frequent target of alterations in colorectal neo-
plastic lesions (Esteller, 2008; Fadda et al., 2018; Galamb et al., 2016). DNA 
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methylation patterns were shown to be highly dynamic with specific variance across 
tissues, cells and diseases, respectively (Sharma et al., 2016). In the advent of studies 
to identify and validate specific biomarkers, differential DNA methylation consequently 
became the focus of attention due to their pivotal role in gene expression. Advances 
in array technologies such as HM450K then allowed the simultaneous analysis not only 
of multiple CpG loci but also of numbers of CpGs on a genome-wide scale, i.e., the 
global methylome (Irizarry et al., 2009; Bibikova et al., 2011). 
Dozens of studies focused on unveiling epigenetic biomarkers and differentially 
methylated CpG positions (DMPs) across the methylome of CRC, adenomas and nor-
mal epithelium (Lam et al., 2016). To this day there is still an imperative for informative 
epigenetic biomarkers. This study sought to discover aberrantly methylated CpG dinu-
cleotides in the methylome of primary colorectal adenomas without recurrence (n=30) 
compared to primary colorectal adenomas with recurrence (n=29), recurrent adeno-
mas (n=10) and normal epithelium (n=3). By utilizing the HM450K array, 329,573 
probes were available after filtering to seek differences across the sample groups. 
However, principal component analysis and unsupervised hierarchical clustering of 
mean β-values were not capable of separating the specimens by recurrence groups. 
Cluster assignment by mean β-values was, instead, associated with adenoma histol-
ogy (P=0.008). This finding leads to the assumption that the observed epigenetic al-
terations also manifest themselves in phenotypical variation. A previous study linked 
adenoma location, i.e., right- or left-sided, to distinct differential methylation patterns 
(Koestler et al., 2014). This observation did not account for the adenoma samples an-
alyzed in our study. Remarkably, Luo and colleagues (2014) identified two epigeno-
types of adenomas defined by low or high methylation frequency. The authors addi-
tionally linked the high methylation phenotype significantly to adenomas progressing 
to CRC. Such a separation was not found in our study.  
Nevertheless, the different mean β-value methylation patterns for the different his-
tologies (tubular or tubule-villous/villous) suggest a crucial role in pathogenesis. This 
epigenetic evidence substantiates previous linkages of recurrence with histologic fea-
tures to assess colonoscopy surveillance intervals (Levine and Ahnen, 2006; Noshir-
wani et al., 2000). In contrast, other studies did not find an association of histology with 
recurrence and, instead, reported adenoma number and size as risk factors (Avidan et 
al., 2002; Bonithon-Kopp et al., 2004; Martinez et al., 2001).  
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Besides average β-values, we sought to unveil DMPs by comparing the grouped 
adenomas. Significant DMPs were not identified when comparing primary adenomas 
without recurrence to primary adenomas with recurrence. This initially suggests that 
the methylation of CpGs is not informative in predicting adenoma recurrence. One ex-
planation for the observation could be the broad level of heterogeneity in epigenetic 
patterns across the primary lesions irrespective of recurrence status. Arguably, while 
recurrence might be triggered by alterations in DNA methylation patterns in several 
patients, the individual impact of DNA methylation across primary adenomas and pa-
tients could (i.e., ITH) prevent the discovery of DMPs. Nevertheless, a previous study 
found the promoters of MLH1, ATM, and FHIT to be hypermethylated in adenomas 
with recurrence (Rengucci et al., 2014; De Maio et al., 2017). While this seems contra-
dictory to our findings, their results must be interpreted with caution as hypermethyla-
tion was considered when methylation exceeded 20% (evaluated by methylation-spe-
cific ligation probe assay). Additionally, FDR was not corrected for multiple testing. The 
failed appearance of DMPs in our dataset of primary adenomas with recurrence versus 
adenomas without recurrence could, theoretically, be due to incomplete resection and 
not caused genetically. In this scenario, adenomatous polyps recur out of a remaining 
residue, and the epigenetic pattern will not reveal substantial differences compared to 
non-recurring adenomas. Corley et al. (2014) named incomplete removal, in fact, a 
biasing factor. Absent identification of DMPs also draws the conclusion that differential 
DNA methylation might be exclusively associated with serrated and CIMP+ lesions 
(serrated pathway of carcinogenesis) (Andrew et al., 2017; Conesa-Zamora et al., 
2015), and not with sporadic adenomatous polyps. 
Similarly, the comparison of matched pairs did not reveal significant DMPs. This 
suggests that ITH combined with small sample counts (n=10 pairs) were, arguably, 
responsible in this matter. However, recurrent adenomas were aberrantly methylated 
(FDR<0.05 and FC>10%) in 674 and 221 CpG sites compared to the set of primary 
adenomas with recurrence (comparison A) and the complete set of primary adenomas 
(comparison B), respectively. Results demonstrated that a significant portion of recur-
rent adenomas underwent an epigenetic shift towards genomic hypermethylation. Ac-
cording to the scientific consensus, genome-wide methylation decreases while CGI 
methylation increases as tumors progress (Esteller et al., 2008). As most of the as-
sessed hypermethylated DMPs are located within CGIs or nearby, i.e., shores and 
shelves, the results suggest adhering to this biological rationale. This is supported by 
the fact that recurrent adenomas were resected at later time points. This argues in 
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favor of a dynamic progression of the landscape of methylation alterations which is in 
concordance to age-related changes (Ahuja et al., 1998). Speculatively, the procedure 
of endoscopic removal might pave the ground for hypermethylated adenomas. 
The list of top genes across recurrent adenomas versus primary adenomas with 
recurrence provided 34 DMPs associated with 31 individual genes. These comprised, 
e.g., STK32B (serine/threonine kinase 32B), LCMT1 (leucine carboxyl methyltransfer-
ase 1), MCC (mutated in colorectal cancers), JAK3 (Janus kinase 3), BMP3 (bone 
morphogenetic protein 3), and GREM2 (gremlin 2). Although methylation of BMP3 was 
previously associated with neoplastic lesions of the colon via stool detection (Ash-
ktorab et al., 2014; Kisiel et al., 2013), solely GREM2 harbored three DMPs within a 
CGI of the gene body. Thus, the gene resembles a preferential validation candidate. 
GREM2, expressed in basal epithelial stem cells of the crypt (Roy and Majumdar, 
2012), is a member of the DAN gene family of bone morphogenetic protein (BMP) 
antagonists which belong to the TGF-β superfamily. Due to BMPs’ involvement in de-
velopment, morphogenesis, cell proliferation and apoptosis (Bragdon et al., 2011; Pelli 
et al., 2016), a dysregulation of these proteins by antagonists can promote both colo-
rectal polyp and cancer formation (Hardwick et al., 2008; Kodach et al., 2008). Pyrose-
quencing of two of these three DMPs validated the differential methylation in primary 
adenomas and recurrent adenomas. Additionally, more informative CpG sites located 
within the DMPs were unveiled. Functionally, hypermethylation of CpGs in the gene 
body of GREM2 in recurrent adenomas may supposedly deactivate the gene transcrip-
tion resulting in a decreased protein expression. Research on stored datasets in the 
Oncomine database (2014) documented a highly significant downregulation of GREM2 
mRNA in colorectal adenomas compared to normal mucosa (Sabates-Bellver et al., 
2007). While GREM2 mRNA was strongly expressed in myofibroblasts, a complete 
knock-down was observed in CRC cell lines (Kosinski et al., 2007). As previously hy-
pothesized, this could result in a deregulation of BMP signaling. In turn, WNT signaling 
is disrupted and promotes colorectal carcinogenesis (Kosinski et al., 2007). 
Comparing colorectal adenomas (n=69) to the normal colorectal epithelium (n=3) 
unveiled 9,266 significant DMPs (FDR<0.05) of which 73% were hypomethylated. Fil-
tering led to 4,179 DMPs (FDR<0.05 and FC>10%) in this setting. Another study iden-
tified 43,999 DMPs when comparing adenomas to normal mucosa (Fadda et al., 2018). 
However, the count of tumor samples was less than a third (n=21) compared to the 
here presented study. Our observation of genome-wide hypomethylation of adenomas 
is in line with the findings by Fadda and coworkers (2018). Additionally, their suggested 
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panel of methylation markers, comprising GRIA4, SLC8A1, and SYN3, for detection of 
CRC and adenomas (in stool) was confirmed in our approach. We discovered signifi-
cant DMPs associated with the respective set of genes. Nevertheless, solely GRIA4 
ranged in the list of 347 top genes identified in our work while the other markers did 
not show Δβ>0.1. Furthermore, there are currently two methylation markers commer-
cially available for noninvasive detection of colorectal adenomas and cancer (Gyparaki 
et al., 2013; Sameer and Nissar, 2016), namely SEPT9 (ColoVantage®) and VIM 
(ColoSure™). Only the latter was among the list of 4,179 significant DMPs, although 
Δβ was lower than any of the 347 top genes. Moreover, from a set of ten cancer-related 
genes frequently aberrantly methylated in CRC (Sugai et al., 2017), probes located in 
SFRP1, DKK3, IGFBP7, and MLH1 were found among the significant DMPs in our 
study. This indicates an early alteration of methylation markers in the carcinogenesis. 
Interestingly, Galamb and colleagues (2016) identified differential methylation of WNT 
pathway genes in adenomas versus normal mucosa. Of these genes, our study con-
firmed AXIN2 (two probes among top genes) and SFRP1. These results underline that 
the list of top genes harbors potential for informative CpG dinucleotide methylation 
biomarkers for the detection of adenomas. 
 
4.2.2 Distribution of DMPs in the genome 
The literature first mentioned the methylation of cytosines, i.e., resulting in 5-methylcy-
tosines. This epigenetic modification was discovered to function as a dynamic regula-
tory element involved in gene repression. Then, studies primarily reported on CpG 
dense regions (CpG islands) in gene promoters being increasingly methylated (Sax-
onov et al., 2006). In recent years, attention has shifted towards epigenetic alterations 
in non-promoter regions with an even sparser density of CpG dinucleotides in neigh-
boring regions of CGIs. Indeed, these regions were positively linked to gene transcrip-
tion (Esteller, 2008; Jones, 2012; Price et al., 2013). The high-throughput DNA meth-
ylation array HM450K assessed CpGs not only located in proximal promoter regions 
such as upstream of the transcription start sites, 5’UTR, and 1st exon but also in the 
gene body and 3’UTR (Bibikova et al., 2011). Besides gene regions, CpG dinucleotides 
distributed in neighboring regions up- and downstream of CpG islands, i.e., the shore 
and shelf regions and the open sea, can be targeted (Bibikova et al., 2011). 
In the present study, a non-random distribution of hyper- and hypomethylated CpGs 
was uncovered when investigating the set of 4,917 DMPs. In the comparison of 
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recurrent adenomas versus primary adenoma or tumor versus normal, one-third of the 
DMPs were located within a CpG island and hypermethylated, while 24% of DMPs 
were localized in the open sea and hypomethylated. This observation is in line with the 
current understanding of alterations in tumors (and their progression). According to 
Esteller (2008), the genome-wide level of 5-methylcytosines decreases whereas the 
level of methylation in CGIs, conversely, increases. Comparing recurrent adenomas to 
primary adenomas with recurrence (comparison A) showed a fraction of 47% of DMPs 
being in CGIs, whereas recurrent adenomas compared to all primary adenomas (com-
parison B) showed 66% of DMPs being in CGIs. In contrast, comparison C (adenomas 
vs normal mucosa) just revealed 37% of DMPs being in CGIs. This could indicate that 
aberrant methylation of CGIs inclines from normal epithelium to adenomatous lesions 
with a linkage to recurrence. Our study unveiled broad hypomethylation of DMPs in 
open sea and shelf regions, whereas CpG island-DMPs were mostly hypermethylated 
and DMPs in shores were found to be balanced. Since recent analysis has shown that 
aberrant methylation of shore regions occurs in colorectal lesions (Irizarry et al., 2009), 
a vast spectrum of CpG positions may account for imbalances in gene regulation. 
Analysis revealed that DMPs located within the proximal promoter were excessively 
hypermethylated. Conversely, the majority of DMPs found in the gene body and 3’UTR 
were hypomethylated. This observation indicates a crucial role of methylation in the 
regulation of transcription. Previous studies have shown that transcription start sites, 
5’UTRs and 1st exons are more prone to be hypermethylated than other regions (Hi-
noue et al., 2012; Naumov et al., 2013; Sharma et al., 2016). Hypermethylation of 
CpGs in the 1st exon is strongly correlated with gene silencing (Brenet et al., 2011). In 
combination with our findings, it supports the assumption that recurrent adenomas 
were affected by more substantial degrees of gene silencing than primary adenomas 
with and without recurrence. However, DMPs in gene body regions have a tremendous 
relevance in colorectal lesions as more than 90% of WNT pathway-associated DMPs 
were not located within the proximal promoter (Galamb et al., 2016). 
The distribution of DMPs with regards to their chromosomal location unveiled that 
more than 20% of DMPS were located on chromosome 1. Although this observation 
was similarly made in CRC cell lines (Sandoval et al., 2011), chromosome 1 is also the 
largest and gene-densest chromosome which arguably increases the odds of a biased 
DMP-identification. However, the results also suggest that DMPs were non-randomly 
distributed throughout the genome with chromosomes 2, 6, 11, 12, 17 and 19 harboring 
more differential CpGs than others such as chromosomes 9, 13, 18, 21 and 22.  
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While the low gene content is a likely explanation for the few DMP counts on chro-
mosomes 13, 18 and 21 (Schneider et al., 2016), other frequencies did not necessarily 
correlate with chromosome size. 
 
4.2.3 Association of DMPs with distinct pathways 
Genes associated with DMPs and identified in comparisons A-C were subject to a 
pathway ontology analysis with stringent criteria to unravel the most significant asso-
ciation between molecular and cellular pathways. Identified genes of comparison A 
were involved in processes of the (adaptive) immune system, cytokine signaling in the 
immune system and inflammation-mediated cytokines such as IL2 and IL4. Further, 
identified genes were also related to antigen processing, i.e., class I MHC-mediated 
antigen processing presentation and antigen processing-cross presentation. This 
highly significant accumulation of genes related to immunologic processes leads to the 
assumption that the microenvironment of the recurrent adenomas was dominated by 
inflammatory conditions in comparison to the primary lesions. Evidence confirms the 
promotion of tumor development by cancer-related inflammation aiding in the prolifer-
ation and survival of malignant cells (Mantovani et al., 2008). Porta and colleagues 
(2009) termed these conditions “smoldering inflammation” which, to their knowledge, 
is supported by the presence of myelomonocytic cells of the immune system secreting 
pro-inflammatory cytokines. The differential methylation of immunologically-related 
genes could both repress or activate gene transcription with respect to the genomic 
location of the CpG site. However, the findings are in line with observations of in-
creased tumor rates in patients suffering from chronic inflammations of the bowel, i.e., 
ulcerative colitis and Crohn’s disease (Sartor, 2006). Hanahan and Weinberg (2011) 
count chronic inflammatory conditions as one of the hallmarks of cancer. 
The second class of pathways was associated with (i) the proteasomal degradation 
of proteins, namely the ER phagosome pathway, (ii) ubiquitin-mediated proteolysis and 
(iii) antigen processing ubiquitination proteasome degradation. Aberrant methylation in 
these genes might be an indicator of a disruption in the proteolytic system of recurrent 
adenoma cells. Deregulation of the proteasome and ubiquitin ligases results in uncon-
trolled proliferation and inclined genomic instability in cancers (Nakayama and Naka-
yama, 2006). These are hallmarks which likely promote the recurrence of an adeno-
matous polyp. Interestingly, the cell cycle is activated by cyclin-dependent kinases 
(CDKs) which are strictly regulated by ubiquitin-mediated proteolysis (Nakayama and 
Discussion 
143 
Nakayama, 2006). By considering the aberrant methylation of genes of the cell cycle 
and mTOR pathway, the analysis suggests a tumor micro-environment beneficial to 
proliferation by cell-cycle disruption, growth promotion, and modulation of inflammatory 
responses (Ciechanover et al., 2000). Third, DMPs associated with genes of the insulin 
pathway were identified suggesting a correlation between colon neoplasia and diabe-
tes, which was previously named as a risk factor for CRC (Tsilidis et al., 2015). Insulin 
production is common in neoplastic transformation (Ashktorab et al., 2014), which hints 
towards a more advanced methylation pattern of recurrent adenomas. Interestingly, 
insulin signaling was found to influence the oncogene Ras (Giovannucci et al., 2010). 
Finally, pathways were unveiled which are associated with aberrantly methylated 
genes across adenomas versus normal mucosa. Multiple genes involved in the for-
mation of the matrisome, the core matrisome, extracellular matrix glycol-proteins, and 
matrisome associated pathway were linked to the DMPs. The extracellular matrix 
(ECM) is responsible for the development and homeostasis of tissues by influencing 
cellular growth, survival, migration, and differentiation (Pickup et al., 2014). Conse-
quently, dysregulation of the matrisome (sum of ECM constituents) was shown to be a 
critical initiation factor for neoplastic lesions as these ECM proteins are empowered to 
modulate and accelerate the multifaceted hallmarks of cancer (Hanahan and Wein-
berg, 2011; Pickup et al., 2014). Besides ECM pathways, genes involved in heterotri-
meric G-protein coupled receptor (GPCR)-ligand binding, GPCR signaling and GPCR 
downstream signaling were strongly positively correlated with the DMPs. GPCRs are 
linked to various intracellular processes, e.g., EGFR-mediated growth signals, and het-
erogeneous expression of these receptors was demonstrated in multiple cancer enti-
ties (Bhola and Grandis, 2008). Remarkably, multiple genes were listed in our compar-
ison which are members of pathways in cancer, MAPK signaling, Ca2+ signaling, p53 
signaling and CREB-signaling via PKC and MAPK. These pathways are classical mo-
lecular signaling targets in the transition of normal tissue towards the formation of a 
neoplastic tumor. This highlights their importance as intracellular receptors are linked 
to growth signaling, cell survival, tumor-repression and cellular homeostasis (Bonni et 
al., 1999; Hanahan and Weinberg, 2011; Vogelstein et al., 2000). Comparing DNA 
methylation of adenomas with normal mucosa revealed genes which were associated 
with the immune system. This fact suggests that an inflammatory microenvironment is 
beneficial for the transition towards a neoplastic lesion (Mantovani et al., 2008).  
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4.3 The role of CNAs in adenoma recurrence 
Unraveling the molecular dynamics leading to recurrence of colorectal adenomas is a 
prerequisite for defining valuable biomarkers for prediction. While the traditional per-
spective of clonal evolution in cancer has been reflected by gradualism (Nowell, 1976), 
evidence suggests that subclonal populations preferably caused ITH. These emerge 
in branched patterns which occur with highly “variable evolutionary tempos” (Burrell 
and Swanton, 2014; Burrell and Swanton, 2016; Cross et al., 2016). The advent of 
single-cell approaches has unveiled the broad existence of ITH which is crucial for 
tumorigenesis and carcinogenesis (Heselmeyer-Haddad et al., 2012; Heselmeyer-
Haddad et al., 2014; Wangsa et al., 2016). A dominant role in promoting ITH of many 
solid tumors attributes to CNAs, i.e., gain or loss of whole chromosomes or fractions, 
leading to chromosome instability (CIN) (Cross et al., 2016). As karyotypical aberra-
tions are frequently identified in colorectal lesions (Bomme et al., 1994; Muleris et al., 
1994; Ried et al., 1996), this study has been conceived to analyze the potential of 
CNAs as a significant genetic signature which distinguishes primary adenomas by their 
status of recurrence. Moreover, the aspect of a putative dynamic landscape of CNAs 
in the clonal evolution of match-paired primary adenomas compared to recurrent 
adenomas has been a matter of analysis with an emphasis on ITH. 
 
4.3.1 Characteristic patterns of CNAs in colorectal adenomas 
Conducting aCGH on the set of colorectal adenomas unveiled the global landscape of 
CNAs present in the tumor bulk per patient. The analysis exhibited copy number gains 
most frequently affecting whole-chromosomes and chromosome arms, namely 7, 13q 
and 20q. Additionally, the most frequently reported copy number loss was documented 
for chr18. These aberrations are generally in line with the characteristic patterns of 
genomic copy number landscapes in colorectal neoplastic lesions and the carcinogen-
esis (Bomme et al., 1994; Borras et al., 2016; Meijer et al., 1998; Quintanilla, 2017; 
Ried et al., 1996). The results underpin the pivotal role of these aberrations as early 
events, i.e., frequently observed in low-grade adenomatous polyps, in the adenoma-
carcinoma sequence (Fearon and Vogelstein, 1990). Although extensive chromosomal 
alterations do not alter single genes only, chromosomal gain tremendously impacts the 
transcriptional dosage of oncogenes (Cross et al., 2016; Murugaesu et al., 2015). 
Defined as “evolutionary karyotypic theory” (Stepanenko and Kavsan, 2012), a 
dysregulation of copy numbers of whole-chromosomes and chromosome-arms affects 
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hundreds of genes and induces changes of both the transcriptome and proteome 
(Cross et al., 2016). CN gain of chromosome 7 comprises well-known proto-oncogenes 
which modulate Ras- and WNT signaling, e.g., EGFR and MET (Flora et al., 2012; 
Roberts et al., 2002; Zeng et al., 2008). Chromosome 13 CNAs are, similarly, mapped 
to colorectal lesions by alteration of proto-oncogenes regulating β-catenin activity, i.e., 
CDK8 (Firestein et al., 2008), and epithelial growth, i.e., CDX2 (Bai et al., 2003; Salari 
et al., 2012). Analogical to the aforementioned CNAs, chromosome-arm 20q harbors 
various oncogenes, e.g., AURKA, ADRM1, NCOA3, and ZNF217, which are 
characteristic for the colorectal carcinogenesis due to altering effects on cellular growth 
and migration (Carvalho et al., 2008; Habermann et al., 2013; Hirsch et al., 2012; 
Quinlan et al., 2007). Conversely, copy number loss of chromosome 18 has a crucial 
impact as the chromosome accommodates TSGs such as SMAD2 and SMAD4 which 
are regulators of the TGF-β pathway and, therefore, repress tumorous growth (Fearon 
and Vogelstein, 1990; Heldin et al., 1997). Whereas previous studies on colorectal 
adenomas and carcinomas had also defined chromosome 8 as a recurring CNA in 
colorectal carcinogenesis (Grade et al., 2006, Ried et al., 2012), adenomas 
investigated in this study were not common targets of chr8-associated aberrations. 
This cicumstance supports the perception of the gain of chr8 as a late event in the 
colorectal tumorigenesis which might be associated with CRC and increased 
malignancy. As a side note, chromosomal aberrations affecting chr19 were recurrently 
observed in the present and previous studies on colorectal adenomas. However, Jones 
et al. (2007) have reported that probes targeting this chromosome might be error-prone 
and would have introduced artifactual bias, justifying their non-consideration. 
Besides alterations of whole-chromosomes and chromosome-arms, the most fre-
quent CNAs in colorectal adenomas were identified to be three focal CNAs:  
(i) the gain of 6p22.1-21.33 harboring a cluster of histone genes, namely HIST1H, 
whose alteration was recently associated with CRC (Brosens et al., 2010; Camps et 
al., 2008). Additionally, the focal gain also affects CLIC1 (chloride intracellular channel 
protein 1) which was identified as a putative biomarker in CRC (Petrova et al., 2008). 
Santos and collaborators (2007) linked aberrations within the entire region of 6p21-
p23 with growth advantages and tumor progression in several cancers; 
(ii) the gain of 7q22 harboring a cluster of membrane-bound mucin genes, i.e., 
MUC3, MUC11, MUC12, and MUC17. Their proteins contain an EGF-like domain, sug-
gesting a role in epithelial growth modulation in colorectal pathogenesis (Byrd and Bre-
salier, 2004; Walsh et al., 2007); 
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(iii) the loss of 16q21 comprising CDH11 (cadherin 11) which was previously re-
ported as a silenced pro-apoptotic tumor suppressor modulating WNT signaling in col-
orectal lesions (Li et al., 2012; van Roy, 2014). 
The distribution of CNAs across the colorectal adenomas was investigated. The re-
sults demonstrated a Poisson distribution of CNAs frequencies with a few adenomas 
exhibiting higher numbers of CNAs. This observation alludes to the existence of CIN 
in only a small fraction of adenomas, which presented an elevated frequency of CNAs. 
This pairs well to recent findings by Jones and colleagues (2007) who concluded that 
CIN occurs in only a few cases of adenomas. It is tempting to speculate whether the 
tetraploid adenomas were first affected by CIN leading to aneuploidy (Sheltzer et al., 
2011), or vice versa (Yuen, 2010). Notably, the unequal distribution of whole- and part-
chromosome alterations implicates the presence of CIN (McGranahan et al., 2012). 
The average number of copy alterations (ANCA) equaled 3.5 CNAs in the adenoma 
cohort, which is comparatively low but in good agreement with previous studies on 
adenomatous polyps (Hirsch et al., 2012; Ried et al., 1999). Furthermore, rectal 
adenomas frequently displayed CNAs, correlated with tubulo-villous histology and 
were increasingly genomically instable expressed by the genomic instability index and 
Shannon entropy. This evidence implies that CNAs are a key driver of pathogenesis in 
rectal adenomas. They seem genetically more advanced than colonic adenomas which 
might hint at the slightly different anatomy compared to the colon (Ponz de Leon and 
Di Gregorio, 2001). Genomic and epigenomic differences in left- or right-sided 
adenomas were recently documented (Koestler et al., 2014). 
While aCGH provides an overview of the landscape of chromosomal aberrations of 
the tumor bulk by comparative analysis with non-tumor DNA (Lassmann et al., 2007), 
the present study was conceived to quantify CNAs additionally with a single-cell-spe-
cific approach. We analyzed the copy number status of fourteen cancer-associated 
genes (i.e., nine oncogenes and five tumor suppressor genes) along centromere 10 in 
the set of colorectal adenoma samples. Except for CCND1, all targeted loci showed 
aberrant copy numbers across the sample set. Specifically, nine of the gene markers, 
i.e., COX2, PIK3CA, CLIC1, EGFR, MYC, CDX2, TP53, HER2, and ZNF217, demon-
strated unidirectional CNAs across the cohort. This suggests that these alterations did 
not occur randomly. Instead, they seem to play a causative role as being targeted by 
providing a beneficial genomic state to the colorectal tumor (Carvalho et al., 2009; 
Habermann et al., 2013; Jehan et al., 2009; Petrova et al., 2008; Wang et al., 2016). 
Conversely, the observation that four markers, i.e., APC, CDH1, SMAD7, and SMAD4, 
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showed bidirectional CNAs could be attributed to genomic instability being randomly 
triggered in these regions. This assumption is substantiated by the fact that neither of 
the markers was homozygously lost nor amplified (Poorman et al., 2015). However, 
the tumor suppressive character was dominant in the complete sample set. 
Abnormal signal counts across the set of adenomas were most frequently found to 
affect the markers EGFR (13%), CDX2 (10.9%), and ZNF217 (10.9%). As these mark-
ers reflect chromosomal aberrations of chromosome-arms 7p, 13q and 20q (Ried et 
al., 1996), the landscape of CNAs detected in single cells of the cohort overlapped with 
the findings by aCGH. Since the total number of altered copy number counts and ASNs 
harbored potential for sampling bias, a 10% threshold was used to call a specific alter-
ation across the sum of single cells. Comparing CNAs called by miFISH and aCGH 
confirmed the valuable threshold since it provided a very good concordance, i.e., 
97.3% (κ=0.861). Herein, the present study achieved high overlaps compared to 
Heselmeyer-Haddad and coworkers (2014) using a FISH detection-threshold of 30% 
and found agreement in 83.3% of aCGH-miFISH comparisons. 
Unsupervised hierarchical clustering based on CNAs separated the adenomas into 
four cluster groups. Cluster distribution 1-4 correlated with aberrations of EGFR, no 
detectable CNA, various CNAs, and alteration of CDX2. The results indicate that EGFR 
and CDX2 gains occurred mutually exclusive. This underpins the relevance of both 
markers for colorectal tumorigenesis (Habermann et al., 2011; Roberts et al., 2002; 
Salari et al., 2012). It leads to the assumption that a gain of any of these markers could 
initiate and promote the formation of adenomatous polyps, irrespective of accumulation 
of additional alterations. 
 
4.3.2 CNAs for prediction of adenoma recurrence 
Utilizing the information of copy number landscapes obtained by aCGH, primary ade-
nomas without recurrence were compared to primary adenomas with recurrence. 
Herein, neither the sheer presence of CNAs nor the ANCA index was capable of dis-
tinguishing both groups from each other. This notion indicates that the quantity of CNAs 
in adenomas is not exclusively linked to adenoma recurrence. It further implies that 
copy number alterations play a dominant role in most adenomas, though irrespective 
of their status of recurrence, in accordance with the adenoma-carcinoma sequence 
(Fearon and Vogelstein, 1990). Interestingly, part-chromosome alterations were signif-
icantly more often observed than whole-chromosome alterations in both groups. This 
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leads to the conclusion that neither the quantity of CNAs nor the base-pair length is 
capable to predict recurrence reliably. When dissecting the frequency plot of primary 
adenomas without and with recurrence, in total 24 differential regions of CNAs became 
evident. Sixteen CNAs were enriched in primary adenomas with recurrence. CNAs 
affecting chromosome 13q were exclusively associated with primary adenomas with 
recurrence. The proto-oncogenes, e.g., CDK8 and CDX2 (Firestein et al., 2008; Salari 
et al., 2012), located on this chromosome might provide growth advantages and pro-
mote cellular survival, which facilitates a recurrence of the adenoma after polypectomy. 
The aCGH data was unsupervised hierarchically clustered and showed no associa-
tion with the adenoma groups. This observation confirms the initial results that the 
number of CNAs fails as a measure to discern primary adenomas with recurrence from 
primary adenomas without recurrence. It underpins that adenomas, irrespective of the 
status of recurrence, harbor various loads of chromosomal alterations. These separate 
individual fractions of specimens ranging from no-detectable CNA to multiple CNAs. 
The observation corroborates previous studies (Hermsen et al., 2002). Adenomas of 
cluster 1, however, showed complex chromosomal aberration patterns with alterations 
in chromosome number and focal CNAs. This complex pattern suggests a reduced 
genomic stability putatively indicative of an underlying CIN (Grady and Carethers, 
2008). Cluster grouping was also associated with the median patient age. Adenomas 
of patients of advanced age also carried a higher CNA burden. These findings support 
the relevance of the adenoma-carcinoma sequence in which tumors accumulate mu-
tations and chromosomal alterations over time (Fearon and Vogelstein, 1990). 
Single-cell miFISH-analysis of CNAs in the set of adenomas revealed that EGFR 
was most-frequently affected by alterations (13/55). However, the marker was not sta-
tistically differentially distributed when comparing primary adenomas without recur-
rence (6/14) to primary adenomas with recurrence (7/28). Although EGFR gain was 
not related to recurrence, the results support the finding of previous studies that EGFR 
CNA is the most common alteration in adenomas and an early, causative factor in 
tumor development (Habermann et al., 2013; Ried et al., 1996). This view is docu-
mented by the correlation of EGFR gains with high instability indices, which implies to 
lead to an accelerated accumulation of instable clones. Functionally, the copy number 
gain gives rise to an overexpression of the transmembrane receptor which comprises 
an intrinsic tyrosine kinase activity. This overexpression confers cellular resistance to 
apoptosis and results in proliferation and expansion of tumor cells (Grünwald and Hi-
dalgo, 2003; Roberts et al., 2002).  
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The second most common alteration observed by miFISH in colorectal adenomas 
was the copy number gain of CDX2 (12/55). Considering that CDX2 is located on chro-
mosome 13q, this finding substantiates previous works revealing that this is a frequent 
target in the colorectal carcinogenesis (Bomme et al., 1994; Borras et al., 2012; Hirsch 
et al., 2012; Meijer et al., 1998; Ried et al., 2012; Xie et al., 2012). Unlike EGFR, the 
gain of CDX2 was non-equally distributed across primary adenomas without and with 
recurrence. Primary adenomas without recurrence failed to present a CNA of CDX2 
(0/14), whereas 25% (7/28) of the primary adenomas with recurrence exhibited an ex-
tra copy of this gene. This result is equivalent to a sensitivity of 25% and a test speci-
ficity of 100% (P=0.040). Mechanistically, a CDX2 gain is attributed with accelerating 
the proliferation capability and with promoting survival of CRC cells (Dang et al., 2006; 
Salari et al., 2012). It seems therefore reasonable to assume that this CN gain provides 
a selective evolutionary advantage to the intestinal cells. It further allows an independ-
ent proliferation which then empowers the lesion to recur after polypectomy. However, 
controversial findings also showed that CDX2 expression was lost in a small subgroup 
of CRCs, suggesting CDX2 as a prognostic biomarker (Choi et al., 2006; Dalerba et 
al., 2016). CDX2 encodes a protein which is expressed in intestinal epithelial cells and 
is involved in intestinal development and differentiation (German et al., 1994; Liu et al., 
2007). The analysis of the expression pattern in a subset of samples of the adenoma 
cohort did not unveil significant differences in expression levels across samples with 
and without CDX2 gain. Nevertheless, this observation could be the correlate of low-
level gains, i.e., no amplifications were detected. Consequently, these gains solely in-
duce alterations in the protein expression pattern which are not distinguishable by im-
munohistochemistry. Previous studies reported that both allelic imbalances and DNA 
methylation of CDX2 were not directly correlated with the gene’s protein expression 
(Koestler et al., 2014; Subtil et al., 2007). 
The predictive value of the CDX2 CNA could be consolidated by an “adenoma re-
currence-risk” panel combining the marker with CLIC1 and ZNF217. Copy number gain 
of any of these markers identified primary adenomas with recurrence with 39% sensi-
tivity (P=0.036). However, specificity was decreased to 93% which is a sign of lesser 
clinical value. This combined leads to the conclusion that adenoma recurrence is a 
complex process orchestrated by various CNAs and other genetic processes. With the 
advent of “personalized medicine,” analyzing the copy number status of CDX2 might 
aid to improve the assessment of an individual risk for adenoma recurrence.  
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4.3.3 CNAs unveil intratumor heterogeneity 
The present study utilized miFISH to assess the copy number status of well-accepted 
oncogenes and tumor suppressor genes in single cells of primary colorectal adenomas 
without and with recurrence, and in recurrent adenomas. Single-cell analysis of genetic 
subclones complemented the analysis of the genomic landscape of the tumor bulk by 
aCGH. The relevance of single cells in “intratumor diversification” of colorectal lesions 
was very recently highlighted (Roerink et al., 2018). 
The set of colorectal adenoma specimens exhibited a major clone population size 
of on average 62.8%. This fraction size implies a stable clonal development of the 
colorectal adenomas with a low-level of clone diversity. This perspective, in turn, might 
reflect the clinical observation of a slow progression of adenomas towards CRC (Sil-
lars-Hardebol et al., 2012). While major clone fractions of primary adenomas without 
and with recurrence did not differ, recurrent adenomas showed a mean major clone 
population size of 85%. This fact indicates that the dominant clone fractions of recur-
rent adenomas had a growth and selection advantage. Interestingly, colorectal adeno-
mas comprised sizeable major clone fractions in comparison to prostate cancers (av-
erage size 20.8%; Heselmeyer-Haddad et al., 2014) and breast lesions (average size 
17.5%; Heselmeyer-Haddad et al., 2012). 
Addressing the average number of CNAs per case, primary adenomas without and 
with recurrence did not exhibit a difference across the subgroups. This finding under-
pins previous studies which report that chromosomal aberrations in colorectal lesions 
are rather heterogenous (The Cancer Genome Atlas, 2012). Nevertheless, dissection 
of primary adenomas with CNAs uncovered that adenomas with recurrence harbored 
clones with more complex signal patterns compared to adenomas without recurrence 
(P=0.016). Hence, it seems reasonable to assume that primary adenomas with com-
plex CNA-pattern clones are more prone to recur. Various selection advantages re-
quired for recurrence might have equipped these adenomas. The number of CNAs per 
clone could arguably be used as a predictor for adenoma recurrence. 
Besides the dominant clone populations, 47.3% of adenoma specimens possessed 
multiple minor clone populations. Although no significant differences were discovered 
between primary adenomas without and with recurrence, more than two-thirds of the 
specimens comprised of one or more clones. These observations corroborate recent 
works which claim the existence of polyclonality in colorectal adenomas (Novelli et al., 
1996; Thirwell et al., 2010) and the presence of ITH in primary CRC (Kim et al., 2015). 
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Multiple CNAs contribute to an ITH. Thus, this study aimed to elucidate the rele-
vance of ITH for adenoma recurrence by an assessment of diversity measures. 
First, a chromosomal instability index was calculated which considers the number 
of signal patterns per 100 cells. This measure ranked on average 4.9 patterns in the 
adenoma cohort, which suggests a low degree of ITH compared to what was demon-
strated in DCIS (62.3 patterns) and IDC (70.6 patterns; Heselmeyer-Haddad et al., 
2012). Although the index failed to discern primary adenomas with recurrence from 
adenomas without recurrence, this accords with the stable clonality of the adenomas 
reflected by dominant and minor clones. Additionally, an association of older patients 
with an increased genomic instability index was documented - highlighting the impact 
of aging on the cellular and genetic homeostasis (Carvalho et al., 2012). 
Second, the diversity measures of Shannon entropy (cohort mean 1.1) and Simpson 
index (cohort mean 0.31) were computed for the adenomatous specimens. No signifi-
cant differences were documented across primary adenomas with and without recur-
rence. Despite that, trends were unveiled linking the most heterogeneous samples, 
i.e., a large number of divergent clones, to primary adenomas with recurrence. This 
association points towards a similar direction, i.e., a correlation with primary adenomas 
with recurrence, as the number of CNAs per clone does. It could be interpreted in the 
way that recurrence becomes more likely as the clonal composition of the adenoma 
becomes more diverse. This perspective complements previous findings which 
showed that a high ITH goes in line with poorer prognosis of cancers (Burrel and Swan-
ton, 2016; Wangsa et al., 2016). Accordingly, tumor cells may have become resistant 
to immune surveillance and therapeutic intervention as the clone count elevated 
(Schwartz and Schäffer, 2017; Sottoriva et al., 2013). 
Third, the accumulated pairwise genetic diversity was computed as a distance met-
ric which is a simplified adaption of the average pairwise genetic divergence (Martinez 
et al., 2016; Rogers, 2015). The formula estimates the genetic distance of a set of 
given clone populations to the normal (i.e., diploid) signal pattern. It showed a wide 
range across the adenomatous polyps. This result supports the impression of a heter-
ogeneous distribution of CNAs beneficial to inter- and intratumor heterogeneity. The 
metric appeared not capable of distinguishing primary adenomas with recurrence from 
adenomas without recurrence. Instead, it was associated with tetraploid clone frac-
tions. This association suggests that computing the genetic distance aids to identify 
whole-genome duplication-affected clone populations, which might eventually gain se-
lective advantages due to tolerance to stress and promotion of transformation (Gordon 
Discussion 
152 
et al., 2012; Quintanilla, 2017; Storchová, 2012). The considerably higher scores in the 
applied diversity measures further emphasized the extraordinary role of tetraploidiza-
tion. Consequently, it justified the exclusion of adenomas with clearly tetraploid clone 
fractions. Rutledge and Cimini (2016) postulated that aneuploidy is beneficial to tumor 
cells. This notion permits the conjecture that the risk of adenoma recurrence might be 
increased. However, the small number of tetraploid adenomas in our cohort could not 
confirm this assumption. 
The analysis of diversity metrics in colorectal adenomas with and without recurrence 
leads to the conclusion that these measures can identify ITH with good precision in a 
wide range of samples. Strongly heterogeneous adenomas regarding clone fractions 
seemed more prone to recur than low-level ITH counterparts. 
 
4.3.4 Clonal evolution via phylogenetic analysis of CNAs 
As the understanding of the relevance of ITH in solid cancer populations advanced, 
more and more studies were conducted targeting the clonal evolution of neoplastic 
lesions by single-cell approaches (Heselmeyer-Haddad et al., 2012; Heselmeyer-Had-
dad et al., 2014; Russnes et al., 2011). The advanced miFISH method provided the 
possibility to infer the phylogenetic evolution from primary adenoma towards the recur-
rent adenoma by utilizing the FISHtree algorithm (Chowdhury et al., 2013; Schwartz 
and Schäffer, 2017). The present study unveiled four distinct clonal evolution patterns 
of adenoma recurrence: (i) simplification pattern, (ii) complexity pattern, (iii) stabiliza-
tion pattern and (iv) “zero” pattern. 
First, matched pairs demonstrating a simplification pattern (14%) suggest the fol-
lowing biological background. While subclonal populations of the primary adenoma 
were competing, the polypectomy of the bulk of the polyp supposedly removed or dam-
aged clonal fractions of the tumor. That, conversely, gave rise to a new dominant clone. 
Additionally, it seems reasonable to assume that a dominant clone has overgrown less 
competitive clones because of positive selection. This linear evolutionary event, 
termed “clonal sweep,” is an essential part of the “selective sweep model” which is 
characterized by a step-wise selection of fitter clones (Burrell and Swanton, 2014; 
Cross et al., 2016). Burrell and Swanton (2016) proposed that early divergence of the 
tumor cells might have caused recurrences of tumors. The fact that the dominant clone 
of the recurrent adenoma was already present in the primary adenoma supports this 
perspective. 
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Second, the complexity pattern, accounting for 21% of the matched pairs, showed 
a shift of the major clone population. This shift implies that the previous dominant clone 
was outcompeted as the selection pressure did not favor an expansion of the given 
clone population. It further suggests that both the tumor microenvironment and the 
growth conditions shifted which facilitated an increased ITH. These findings are in line 
with the scenario of a branched evolution (Burrell et al., 2013). Moreover, the appear-
ance of multiple clone fractions balanced in population sizes underpins the existence 
of a neutral growth as proposed by Cross et al. (2016). Taken together, evidence sug-
gests that the complexity pattern shares characteristics of the “Big Bang growth model” 
defined for CRC (Sottoriva et al., 2015). Recently, a study also demonstrated a 
branched evolution in CRC accompanied by excessive ITH via genomic and epige-
nomic assessment of spatially distant tumor regions (Uchi et al., 2016). In our study, 
pair P7 showed a distinctive feature as aneuploid clones with a 4N karyotype were 
observed in the recurrent adenoma. It implies a whole-genome duplication (WGD) in 
the process of recurrence. This WGD granted multiple advantageous growth features 
to these clones empowering them to outcompete clones with 2N karyotypes (Kuz-
netsova et al., 2015; Rutledge and Cimini, 2016). 
Third, the stabilization pattern, accounting for 36% of the matched pairs, describes 
adenoma pairs in which CNAs and clonal populations of the primary lesion have not 
changed compared to the recurrent lesion. This stability buttresses the presence of an 
evolutionary tempo termed “stasis,” according to which the tumor has adapted to the 
environment and developed a “fitness peak” (Cross et al., 2016). It was reported that 
adenomas might remain stable for years (Hofstad et al., 1996). An interesting aspect 
is added by the clonally dominant gains of EGFR and CDX2, respectively, being ex-
clusively associated with the stabilization pattern. This exclusivity might indicate that 
chromosomal aberrations comprising any of these genes provide a growth advantage 
to the clones (Lockhart et al., 2005; Salari et al., 2012). Presumably, a negative selec-
tion then penalizes clones with additional or diverging CNAs. 
Fourth, the “zero” pattern, seen in 29% of matched pairs, combined matched ade-
noma pairs which did not display clonal CNA present in more than 10% of the cells. 
The lack of CNAs further indicates that other genetic drivers might have played a role 
in the tumorigenesis of these adenomas (Snover, 2011). Nevertheless, expression of 
DNA MMR proteins was found to be retained in these samples, suggesting that the 
formation of adenomas did not occur via the MSI pathway. This microsatellite stability 
leads to the assumption that these adenomas might be affected by other driver-gene 
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mutations, e.g., affecting APC or KRAS (Vogelstein et al., 2015). However, somatic 
mutational screening was not part of this study. 
The presented identification of the clonal evolution patterns of adenoma recurrence 
seems to support and complement the emerging paradigm of an evolutionary “punctu-
ated equilibrium” in CRCs, i.e., variable tempos of stasis, gradualism, and punctuation 
(Cross et al., 2016). This notion would explain why adenomas following any of the 
shifting patterns, i.e., simplification and complexity pattern, tended to recur earlier than 
adenomas of rather stable types, i.e., stabilization and “zero” pattern. A punctuated 
evolution will show an accelerated tempo compared to a stasis (Cross et al., 2016). 
Comparing the adenoma recurrence patterns with the progression from ductal car-
cinoma in situ (DCIS) to invasive ductal carcinoma (IDC) unveils an overlap in clonal 
evolution patterns resembling the stabilization and the complexity type (Heselmeyer-
Haddad et al., 2012). Notwithstanding, the presence of neither the simplification nor 
the “zero” pattern was demonstrated in these breast lesions. An explanation is an ob-
servation that these tumors are far more progressed. This view is underpinned by the 
manifestation of utterly higher ITH measured via genomic instability index. 
The role of incomplete resection of polyps seems a critical point of this study. On 
the one hand, the identification of adenoma pairs sharing concordant clonal popula-
tions across the primary and the recurrent adenoma encourages suspicion about an 
incomplete resection of the polyps. Indeed, the study was only comprised of adenomas 
which were endoscopically completely resected. Histopathologic complete resection is 
arguably tricky to diagnose when tissue has been fragmented. This complex of prob-
lems supports a perspective in which the adenomas might have been incompletely 
resected as this is a likely assumption of recurrent adenomas (Corley et al., 2014). On 
the other hand, a body of evidence suggests that incomplete resection is not irrevoca-
bly evident in our cohort. A longer timespan of recurrence in stable versus shifting 
patterns and the exclusive association of the stabilization pattern with EGFR or CDX2 
gains argue in favor of a non-relatedness to incomplete resection. The effect of field 
cancerization affecting normal histopathological epithelium is another possible contrib-
utor to recurrence (De Maio et al., 2017). Altogether, we cannot rule out that incomplete 
resection gave rise to recurrence but do see much more molecular evidence that four 
characteristic clonal evolution patterns dominate adenoma recurrence. 
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5 SUMMARY 
Colorectal adenomas are precursors to colorectal cancer, one of the most common 
types of cancer diagnosed in both men and women in the Western world. Therefore, 
endoscopic resection of adenomatous polyps via polypectomy performed during co-
lonoscopy provides the opportunity to reduce cancer risk. However, recurrence of ad-
enomas after polypectomy is a common finding and affects one-third of the patients. 
This fact manifests both a cost and a health burden for the affected patients. For cost 
reduction and to individualize endoscopic surveillance strategies, identifying epigenetic 
and genetic alterations which predict adenoma recurrence would be of importance. 
Additionally, our knowledge of understanding the evolutionary processes of recurrence 
needs improvement. 
Here, formalin-fixed paraffin-embedded tissues of primary adenomas without recur-
rence (n=30), primary adenomas with recurrence (n=19), matched-pair samples (n=19; 
primary adenoma and corresponding recurrent adenoma) and normal epithelium (n=3) 
were collected. Global epigenetic analysis of the methylome of the colorectal adeno-
mas was conducted by Illumina’s HumanMethylation450K BeadChip array (HM450K) 
to identify differentially methylated positions (DMPs). Array validation was performed 
via pyrosequencing. The genetic landscape of copy number alterations (CNAs) was 
investigated by array-comparative genomic hybridization (aCGH) and single-cell mul-
tiplex-interphase fluorescence in situ hybridization (miFISH). This assay comprised fif-
teen probes, 14 gene probes targeting colorectal cancer-related oncogenes and tumor 
suppressor genes along with a centromere 10 probe. 
Filtering of methylation data provided 329,573 probes. Unsupervised clustering 
demonstrated an association of methylation patterns with the histologic subtype 
(P=0.008). 5,094 DMPs could be revealed across the comparisons of subgroups: 
2,824 (55.4%) DMPs were hypermethylated and 2,270 (44.6%) DMPs were hypometh-
ylated. DMPs located in CpG islands were strongly hypermethylated (86%), while 
DMPs in open sea regions and shelves were hypomethylated (83% and 79%, respec-
tively). DMP-associated genes were enriched in inflammatory- and cancer-related 
pathways such as the MAPK signaling pathway, for instance. DMP discovery unveiled 
panels of 35 and 347 top gene DMPs across recurrent adenomas versus primary ad-
enomas with recurrence and adenomas versus normal epithelium, respectively. De-
spite that, no DMPs could be identified across primary adenomas with and without 
recurrence. Array validation via pyrosequencing used the methylation of the GREM2 
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gene. The genetic landscape of adenomas unveiled by aCGH exhibited typical CNAs 
in colorectal tumorigenesis: chromosomes 7, 13q, 18 and 20. Most frequent focal ab-
errations (≤10 Mb) were located on 6p22.1-p21.33 (33.3%), 7q22.1 (31.4%) and 16q21 
(29.4%). Single-cell miFISH showed frequent copy number gains within the colorectal 
adenomas affecting the markers EGFR (23.6%), CDX2 (21.8%) and ZNF217 (18.2%). 
Remarkably, copy number gains of CDX2 were exclusively observed in primary ade-
nomas with recurrence (25%) and recurrent adenomas (38.5%), while this CNA was 
absent in primary adenomas without recurrence (0%). The presence of major clone 
(defined as >40%) populations (average size 62.8%) accompanied by multiple minor 
clones was present in most adenomas (52.7%). While few adenomas were mainly 
composed of diploid cells (29.1%), a few adenomas were highly heterogeneous with-
out a major clone population (16.4%) as confirmed by four quantitative diversity 
measures. Inferring of phylogenetic trees unraveled four distinct patterns of clonal evo-
lution from primary adenomas towards recurrent adenomas: simplification pattern, 
complexity pattern, stability pattern and zero pattern. Noteworthy, copy numbers de-
tected by aCGH and miFISH were concordant in 97.3% of observations (κ=0.861). 
Collectively, the findings underpin that adenoma development and recurrence are 
complex processes orchestrated by genetic and epigenetic alterations. Whereas CpG 
methylation patterns appeared to be inconclusive for adenoma recurrence, the evalu-
ation of CNAs affecting CDX2 in single cells via miFISH might bear potential as a pre-
dictor of recurrence. 
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7 SUPPLEMENTARY TABLES 
Supplemental Table 1. BAC clone contig probe panels for miFISH. 
Panel Fluorophore Gene Locus BAC clone Build (UCSC) 
Gene 
location 
Start Stop Total bp 
Contig 
size° 
I 
DY-415-
dUTP (Dyom-
ics) 
MYC 8q24.21 
RP11-1136L8 GRCh37/hg19 
128,748,315 
-
128,753,680 
128,555,811 128,714,938 159,128 
694,889 
CTD-3056O22 GRCh37/hg19 128,660,772 128,808,586 147,815 
RP11-55J15 GRCh37/hg19 128,870,291 129,064,392 194,102 
RP11-709E21 NCBI 37/hg3 129,154,373 129,250,700 96,328 
DY-505-
dUTP 
(Dyomics) 
CCND1 11q13.3 
CTD-2507F7 GRCh37/hg19 
69,228,803 
-69,242,171 
69,332,248 69,523,715 191,468 
664,147 RP11-300I6 GRCh37/hg19 69,453,281 69,614,785 161,505 
RP11-186D19 NCBI 37/hg3 69,846,911 69,996,395 149,485 
DY-547-
dUTP 
(Dyomics) 
SMAD4 18q21.2 
CTD-3236H18 GRCh37/hg19 
48,494,387 
-48,584,614 
48,285,441 48,479,444 194,004 
349,039 
RP11-729G3 GRCh37/hg19 48,478,296 48,634,480 156,185 
DY-590-
dUTP 
(Dyomics) 
CDX2 13q12.2 
RP11-328P22 GRCh37/hg19 
28,536,274 
-28,543,505 
28,488,636 28,517,161 28,526 
297,570 RP11-136G6 GRCh37/hg19 28,502,226 28,683,446 181,221 
RP11-486I19 GRCh37/hg19 28,629,619 28,786,206 156,588 
DY-651-
dUTP 
(Dyomics) 
PIK3CA 3q26.32 
RP11-355N16 GRCh37/hg19 178,866,311 
- 
178,952,497 
178,711,249 178,905,842 194,594 
554,087 RP11-245C23 GRCh37/hg19 178,830,412 179,014,819 184,408 
RP11-145M9 GRCh37/hg19 179,091,279 179,265,336 174,058 
II 
DY-415-
dUTP 
(Dyomics) 
EGFR 7p11.2 
RP11-23F4 GRCh37/hg19 55,086,725 
- 
55,275,031 
54,912,535 55,082,244 169,710 
506,308 RP11-815K24 GRCh37/hg19 55,049,736 55,246,161 196,426 
RP11-97C21 GRCh37/hg19 55,239,327 55,418,843 179,517 
DY-505-
dUTP 
(Dyomics) 
COX2 
(PTGS2) 
1q31.1 
RP11-1149C23 GRCh37/hg19 186,640,944 
- 
186,649,559 
186,290,778 186,428,689 137,912 
503,451 CTD-2509N15 GRCh37/hg19 186,448,188 186,651,391 203,204 
RP11-809N5 GRCh37/hg19 186,606,706 186,794,229 187,524 
DY-547-
dUTP 
(Dyomics) 
APC 5q22.2 
RP11-159K7 GRCh37/hg19 112,043,202 
- 
112,181,936 
111,842,788 112,021,220 178,433 
467,340 RP11-124K18 GRCh37/hg19 112,014,487 112,198,755 184,269 
RP11-1104F23 GRCh37/hg19 112,134,536 112,310,128 175,593 
DY-590-
dUTP 
(Dyomics) 
CLIC1 6p21.33 
RP11-184F16 GRCh38/hg38 31,698,358 
- 
31,704,341 
31,437,976 31,628,870 190,895 
535,964 RP11-1104F14 GRCh38/hg38 31,627,621 31,797,832 170,212 
CTD-2652P14 GRCh38/hg38 31,757,045 31,973,940 216,896 
DY-651-
dUTP 
(Dyomics) 
SMAD7 18q21.1 
RP11-164C15 GRCh37/hg19 46,446,223 
- 
46,469,177 
46,182,137 46,332,593 150,457 
505,472 RP11-956P18 GRCh37/hg19 46,357,409 46,552,744 195,336 
RP11-15F12 GRCh37/hg19 46,516,511 46,687,609 171,099 
III 
DY-415-
dUTP 
(Dyomics) 
ZNF217 20q13.2 
RP4-669H2 GRCh37/hg19  51,617,017 
- 
51,633,043 
51,901,748 52,021,567 119,820 
465,525 RP11-299B10 GRCh37/hg19 52,026,197 52,239,348 213,152 
CTD-2573N1 GRCh37/hg19 52,228,296 52,367,273 138,978 
DY-505-
dUTP 
(Dyomics) 
CDH1 16q22.2 
RP11-615I2 NCBI 37/hg3 68,771,195 
- 
68,869,444 
68,576,846 68,693,621 116,776 
344,455 RP11-354M1 NCBI 37/hg3 68,693,622 68,875,324 181,703 
RP11-354N7 GRCh37/hg19 68,761,021 68,921,301 160,281 
DY-547-
dUTP 
(Dyomics) 
TP53 17p13.1 
CTD-3028L6 GRCh37/hg19 
7,512,469 - 
7,531,642 
7,420,243 7,596,553 176,311 
382,551 RP11-89D11 GRCh37/hg19 7,495,729 7,663,042 167,314 
RP11-709J3 GRCh37/hg19 7,631,225 7,802,794 171,570 
DY-590-
dUTP 
(Dyomics) 
HER2 
(ERBB2) 
17q12 
RP11-94L15 GRCh37/hg19 37,856,254 
- 
37,884,915 
37,811,809 37,973,609 161,801 
425,589 CTD-3211L18 GRCh37/hg19 37,953,501 38,194,528 241,028 
CTD-2248E4 GRCh37/hg19 38,115,365 38,237,398 122,034 
CCP10 (Cy-
toTest) 
CEP10 10 
      
        
Clones covering the gene are marked in bold. 
°Length in base pairs (bp). Contig size is defined by stop-base of the distal clone minus start-base of the proximal clone. 
Locations were depicted from Genome Browser (https://ucsc.genome.edu) and BAC clones were provided by BACPAC Resources 
Center (http://bacpacresources.org). 
 
  
Supplementary Tables 
182 
Supplemental Table 2. List of 35 top genes-DMPs of comparison A. Listed are genes with q≤0.05, 
fold change >10% and absolute change ≥|0.1|. Sex-chromosome probes were excluded. ●, more than 
one probe was significant within this gene. 
CpG ID β-value 
Recurrent 
adenomas 
β-value 
Primary 
ade-
nomas 
Fold 
change 
Abso-
lute 
change 
P-value Q-value 
(adjusted 
P-value) 
Chr. Coordinate Gene  
symbol 
(UCSC) 
Methylation 
status 
Gene 
 region 
(UCSC) 
Relation to 
CGI (UCSC) 
cg07362278 0.728 0.623 1.168 0.105 1.61E-08 0.002 19 45737011 EXOC3L2 hypermeth. 5'UTR N shore 
cg17263323 0.649 0.535 1.213 0.114 4.42E-07 0.007 4 5238459 STK32B hypermeth. Body Open sea 
cg14796563 0.791 0.655 1.206 0.135 5.89E-06 0.017 19 1287576 EFNA2 hypermeth. Body Island 
cg17001652 0.615 0.513 1.198 0.101 1.36E-05 0.022 4 78432403 CXCL13 hypermeth. TSS1500 Open sea 
cg01452189 0.603 0.492 1.227 0.112 1.60E-05 0.023 16 25189426 LCMT1 hypermeth. 3'UTR Open sea 
cg19880608 0.714 0.605 1.181 0.110 2.97E-05 0.025 5 112568208 MCC hypermeth. Body Open sea 
cg24671202 0.589 0.416 1.416 0.173 3.45E-05 0.026 6 116938100 RSPH4A hypermeth. 1stExon Open sea 
cg01809217 0.716 0.613 1.169 0.103 3.93E-05 0.026 1 240656342 GREM2▪ hypermeth. Body Island 
cg14847483 0.589 0.456 1.291 0.133 4.93E-05 0.027 15 34516640 TMEM85▪ hypermeth. TSS1500 Open sea 
cg07573078 0.667 0.560 1.191 0.107 5.34E-05 0.028 1 207626214 CR2 hypermeth. TSS1500 N shore 
cg03206537 0.455 0.350 1.300 0.105 6.24E-05 0.028 20 44521739 CTSA hypermeth. Body S shore 
cg26699569 0.497 0.377 1.319 0.120 6.96E-05 0.030 4 81952653 BMP3 hypermeth. 1stExon Island 
cg06402590 0.671 0.568 1.182 0.103 7.18E-05 0.030 16 2820155 SRRM2 hypermeth. Body S shelf 
cg12301695 0.569 0.454 1.255 0.116 8.27E-05 0.030 2 165812159 SLC38A11 hypermeth. TSS200 Open sea 
cg16895026 0.693 0.569 1.218 0.124 7.90E-05 0.030 4 30745743 PCDH7 hypermeth. Body Open sea 
cg25198275 0.645 0.524 1.232 0.122 8.09E-05 0.030 12 29650692 OVCH1 hypermeth. TSS200 Open sea 
cg08496964 0.595 0.495 1.203 0.100 1.14E-04 0.032 16 8729419 C16orf68 hypermeth. Body Open sea 
cg24553547 0.755 0.654 1.154 0.101 1.22E-04 0.032 17 19247920 MIR1180 hypermeth. TSS200 Island 
cg00608965 0.629 0.506 1.243 0.123 1.33E-04 0.033 12 91572191 DCN hypermeth. 1stExon Open sea 
cg01946191 0.473 0.373 1.270 0.101 1.52E-04 0.035 12 54444463 HOXC4 hypermeth. 5'UTR N shore 
cg00606880 0.607 0.505 1.203 0.102 1.91E-04 0.037 10 63213784 TMEM26 hypermeth. TSS1500 S shore 
cg12949483 0.589 0.477 1.233 0.111 2.28E-04 0.039 15 34516777 TMEM85▪ hypermeth. TSS1500 Open sea 
cg22758700 0.053 0.178 0.295 -0.125 2.26E-04 0.039 7 99156126 ZNF655 hypometh. TSS1500 Island 
cg08325898 0.737 0.623 1.184 0.114 2.50E-04 0.040 8 71096899 NCOA2 hypermeth. Body Open sea 
cg23629643 0.680 0.579 1.174 0.101 2.47E-04 0.040 4 77547320 SHROOM3 hypermeth. Body Open sea 
cg11612852 0.707 0.597 1.185 0.110 3.09E-04 0.042 4 21699745 KCNIP4 hypermeth. 5'UTR Open sea 
cg17078427 0.473 0.354 1.336 0.119 3.57E-04 0.044 3 170137552 CLDN11 hypermeth. Body Island 
cg24811290 0.579 0.477 1.213 0.102 3.58E-04 0.044 4 159092553 FAM198B hypermeth. 5'UTR Open sea 
cg17423207 0.411 0.309 1.331 0.102 3.79E-04 0.044 19 17958892 JAK3 hypermeth. TSS200 S shore 
cg18411108 0.494 0.382 1.295 0.112 3.91E-04 0.045 3 63955727 ATXN7 hypermeth. Body Open sea 
cg04391463 0.642 0.533 1.205 0.109 3.97E-04 0.045 1 240656667 GREM2▪ hypermeth. Body Island 
cg09826050 0.691 0.557 1.240 0.134 4.19E-04 0.046 1 217310174 ESRRG hypermeth. 5'UTR N shore 
cg04845649 0.647 0.544 1.190 0.103 4.37E-04 0.046 16 67199463 HSF4 hypermeth. Body Island 
cg02577267 0.781 0.680 1.148 0.101 5.30E-04 0.048 1 240656513 GREM2▪ hypermeth. Body Island 
cg19063972 0.576 0.426 1.351 0.150 5.59E-04 0.049 13 95364908 SOX21 hypermeth. TSS1500 Island 
 
 
Supplemental Table 3. List of 7 top genes-DMPs of comparison B. Listed are genes with q≤0.05, 
fold change >10% and absolute change ≥|0.05|. Sex-chromosome probes were excluded. 
CpG ID β-value 
Recurrent 
adenomas 
β-value 
Primary  
adenomas 
Fold 
change 
Absolute 
change 
P-value Q-value 
(ad-
justed  
P-value) 
Chr. Coordi-
nate 
Gene  
symbol 
(UCSC) 
Methylation 
status 
Gene re-
gion 
(UCSC) 
Relation to 
CGI 
(UCSC) 
cg07362278 0.728 0.646 1.127 0.082 9.06E-09 0.001 19 45737011 EXOC3L2 hypermeth. 5'UTR N shore 
cg17263323 0.649 0.566 1.146 0.082 1.22E-06 0.008 4 5238459 STK32B hypermeth. Body Open sea 
cg09635768 0.581 0.525 1.107 0.056 7.18E-06 0.018 1 8601318 RERE hypermeth. Body Open sea 
cg13771471 0.582 0.525 1.110 0.057 1.23E-05 0.022 10 1505595 ADARB2 hypermeth. Body N shore 
cg22177309 0.659 0.591 1.115 0.068 3.00E-05 0.033 19 48260285 GLTSCR2 hypermeth. 3'UTR Open sea 
cg22758700 0.053 0.141 0.374 -0.088 4.44E-05 0.036 7 99156126 ZNF655▪ hypometh. TSS1500 Island 
cg21950525 0.118 0.200 0.591 -0.082 5.79E-05 0.040 7 99155767 ZNF655▪ hypometh. TSS1500 N shore 
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Supplemental Table 4. List of best-50 top genes-DMPs of comparison C. Listed are genes with 
q≤0.001, fold change >10% and absolute change ≥|0.1|. Sex-chromosome probes were excluded. Total 
number of DMPs in this comparison were 347. ●, more than one probe was significant within this gene.  
CpG ID β-value 
Recurrent 
adenomas 
β-value 
Primary a-
denomas 
Fold 
change 
Abso-
lute 
change 
P-value Q-value 
(adjusted 
P-value) 
Chr Coordinate Gene symbol 
(UCSC) 
Methyla-
tion status 
Gene re-
gion 
(UCSC) 
Relation 
to CGI 
(UCSC) 
cg16879115 0.275 0.421 0.654 -0.146 3.18E-27 8.64E-22 12 7819180 APOBEC1 hypometh. TSS1500 Open sea 
cg19378216 0.369 0.524 0.704 -0.155 1.77E-25 1.61E-20 20 31870775 C20orf114 hypometh. TSS200 Open sea 
cg07074042 0.366 0.504 0.727 -0.138 3.87E-23 2.63E-18 22 30783944 RNF215 hypometh. TSS1500 S shore 
cg23875663 0.329 0.447 0.735 -0.118 4.93E-23 2.68E-18 20 17299350 PCSK2 hypometh. Body S shelf 
cg02265239 0.336 0.467 0.721 -0.130 9.73E-23 4.41E-18 14 59748448 DAAM1 hypometh. Body Open sea 
cg25730020 0.458 0.586 0.781 -0.128 1.13E-21 3.40E-17 18 56701518 LOC390858 hypometh. TSS1500 Open sea 
cg15676837 0.646 0.771 0.838 -0.125 7.45E-20 1.28E-15 1 202137199 PTPRV hypometh. Body Open sea 
cg08590987 0.484 0.586 0.825 -0.102 1.02E-18 1.27E-14 8 110702751 GOLSYN hypometh. 5'UTR N shore 
cg01156373 0.435 0.545 0.798 -0.110 1.87E-17 1.54E-13 2 213248884 ERBB4 hypometh. Body Open sea 
cg23696618 0.426 0.537 0.793 -0.111 2.37E-17 1.74E-13 18 61583699 SERPINB10 hypometh. Body Open sea 
cg14479014 0.495 0.621 0.798 -0.125 3.20E-17 2.23E-13 6 49460031 CENPQ hypometh. 3'UTR Open sea 
cg02320784 0.619 0.752 0.822 -0.134 4.54E-17 2.94E-13 12 26195988 RASSF8 hypometh. 5'UTR Open sea 
cg13302785 0.191 0.323 0.592 -0.132 1.19E-16 6.90E-13 3 51104051 DOCK3 hypometh. Body Open sea 
cg12768447 0.465 0.616 0.755 -0.151 2.24E-16 1.22E-12 10 69425930 CTNNA3 hypometh. TSS1500 Open sea 
cg15651267 0.470 0.590 0.797 -0.120 3.92E-16 2.01E-12 5 167028535 ODZ2 hypometh. Body Open sea 
cg13455326 0.283 0.394 0.718 -0.111 5.68E-16 2.71E-12 19 10043341 OLFM2 hypometh. Body N shelf 
cg15133719 0.624 0.507 1.231 0.117 7.64E-16 3.53E-12 2 223163804 PAX3▪ hypermeth TSS200 Island 
cg23530543 0.512 0.621 0.824 -0.110 9.70E-16 4.19E-12 11 124788414 HEPN1 hypometh. TSS1500 N shelf 
cg01687040 0.283 0.391 0.724 -0.108 3.46E-15 1.21E-11 12 55043559 DCD hypometh. TSS1500 Open sea 
cg07000713 0.328 0.439 0.747 -0.111 7.19E-15 2.22E-11 12 62463441 FAM19A2 hypometh. 5'UTR Open sea 
cg06119894 0.408 0.282 1.448 0.126 1.00E-14 2.75E-11 11 105480347 GRIA4 hypermeth TSS1500 N shore 
cg24242823 0.574 0.441 1.299 0.132 1.01E-14 2.75E-11 7 24323675 NPY hypermeth TSS200 Island 
cg10075287 0.513 0.619 0.829 -0.106 2.07E-14 4.94E-11 2 180727677 ZNF385B hypometh. TSS1500 S shore 
cg11019211 0.526 0.366 1.436 0.160 2.47E-14 5.42E-11 17 56833043 PPM1E hypermeth TSS200 Island 
cg07999090 0.456 0.562 0.810 -0.107 2.77E-14 6.02E-11 13 28882299 FLT1 hypometh. Body Open sea 
cg06186245 0.429 0.570 0.752 -0.142 5.57E-14 1.09E-10 3 100245062 TMEM45A hypometh. 5'UTR Open sea 
cg21049958 0.338 0.442 0.764 -0.104 6.00E-14 1.16E-10 19 42134128 CEACAM4 hypometh. TSS1500 Open sea 
cg26929012 0.409 0.264 1.548 0.145 1.09E-13 1.89E-10 19 57988860 ZNF772 hypermeth 1stExon Open sea 
cg26822330 0.607 0.710 0.855 -0.103 1.22E-13 2.10E-10 13 36867876 C13orf38▪ hypometh. Body N shelf 
cg07784084 0.417 0.518 0.804 -0.101 1.48E-13 2.43E-10 3 26751141 LRRC3B hypometh. 5'UTR Open sea 
cg03646889 0.516 0.402 1.284 0.114 2.30E-13 3.46E-10 1 99729807 LPPR4 hypermeth TSS200 N shore 
cg01866434 0.612 0.718 0.852 -0.106 2.89E-13 4.23E-10 5 55479377 ANKRD55 hypometh. Body Open sea 
cg24389611 0.624 0.761 0.821 -0.136 7.56E-13 9.61E-10 4 39056150 KLHL5 hypometh. 5'UTR Open sea 
cg13464924 0.350 0.234 1.500 0.117 1.38E-12 1.61E-09 1 190447603 FAM5C hypermeth TSS1500 Open sea 
cg17735563 0.557 0.701 0.794 -0.145 1.70E-12 1.96E-09 2 33738079 RASGRP3 hypometh. 5'UTR Open sea 
cg22545168 0.314 0.417 0.753 -0.103 1.73E-12 1.98E-09 19 54866514 LAIR1 hypometh. 3'UTR Open sea 
cg21983531 0.491 0.616 0.797 -0.125 3.63E-12 3.70E-09 7 74075317 GTF2I hypometh. 5'UTR S shelf 
cg16545821 0.470 0.585 0.802 -0.116 6.16E-12 5.74E-09 1 204118840 ETNK2 hypometh. Body N shore 
cg06577005 0.484 0.375 1.290 0.109 6.28E-12 5.81E-09 1 26758228 DHDDS hypermeth TSS1500 N shore 
cg13888600 0.485 0.381 1.272 0.104 1.26E-11 1.04E-08 15 89911317 MIR9-3 hypermeth Body Island 
cg10208609 0.595 0.696 0.856 -0.100 1.62E-11 1.27E-08 1 90331229 LRRC8D hypometh. 5'UTR Open sea 
cg08567913 0.590 0.732 0.807 -0.141 1.94E-11 1.49E-08 11 114082594 ZBTB16 hypometh. Body Open sea 
cg08638917 0.520 0.641 0.811 -0.121 2.12E-11 1.59E-08 16 58299153 CCDC113 hypometh. Body Open sea 
cg14544666 0.526 0.414 1.273 0.113 2.59E-11 1.89E-08 5 179634789 RASGEF1C hypermeth 5'UTR Island 
cg10201297 0.466 0.279 1.667 0.186 2.69E-11 1.94E-08 1 32930832 ZBTB8B hypermeth 5'UTR Island 
cg08321129 0.587 0.451 1.300 0.136 2.79E-11 1.99E-08 13 78493878 EDNRB▪ hypermeth TSS1500 S shore 
cg00341204 0.676 0.776 0.871 -0.100 3.11E-11 2.17E-08 19 11520483 RGL3 hypometh. Body S shelf 
cg14154381 0.453 0.560 0.808 -0.108 3.41E-11 2.33E-08 15 25476386 
SNORD115-
15 
hypometh. Body Open sea 
cg04658772 0.466 0.317 1.469 0.149 3.81E-11 2.56E-08 16 77822433 VAT1L hypermeth TSS200 Island 
cg13780718 0.316 0.467 0.676 -0.152 4.69E-11 3.00E-08 20 44513768 ZSWIM1 hypometh. 3'UTR Open sea 
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Supplemental Table 5. ASNs per miFISH gene marker in matched pair-samples. ASNs represent 
the mean signal count per probe of the total number of analyzed nuclei within the respective sample.  
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P 1a 2.00 2.00 2.00 2.16 2.00 2.00 2.02 3.23 2.00 1.99 2.04 2.01 1.99 2.01 
P 1b 2.00 2.00 1.98 2.04 2.00 2.00 2.02 3.75 2.00 1.98 2.00 2.00 2.00 1.98 
P 2a 2.00 2.01 2.00 2.02 2.00 2.00 2.00 2.01 1.99 1.97 2.00 1.99 1.99 2.00 
P 2b 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.04 2.00 2.00 2.00 2.00 1.99 2.00 
P 3a 2.00 2.00 2.00 2.01 2.00 2.00 2.00 2.00 1.96 1.99 2.00 1.99 1.99 2.00 
P 3b 2.02 2.11 2.05 2.18 2.22 2.09 2.04 2.24 2.16 2.07 2.11 2.00 2.00 2.19 
P 4a 2.00 2.00 2.15 2.03 2.23 2.26 2.00 2.32 2.08 1.51 2.27 2.19 2.18 2.61 
P 4b 1.99 2.00 1.98 2.01 2.00 2.00 2.00 2.03 2.01 1.61 2.15 2.00 2.00 2.01 
P 5a 2.00 2.00 1.99 1.99 2.05 2.00 2.00 2.05 1.99 1.98 2.00 1.99 1.99 2.00 
P 5b 1.99 2.00 1.99 2.00 2.00 2.00 2.00 2.01 2.00 2.00 2.00 2.01 2.00 2.01 
P 6a 2.00 1.99 2.00 2.04 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 
P 6b 2.00 2.00 1.98 2.01 2.00 2.00 2.00 2.01 1.99 1.98 1.99 2.00 2.00 2.00 
P 7a 1.99 2.00 2.01 2.01 2.83 2.01 2.00 2.00 2.00 1.99 2.00 2.02 2.00 2.04 
P 7b† 2.76 3.04 3.52 3.57 3.57 3.57 2.80 3.57 2.72 3.49 3.59 2.75 2.74 3.57 
P 8a 2.01 2.00 2.00 2.04 2.01 2.01 2.01 2.02 1.98 2.00 2.01 2.01 2.01 2.01 
P 8b 2.00 2.00 1.99 2.01 2.00 2.00 2.00 2.00 1.16 2.00 2.00 2.00 2.00 2.00 
P 9a 1.99 1.98 2.00 2.00 2.00 2.01 1.99 2.92 2.00 2.00 2.00 2.00 2.00 2.00 
P 9b 1.96 1.97 1.95 2.01 2.00 2.00 1.99 2.92 1.99 2.00 2.01 1.99 1.99 2.00 
P 10a 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.40 2.00 1.64 2.00 1.60 1.60 2.39 
P 10b 2.00 2.00 2.18 2.00 2.00 2.00 2.00 2.26 2.00 1.76 2.00 1.74 1.74 2.24 
P 11a 2.00 2.00 2.00 2.00 2.77 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.02 2.06 
P 11b 2.00 2.00 2.00 2.01 2.84 2.00 2.00 2.01 2.00 2.00 2.00 2.00 2.01 2.01 
P 12a 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 
P 12b 2.00 2.00 2.00 2.00 2.00 2.00 2.00 2.00 1.99 2.00 2.00 2.00 2.00 2.00 
P 13a 2.00 2.00 2.00 2.01 2.00 2.00 2.00 2.90 2.00 2.00 2.00 2.00 2.00 2.86 
P 13b 2.00 1.99 1.99 2.01 2.00 2.00 2.00 2.87 2.01 2.00 2.00 2.00 2.00 2.85 
P 14a 2.00 2.01 2.00 2.01 2.00 2.00 2.00 2.00 2.00 2.00 2.01 2.00 2.00 2.00 
P 14b 2.00 1.99 2.00 2.00 2.00 2.00 2.00 2.00 2.00 1.99 2.01 1.97 2.00 2.00 
†, excluded from analysis; green, CN gain detected in more than 10% of the total number of nuclei; red, CN loss 
detected in more than 10% of the total number of nuclei. 
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Supplemental Table 6. Correlation matrix of ASNs and clinicopathological features. Observed 
average signal numbers of the gene markers were correlated with the clinicopathological data using 
Spearman rank correlation coefficient. 
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Age at diagnosis 0.775 0.898 0.588 0.465 0.572 0.209 0.685 0.107 0.202 0.425 0.703 0.946 0.341 0.113
Age  (dichot. median=67y) 0.426 0.989 0.581 0.793 0.582 0.170 0.339 0.491 0.103 0.189 0.677 0.845 0.375 0.294
CN change  (yes vs no) 0.809 0.563 0.142 0.005 0.001 0.209 0.102 0.021 0.005 0.680 0.850 0.013 0.149 0.000
Gender (F vs M) 0.171 0.693 0.385 0.919 0.719 0.599 0.524 0.323 0.384 0.308 0.459 0.097 0.091 0.337
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Localization (Cecum, 
Ascendens, Transverse, 
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Recurrence  (time in months) 0.656 0.408 0.708 0.549 0.600 0.126 0.563 0.116 0.006 0.277 0.038 0.696 0.743 0.956
Recurrence (yes vs no) 0.652 0.033 0.822 0.587 0.070 0.244 0.460 0.790 0.132 0.302 0.084 0.071 0.025 0.823
Supplementary Tables 
186 
Figure 16. GREM2 gene card and representative “pyrogram”. 
Figure 17. miFISH probe panel 1. 
Figure 18. miFISH probe panel 2. 
Figure 19. miFISH probe panel 3. 
Figure 20. Exemplarily translation of probe signal counts into gain and loss signal pattern dis-
plays. 
Figure 21. A representative example of a signal pattern miFISH tree. 
Figure 22. DNA methylation in colorectal adenomas: PCA, cluster analysis, and correlations. 
Figure 23. Scatter plot distribution of DMPs identified by HM450K. 
Figure 24. Venn-diagram and distribution of DMPs by multiple comparisons. 
Figure 25. Distribution of DMPs by genome localizations and chromosomes. 
Figure 26. Distribution of DMPs according to pathway analysis/gene ontology. 
Figure 27. CpG methylation validation by pyrosequencing. 
Figure 28. GREM2 gene body methylation in colorectal adenoma subgroups. 
Figure 29. CNAs detected by aCGH. 
Figure 30. Chromosomal aberrations in colorectal adenomas identified by aCGH. 
Figure 31. Chromosomal aberrations in primary colorectal adenomas without and with recur-
rence. 
Figure 32. CNAs detected by aCGH correlate with the localization of the primary adenomas. 
Figure 33. Heatmap of CNAs in colorectal adenomas detected by aCGH. 
Figure 34. Heatmap cluster group correlations. 
Figure 35. Comparison of chromosomal aberrations in matched adenoma pairs. 
Figure 36. Representative image of a colorectal adenoma nucleus hybridized by miFISH. 
Figure 37. CNAs in colorectal adenomas identified by miFISH. 
Figure 38. Summary of color displays of signal pattern clones in primary colorectal adenomas 
without recurrence (n=15). 
Figure 39. Summary of color displays of signal pattern clones in primary colorectal adenomas 
with recurrence (n=15). 
Figure 40. Summary of color displays of signal pattern clones in match-paired colorectal ade-
nomas (Part I). 
Figure 41. Summary of color displays of signal pattern clones in match-paired colorectal ade-
nomas (Part II). 
Figure 42. Summary of color displays of signal pattern clones in match-paired colorectal ade-
nomas (Part III). 
Figure 43. Summary of color displays of signal pattern clones in match-paired colorectal ade-
nomas (Part IV). 
Figure 44. Summary of color displays of signal pattern clones in match-paired colorectal ade-
nomas (Part V). 
Figure 45. Average gain and loss frequencies of all miFISH gene markers. 
Figure 46. Average signal numbers of miFISH markers in colorectal adenomas. 
Figure 47. CNAs in primary adenomas without and with recurrence. 
Figure 48. Heatmap clustering of 55 colorectal adenomas by CNAs of miFISH. 
Figure 49. Clonal populations and instability indices of colorectal adenomas. 
Figure 50. Tumor heterogeneity assessed by Shannon and Simpson diversity indices. 
Figure 51. Tumor heterogeneity assessed by genetic distance. 
Figure 52. ASNs in match-paired adenomas. 
Figure 53. Phylogenetic trees of simplification pattern-adenomas. 
Figure 54. Phylogenetic tree of complexity pattern-adenoma P3. 
Figure 55. Phylogenetic trees of complexity pattern-adenomas. 
Figure 56. Phylogenetic trees of stabilization pattern-adenomas. 
Figure 57. Schematic presentations of the stabilization and “zero” clonal evolution patterns. 
Figure 58. Tree-levels and clonal evolution patterns in matched pairs. 
Figure 59. Correlations of clinical features in colorectal adenomas. 
Figure 60. Correlations of clinical features and CNAs detected by miFISH. 
Figure 61. Correlation matrix of copy number results by aCGH and miFISH. 
Figure 62. Immunohistochemical detection of MMR proteins in colorectal adenomas. 
Figure 63. CDX2 immunostaining of primary colorectal adenomas. 
Supplementary Tables 
187 
List of tables 
Table 1. Guidelines for post-polypectomy surveillance. 
Table 2. List of kits. 
Table 3. List of consumables. 
Table 4. List of reagents and chemicals. 
Table 5. List of technical equipment. 
Table 6. List of software and databases. 
Table 7. Clinicopathological features of specimens of the adenoma cohort. 
Table 8. Patient groups. 
Table 9: Thermal profile real-time-PCR.  
Table 10. Bisulfite reaction setup. 
Table 11: Thermal profile bisulfite conversion. 
Table 12. Pyrosequencing primers for pre-PCR and sequencing. 
Table 13: Pyrosequencing pre-PCR setup. 
Table 14: Thermal profile pyrosequencing pre-PCR. 
Table 15. aCGH labeling master mix. 
Table 16. aCGH hybridization master mix. 
Table 17. Nick translation input volumes per probe clone. 
Table 18. Large-scale DNA precipitation scheme. 
Table 19. Criteria for an exclusion of nuclei from the miFISH analysis. 
Table 20. Significant differentially methylated CpG positions (DMPs) in adenoma groups. 
Table 21. Summary of copy number alterations detectable by aCGH. 
Table 22. Differential CNAs in primary adenomas without and with recurrence. 
Table 23. Clinicopathological features of primary adenomas without and with recurrence. 
Table 24. Statistical evaluation of ASNs of miFISH analysis on adenomas. 
Table 25. Aberration frequencies detected by miFISH. 
Table 26. Signal patterns of the largest aberrant clone populations and instability indices. 
Table 27. IHC of DNA MMR proteins in colorectal adenomas. 
 
Supplemental Table 1. BAC clone contig probe panels for miFISH. 
Supplemental Table 2. List of 35 top genes-DMPs of comparison A. 
Supplemental Table 3. List of 7 top genes-DMPs of comparison B. 
Supplemental Table 4. List of best-50 top genes-DMPs of comparison C. 
Supplemental Table 5. ASNs per miFISH gene marker in matched pair-samples. 
Supplemental Table 6. Correlation matrix of ASNs and clinicopathological features. 
 
List of formulas 
Formula (1): Average threshold cycles. 
Formula (2): Delta threshold cycles. 
Formula (3): Signal intensity. 
Formula (4): Degree of labeling. 
Formula (5): Specific activity. 
Formula (6): Yield. 
Formula (7): Genomic instability index. 
Formula (8): Shannon entropy. 
Formula (9): Simpson diversity index. 
Formula (10): Accumulated pairwise genetic diversity. 
  
Curriculum Vitae 
188 
8 CURRICULUM VITAE 
Personal details 
 
Name and surname: David Fiedler 
Date of birth: August 9th, 1985 
Place of birth: Berlin-Friedrichshain (Germany) 
Marital status: Single 
Father: Thorsten Andreas Fiedler 
Mother: Susanne Moesner (née Hertel) 
 
 
Education 
 
1992 – 1995 
Elementary school: 
Grundschule am Brandenburger Tor, Berlin-Mitte (Germany) 
1995 – 1998 
Elementary school: 
Otfried-Preußler-Grundschule, Großbeeren (BRB, Germany) 
1998 – 2005 
Comprehensive secondary school: 
Peter-Joerres-Gymnasium, Ahrweiler (RLP, Germany) 
Mar. 12th, 2005 Abitur (ø 1.6) 
 
 
Academic education 
 
Fall semester 
2005/2006 
Start of studies in Biology at the Rheinisch-Westfälisch Tech-
nische Hochschule (RWTH) Aachen (NRW, Germany) 
Sep. 24th, 2007 
Graduation of the basic study period:  
intermediate diploma (mark: good) 
2007 – 2011 Advanced study period 
Apr. – Oct. 2010 
Research internship at the Cell and Molecular Biology Group, 
NTNU Trondheim (Norway) 
(“Allyl iso-thiocyanate affects beta-tubulin in A.thaliana”) 
2011 
Diploma thesis at the Institute of Pathology, University Hospital 
Aachen (“Characterization of the DNA methylation of ECRG4 
and EDN3 as biomarkers in human bladder cancer“) 
Sep. 19th, 2011 Diploma (mark: excellent) 
2012 - 
Start of doctorate studies at the Institute of Pathology, Univer-
sity Hospital Mannheim, Heidelberg University (Germany) 
  
Proof of publication 
189 
9 PROOF OF PUBLICATION 
D. Fiedler, K. Heselmeyer-Haddad, D. Hirsch, L. Hernandez, I. Torres, D. Wangsa, Y. 
Hu, L. Zapata, J. Rüschoff, S. Belle, T. Ried, and T. Gaiser 
“Single-cell genetic analysis of clonal dynamics in colorectal adenomas indicates 
CDX2 gain as a predictor of recurrence” 
Publication; Epub: 19.09.2018; 
Volume 144, Issue 7, pp.1561-1573, 01.04.2019; DOI: 10.1002/ijc.31869 
International Journal of Cancer, Germany (IF-2017: 7.36) 
 
D. Fiedler, K. Heselmeyer-Haddad, D. Hirsch, L. Hernandez, I. Torres, S. Belle, T. 
Ried, and T. Gaiser 
“Genomische Instabilität in rezidivierenden und nicht-rezidivierenden Kolonadenomen” 
101. Annual Meeting of the German Society of Pathology (Deutsche Gesellschaft für 
Pathologie, DGP) 
Oral Presentation; June 22nd – 24th, 2017 
Heinrich Lades Halle, Erlangen (BY), Germany 
 
D. Fiedler, K. Heselmeyer-Haddad, D. Hirsch, L. Hernandez, I. Torres, S. Belle, T. 
Ried, and T. Gaiser 
“Genomic Instability in Colorectal Adenomas with and without Recurrence” 
Symposium on Chromosomal Aberrations in Cancer 
Oral Presentation; February 13th, 2017 
Institute of Pathology, University Hospital Mannheim of Heidelberg University, Mann-
heim (BW), Germany 
 
D. Fiedler, K. Heselmeyer-Haddad, D. Hirsch, L. Hernandez, I. Torres, S. Belle, T. 
Ried, and T. Gaiser 
“Genomic Instability in Colorectal Adenomas with and without Recurrence” 
International Workshop on Translating Colorectal Cancer Research 
Oral Presentation; February 9th-10th, 2017 
Instituto Português de Oncologia, Porto, Portugal 
 
D. Fiedler, K. Heselmeyer-Haddad, N. El Hajj, H. Yang, S. Belle, T. Haaf, A. Marx, T. 
Ried, T. Gaiser 
“Genomic Instability in Recurring and Nonrecurring Adenomas of the Colon” 
16th Annual NCI CCR-Fellows and Young Investigators Colloquium 
Oral Presentation; March 31st – April 1st, 2016 
National Cancer Institute, Shady Grove Campus, Bethesda (MD), USA 
 
D. Fiedler, K. Heselmeyer-Haddad, N. El Hajj, H. Yang, S. Belle, T. Haaf, A. Marx, T. 
Ried, T. Gaiser 
“Genomic Instability in Recurring and Nonrecurring Adenomas of the Colon” 
Fourth Symposium on Translational Genomics with a Special Focus on Liver Cancer 
Poster Presentation; March 17th -18th, 2016 
National Institutes of Health / National Cancer Institute, Bethesda (MD), USA 
 
Acknowledgements 
190 
10 ACKNOWLEDGEMENTS 
Mein herzlichster Dank gilt meinem Doktorvater, Herrn Prof. Dr. Timo Gaiser, welcher mir die 
Möglichkeit gab in einem inspirierenden Umfeld eigenständig zu forschen. Darüber hinaus bin 
ich sehr dankbar für die unzähligen motivierenden Ratschläge und die Investition von Zeit in 
die Betreuung, ohne die das Projekt nicht erfolgreich gewesen wäre. Ich bin dankbar, dass die 
Durchführung von Teilprojekten in den USA stets breite Unterstützung fand. 
 
Ein besonderer Dank richtet sich an Herrn Prof. Dr. Thomas Ried, welcher mir die Gelegenheit 
gab in seinem Labor mit einem familiären, internationalen Team zu forschen und meinen Wis-
sensstand im Austausch mit ihm und führenden Forschern in der Tumor- und Zytogenetik zu 
erweitern. Ich danke dabei auch insbesondere Frau Dr. Kerstin Heselmeyer-Haddad, die mich 
während meines Aufenthalts in den Laboren des NCI immer tatkräftig unterstützte und deren 
kompetente wissenschaftliche Betreuung unschätzbar für diese Arbeit waren. 
 
Mein Dank gilt darüber hinaus Herrn Prof. Dr. Alexander Marx und all den Mitarbeitern der 
Arbeitsgruppen am Institut für Pathologie (Mannheim) und dem Genetics Branch-Labor (Be-
thesda), welche mir im Arbeitsalltag unterstützend zur Seite standen. Insbesondere dankbar 
bin ich dabei Frau Dr. Daniela Hirsch für die ausnahmslos fachlich-kompetenten Ratschläge 
und die stets inspirierende Forscher-Attitüde. Frau Dr. Katja Simon-Keller und Frau Anna Seils 
danke ich für die vielen motivierenden Gespräche im Forschungsalltag. Frau Dr. Darawalee 
Wangsa, Frau Leanora Hernandez und Frau Romina Laegel gehört mein Dank für die Hilfe 
und Expertise, welche zur erfolgreichen Umsetzung der Labor-Experimente beitrugen. 
 
Die Erhebung der DNA-Methylierungs-Ergebnisse in den Adenomen wäre ohne die Mitarbeit 
der bioinformatischen Spezialisten am NCI (Bethesda, MD, USA) um Herrn Dr. Howard Yang, 
Herrn Dr. Maxwell Lee und Herrn Dr. Yue Hu nicht möglich gewesen. Ich danke auch Herrn 
Dr. Nady El Hajj (Julius-Maximilians-Universität Würzburg) für die Hilfe bei den Durchführun-
gen der Methylierungsarbeiten. Mein Dank gehört auch Herrn Dr. Jordi Camps und Herrn Dr. 
Luis Zapata von der Universität Barcelona, welche bei der phylogenetischen Analyse der Fälle 
halfen. Frau Prof. Dr. Christel Weiß (UMM Mannheim) danke ich für die Sprechstunden in 
medizinischer Statistik. 
 
Ich danke dem Prüfungsausschuss und den Zweitgutachtern (Frau Prof. Dr. Heike Allgayer 
und Herrn Prof. Dr. Georg Kähler) für die Übernahme der Gutachten und den damit verbunde-
nen Zeitaufwand. Der Boehringer-Ingelheim Stiftung danke ich für die Bewilligung eines Reise-
Stipendiums, welches den USA-Aufenthalt finanziell ermöglichte. 
 
Acknowledgements 
191 
Mein besonderer Dank gilt zudem Frau Dr. Eveline Bennek, Herrn Marek Endrich, Frau Sarah 
Fiedler, Frau Leanora Hernandez, Frau Dr. Daniela Hirsch, Herrn Dr. Andreas Knaut und Herrn 
Robert Lindner, die jeweils Zeit und Kraft investiert haben um Passagen der Dissertation zu 
lesen und zu korrigieren. 
 
Mein außerordentlicher Dank gilt all meinen Freunden, die mich in der gesamten Zeit der For-
schungsarbeit bedingungslos unterstützten und immer an mich geglaubt haben! Die Geduld, 
das Verständnis und die offenen Ohren waren genauso essentiell für den Abschluss dieser 
Arbeit, wie die gemeinsamen Momente der Ablenkung vom Forschungsalltag. 
 
Mein größter Dank richtet sich an meine Eltern und Stiefeltern, sowie meine Schwester und 
die gesamte Familie. Sie waren alle stets für mich da und haben die Doktorandenphase mit 
allen Höhen und Tiefen begleitet. Erst diese unerschütterliche Unterstützung machte es mög-
lich Ziele zu erreichen, die vormals undenkbar zu sein schienen. 
